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Abstract 
Nowadays, the development of cell therapy relies mainly on the advances made toward cell 
microencapsulation which allows to evade the need for immunosuppression during cell 
transplantation. Among the materials considered for cell encapsulation, hydrogels distinguish 
themselves by their exceptional properties. Due to its gelling properties in contact with divalent 
cations, the biopolymer sodium alginate (Na-alg), has been widely studied for the 
microencapsulation and transplantation of cells. However, several drawbacks, notably defects 
in permselectivity and a poor durability in vivo are limiting the translation of alginate-based 
hydrogels in clinical applications. In addition, the transplantation of cells without 
immunosuppressive treatment exposes the cells to adverse host responses such as inflammation 
and fibrosis. At this time, several approaches have been considered for the development of an 
ideal material for cell encapsulation; however many challenges still remain to be overcome in 
this domain. Hence, the present research project is focused on the further development of 
hydrogels in order to improve their properties toward cell encapsulation. 
 
The first part of this research focused on the development of new types of one-component 
hybrid alginate-based hydrogels. These hydrogels combine the gelling properties of Na-alg with 
covalent crosslinking within the same polymeric structure. In order to do so, a new synthetic 
approach was developed allowing the functionalization on the hydroxyl position of alginate 
with heterobifunctional poly(ethylene glycol) (PEG) linkers through carbamate bond. This 
allowed to maintain the carboxyl moieties available for the formation of electrostatic 
interactions. Two types of one-component hybrid hydrogel were developed with this method 
adding either thiols or lipoyl moieties on alginate leading to an improvement of mechanical 
properties while preserving a good biocompatibility. 
 
Yet, transplantation of encapsulated cells in a foreign host body have to face immune response, 
in particular inflammation and pericapsular fibrosis overgrowth (PFO) which ultimately leads 
to necrosis of the encapsulated cells and loss of graft functionality. Therefore, the second part 
of this research project focuses on tuning the composition of the polymeric components of the 
hydrogels with anti-inflammatory agents which would reduce PFO in vivo. Different anti-
inflammatory agents were considered for this purpose. The best candidate (ketoprofen) was 
then PEGylated via either ester or amide bonds and grafted on the backbone of alginate to 
ensure a controlled release at the site of transplantation. By analyzing the fibrotic tissue around 
the microspheres, it was observed that the incorporation of ketopreofen in the structure of the 
hydrogel significantly reduced PFO 30 days after transplantation. 
In summary, Na-alg was functionalized with a new synthetic methodology allowing the 
incorporation of either functionalities reinforcing the mechanical resistance of the hydrogel or 
anti-inflammatory compounds improving the biocompatibility of the graft. 
Keywords: Alginate, cell microencapsulation, cell therapy, controlled release, 
functionalization, microspheres, hydrogel.  
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Résumé 
De nos jours, le développement de thérapies cellulaires repose essentiellement sur l’avancement 
des technologies liées à l’encapsulation cellulaire. Cette approche permet la transplantation 
cellulaire sans avoir recours à des traitements immunosuppressifs. Parmi les matériaux 
considérés pour l’encapsulation cellulaire, les hydrogels se démarquent par leurs propriétés 
exceptionnelles. Compte tenu de sa faculté de gélation en contact avec des cations divalents, le 
biopolymère alginate de sodium (Na-alg), a été largement étudié pour la microencapsulation et 
transplantation de cellules. Cependant, plusieurs limitations, en particulier des défauts de 
perméabilité sélective et le manque de durabilité in vivo, ont fortement ralenti son 
développement dans des applications cliniques. De plus, la transplantation cellulaire sans 
traitement immunosuppressif doit faire face aux réponses adverses du corps telles que 
l’inflammation et la fibrose. Actuellement, plusieurs approches ont été considérées afin de 
développer le matériel idéal pour l’encapsulation cellulaire; toutefois de grand progrès restent 
à faire dans ce domaine pour permettre le succès d’applications cliniques. Par conséquent, ce 
travail de recherche est focalisé sur le développement des hydrogels afin d’améliorer leurs 
propriétés en relation avec l’encapsulation cellulaire.  
 
Dans un premier temps, ce travail de recherche s’est concentré sur le développement de 
nouveaux hydrogels hybrides à un seul composant dérivant de l’alginate. Ce type d’hydrogels 
combine les propriétés de gélification de Na-alg avec des liaisons covalentes dans une même 
structure polymérique. A cet effet, une nouvelle voie de synthèse a été développée permettant 
la fonctionnalisation des groupements hydroxyle de l’alginate avec des poly(ethylène glycol) 
(PEG) hétérobifonctionnels via une liaison carbamate. Cette approche permet de garder les 
groupements carboxyle de l’alginate disponibles pour la formation d’interactions 
électrostatiques. Deux types d’hydrogel ont été développés de cette manière, en ajoutant des 
groupements thiols ou lipoyl sur l’alginate résultant dans les deux cas de figures en une 
amélioration des propriétés mécaniques tout en préservant une bonne biocompatibilité. 
 
Cependant, la transplantation cellulaire est confrontée aux réponses immunitaires du receveur 
telles que l’inflammation et la prolifération de fibrose pericapsulaire (PFP) qui provoque à 
terme la nécrose des cellules encapsulées et donc la perte de fonctionnalité de la greffe. Par 
conséquent, la deuxième partie de ce travail de recherche s’est focalisée sur la modification de 
la composition des composés polymériques de l’hydrogel avec des agents anti-inflammatoires 
capable de réduire la PFP in vivo. Plusieurs anti-inflammatoires ont été considérés à cet effet. 
Le meilleur candidat (ketoprofen) a été PEGylé via une liaison ester ou une liaison amide puis 
lié sur la structure de l’alginate pour assurer sont relargage contrôlé localisé sur le site de 
transplantation. L’analyse des tissus fibreux autours des microsphères a permis de démontrer 
l’effet positif de l’incorporation du kétoprofène dans la structure de l’hydrogel en observant 
une réduction significative de la PFP 30 jours après la greffe. 
En résumé, l’alginate a été fonctionnalisé à l’aide d’une nouvelle voie de synthèse permettant 
l’incorporation de fonctionnalités renforçant les propriétés mécaniques de l’hydrogel ou de 
composés anti-inflammatoires améliorant la biocompatibilité de la greffe. 
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Mots-Clés : Alginate, fonctionnalisation, hydrogel, microsphères, microencapsulation 
cellulaire, relargage, thérapie cellulaire. 
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1 INTRODUCTION 
1.1 DIABETES AND THERAPY 
Diabetes is a disease characterized by the inability of the metabolism to regulate blood sugar 
levels. The level of sugar, more specifically glucose, in the blood is controlled by cellular intake 
which relies on several mechanisms such as the insulin transduction pathway. Insulin is a 
hormone produced in the pancreas often described as the “key” that opens the cells to glucose 
which makes it an essential element for the blood sugar levels regulation.1,2 Diabetic patients 
either lack of insulin or their cells are unresponsive to it. To differentiate those two cases, 
diabetes has been categorized into two types commonly called type 1 diabetes (T1D) and type 
2 diabetes (T2D). The former referring to the alienation of the immune system leading to the 
destruction of the cells responsible for insulin production (beta cells) resulting in a lack of 
insulin in the whole metabolism. The second (T2D) refers to insulin insensitivity.3 In this case 
insulin is still produced but cells do not respond properly to it and cannot use the glucose present 
in the blood. Both types of diabetes have the same consequence which is an alteration of the 
insulin transduction pathway compromising the regulation of blood sugar level. Dysfunctional 
blood glucose control is the major factor causing many complications such as chronic kidney 
disease, lower limb amputation, retinopathy resulting in blindness, heart attack, strokes and 
nerve damage. These severe complications are life-threatening and therefore, constant 
regulation of blood sugar level is imperative for the well-being of diabetic patients. 
The growing incidence of diabetes has become a major health concern in recent years. 
According to the World Health Organization (WHO), diabetes is the eighth leading cause of 
death worldwide. In 2012, 1.5 million deaths were related to diabetes. The number of people 
over 18 years old living with diabetes was estimated globally to 422 million in 2014. As 
illustrated in Figure 1.1, the incidence of diabetes has steadily increased over the last decades. 
This is due to several parameters such as the population growth, longer life expectancy, and the 
rise in prevalence of diabetes at each age. During the last 30 years the amount of people with 
diabetes has almost quadrupled and it has been estimated that 28% of this increase results from 
a rise in age specific prevalence.4 
  Introduction 
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Figure 1.1 Trend in prevalence of diabetes, 1980-2014, by WHO region. Graphic taken from “Global Report on 
Diabetes; World Health Organization, 2016”.4 
Several therapeutic modalities are currently proposed to diabetic patients depending on the type 
of diabetes and the stage of the disease.  Diet and exercise alone can be sufficient to regulate 
blood sugar level in the certain cases of T2D. In addition, T2D patients can receive medication 
to stimulate insulin release and enhance the sensitivity of body tissues to insulin.  For patients 
with insulin-dependent diabetes (mainly T1D patients), the standard treatment relies on intense 
blood glucose monitoring and exogenous insulin supply. Given that insulin is degraded by the 
stomach enzymes, insulin cannot be given orally and it is usually administered under the skin 
using a syringe, or insulin pumps guided by glucose sensors. This therapy was initially 
developed by Dr. Frederick Banting in 1921 who was able to isolate insulin from a dog’s 
pancreas for injection to a diabetic patient, resulting in the regulation of his blood sugar level.5,6 
Since then, the biosynthesis of insulin was developed allowing the production of “human” 
insulin through genetic engineering. Nowadays, most insulins on the market originate from 
genetic engineering, thus avoiding animal sources.7 Even though insulin therapy tremendously 
improved the life condition of diabetic patients, it cannot fully prevent hypoglycemia insults 
and long-term side complications. In particular, insulin supply has to be adjusted to many 
parameters such as food intake (type and amount), the activity of the patient, his level of 
exercise and also his general state. For instance, stress can greatly influence the need for insulin. 
To overcome some of these limitations, insulin analogues were developed to achieve more 
reliable duration of therapeutic effect. The choice of insulin source is thus an important 
parameter that has to be closely controlled to insure the proper regulation of blood sugar level 
in diabetic patients. 
A new paradigm regarding the treatment of insulin-dependent diabetes and several other 
diseases appeared with the discovery of cell therapy which was defined in 1993 by the Food 
and Drug Administration (FDA) as "the prevention, treatment, cure, diagnosis or mitigation of 
diseases or injuries in humans by the administration of autologous, allogeneic, or xenogeneic 
cells that have been manipulated or altered ex vivo".8 
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1.2 CELL THERAPY 
Cell therapy involves the transplantation of living cellular material in a host body. The 
beneficial effect of such treatment relies on the ability of the transplanted living cells to produce 
a therapeutic effect through the sustained secretion of biomolecules such as cytokines, 
hormones, etc. or even to substitute cells which were dysfunctional or not initially present in 
the host. 
The pioneering input for such strategy appeared back in 1931 when professor Paul Niehans 
directly administered fresh animal cells to several patients suffering from various health 
conditions; however, the success of this method was very mitigated at that time.9,10 Three 
decades later, in 1968, the first successful human transplantation of bone marrow in a 5 month 
old victim of lymphopenic immunological deficiency was reported.11–13 Since then, the field of 
cell therapy has been intensively investigated as it holds great promise for several clinical 
applications, including the replacement of injured or dysfunctional cells, and the treatment of 
metabolic disorders, degenerative disorders, cancer and end-stage organ failure such as acute 
liver failure.14,15 Even though the vast potential of cell therapy brought the attention of a wide 
public, only a few translations to clinics have been achieved so far. One can mention the 
engineering of autologous hematopoietic stem cells for cancer immune therapy.16 Other 
successful approaches are related to the engraftment of manipulated epidermal cells for the 
treatment of severely burnt patients17 and the engraftment of cultured limbus containing stem 
cells for corneal therapy.18 While the use of stem cells in therapeutic products raises high 
expectations due to their potential for differentiation into a variety of cell types, several ethical 
and safety concerns hampered their development in clinical protocols.19–23  
Concerning the treatment of insulin-dependent diabetes, recent reports highlighted the 
beneficial effect of the transplantation of human pancreatic islets for patients suffering from 
incomplete glucose control despite exogenous insulin supply. For 44% of the recipients, optimal 
glycemic control was restored for over 3 years, thus significantly improving their quality of 
life.24 However, the transplantation of human pancreatic islets, as well as other cell-based 
therapies, are limited by the shortage of suitable human donor cells. Moreover, the quality of 
cells harvested from human donors is highly variable, which greatly compromises the 
reproducibility of such treatments. Finally, in most cases, permanent immunosuppressive 
medication is needed to avoid the rejection of the transplant and these treatments cause 
detrimental effects to both the recipients and grafted cells.25 
To overcome these limitations, immunoprotection of effector cells by microencapsulation into 
three-dimensional semi-permeable hydrogels appears as an attractive alternative to maintain 
cell functionality without the need for immunosuppressive regimen.26 
1.3 MICROENCAPSULATION 
Microencapsulation is a general term referring to a process in which gas, liquid, or solid are 
surrounded by a coating material forming so capsules in the micrometer range. Numerous 
applications relying on microencapsulation were developed for the immobilization of a large 
variety of components including food ingredients, drugs, cosmetics and construction materials. 
In parallel, several techniques became available to manufacture microcapsules with adjustable 
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properties depending on the targeted applications. The engineering of the coating material 
highly depends on the purpose of the encapsulation, which can vary from simple protection of 
the ingredients to their controlled release or even improvement of their properties. Each 
application calls for specific materials and encapsulation methods. The encapsulation of 
biologically active components (bioencapsulation) such as cells, tissues, enzymes, bacteria, or 
nucleic acids has also been widely investigated. The entrapment of living cells remains one of 
the most challenging processes as it imposes many constraints on both the hydrogel materials 
and the encapsulation technology to maintain cell viability and sustained metabolic 
functionality. 
 Cell microencapsulation 
The microencapsulation of cells was initially proposed in 1933 by Bisceglie27 who 
demonstrated the sustained metabolic activity of Langerhans islets over more than two weeks 
after immobilization into polymer-based hydrogels (section 1.4). The concept of "artificial 
cells" was proposed three decades later by Chang,28 relying on the use of a semi permeable 
membrane to isolate encapsulated material from the immune system, creating immuno-
protected transplantable cells. The main principle of such system is illustrated in Figure 1.2.  
In view of the different important roles that should be fulfilled by the surrounding matrix, the 
encapsulation materials should meet specific requirements. To protect the inner cells from 
mechanical stress and deteriorating environment, the material should exhibit an adequate 
resistance. Permeability of the membrane should allow the diffusion of nutrients, oxygen and 
cell metabolic products while preventing direct contact with host antibodies and immune cells. 
The benefit of this approach is not only to evade the need for immunosuppressive treatment but 
it also provides the opportunity for transplantation of xenogeneic cells which would ensure a 
more standardized and larger-sized source of cells.29 Cell microencapsulation could in theory 
be applied to any transplantation therapy aiming at the on-demand supply of metabolites.30 In 
the case of insulin-dependent diabetes, the transplantation of xenogeneic insulin-producing 
cells could overcome the lack of human donors31 and decrease or even avoid the recourse to 
permanent immunosuppressive medication. 
The perspective of cell transplantation without immunosuppression would be a major 
breakthrough for patients suffering from severe diseases which already weakened their health 
conditions, such as liver failure,32–34 renal failure,35–37 cancer,38 and diabetes mellitus.39–41
Figure 1.2 Principle of cell microencapsulation 
Introduction 
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Promising results in the field of microencapsulated cell therapies were reported, including 
xenotransplantation studies.42  
The generic term used for cell containing microcapsules is microspheres (MS) which refers to 
the shape and size of the material. Microspheres have also been called microbeads when 
addressing homogeneous hydrogel. If the hydrogel exhibits a heterogeneous three-dimensional 
network, or consists of microbeads surrounded by a membrane, the term microcapsule is most 
frequently used. 
1.4 HYDROGELS
Following the pioneering work of Wichterle43 on cross-linked poly(hydroxyethyl methacrylate) 
as an alternative to plastic in view of medical applications, hydrogels have been widely 
recognized as versatile biomaterials44–49 with outstanding characteristics for 
bioencapsulation50–53 due to their high water content. Composed of natural or synthetic polymer 
chains, hydrogels form three-dimensional matrices of various stiffness. Two main classes of 
hydrogels have been studied and are described as physical and chemical hydrogels. Physical 
hydrogel refers to polymeric network assembled through physical forces only such as 
electrostatic interactions, whereas chemical hydrogels refers to a network of polymers 
covalently linked through specific chemical binding reactions. 
Physical hydrogel
The network of physical hydrogels is held by the interaction of junction domains present in the 
polymer. These junction domains can be sites for ionic bonding, hydrogen bonding or even 
hydrophobic interactions.54–56 This type of hydrogels rapidly became popular since they can be 
easily obtained in a one-step process without the need for cross-linking agents. Most of the 
physical hydrogels developed for bioencapsulation rely on ionic bonding between a 
polyelectrolyte and multivalent ions of opposite charges. Due to its advantageous gelling
properties in contact with divalent cations (Ba2+, Ca2+), the natural polysaccharide sodium 
alginate (Na-alg, Figure 1.3) is by far the most widely used biomaterial for cell immobilization.  
Figure 1.3 Sodium alginate structure; D-mannuronic acid (M) and L-guluronic acid (G) residues 
Na-alg is composed of D-mannuronic (M) and L-guluronic acid (G) residues. The numerous 
charges present on its chemical structure confers to Na-alg the ability to interact with 
multivalent cations to form "ionotropic" hydrogel (Figure 1.4) or with polyelectrolyte 
displaying opposite charge (polycations) to form a polyelectrolyte complex (or simplex). Using 
divalent cation is the most straightforward method to form hydrogel from Na-alg. 
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Figure 1.4 Junction domain of alginate with divalent cation Ca2+ 
One of the easiest and most common way to form alginate-based hydrogels consists in dropping 
an aqueous solution of the polymer (Na-alg) into a solution containing divalent cations such as 
Ca2+ called a gelation bath. Under neutral conditions and at room temperature, Na-alg rapidly 
builds a rigid network by formation of ionic bonds between the GG sequences (junction 
domains) present in the biopolymers. Among the variety of cell microencapsulation 
applications reported with Na-alg, illustrative examples are listed in Table 1. 
Table 1 – Selected alg-based physical hydrogels applied for cell microencapsulation. BMSC: Bone marrow 
mesenchymal stem cells; ADSC: Adipose-derived stem cells; CSP: Human mesenchymal progenitor cells from the 
subchondral bone marrow; WJMSC: Wharton’s jelly mesenchymal stem cells; ARPE-19: Human retinal pigment 
epithelial cells. 
Divalent ions Cell type Target 
Ca2+ 
BMSC 
Hepatocytes 
Pig islets 
ADSC 
CSP 
Treatment of stress urinary incontinence57 
Development of bio-artificial liver58 
Impact of implantation sites on the biocompatibility59 
Study of angiogenic and osteogenic potential of ADSC60,61 
Therapeutic approach for cartilage regeneration62 
Ba2+ 
Rat islets 
Neuroblastoma 
WJMSC 
Study of islets function in vitro and in vivo63 
Cryopreservation of neurospheres by encapsulation64 
Optimized microencapsulation of MSC by vibrational nozzle65 
Ba2+/Ca2+ Human islets ARPE-19 
Viability and function after transplantation into diabeticmice66 
In vitro study of encapsulated human retinal pigment epithelial cells67 
Although the formation of hydrogels from Na-alg is a straightforward process, the properties 
of the resulting MS depend on several parameters including molar mass, configuration and 
constitution of the starting polymer as well as the preparation conditions (section 1.5).  In 
particular, sequences of two L-guluronic residues display favorable conformation for ionic 
bonding while D-mannuronic residues do not contribute to ionotropic interactions but bring 
more flexibility to the resulting network. Different ratios of these residues can thus lead to 
drastic changes in the hydrogel properties.68 In addition, one of the major drawbacks of alg-
based physical hydrogels is their limited mechanical stability and their lack of durability for 
long-term applications. These hydrogels generally dissolve when chelators such as phosphate, 
lactate or citrate and non-gelling cations are present in the environment above a certain 
concentration.69 Different methods have been investigated to overcome this limitation. Coating 
the MS with polycations such as poly(L-lysine) (PLL), poly(L-ornithine) or chitosan to form 
polyanion-polycation complexes on the surface of the MS have been suggested to reinforce the 
MS. However, even by adding a final layer of Na-alg to neutralize the excess of positive 
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charges, biocompatibility issues were reported with these systems primarily due to surface 
attachment of proteins (section 1.7.3). Polycation-containing hydrogels activate inflammatory 
cascades which leads, ultimately, to the death of the encapsulated cells.70 
  Chemical hydrogel 
The main advantage of chemical hydrogels rises from their resistance and long term durability. 
These properties arise from the matrix of chemical hydrogels which is based on the combination 
of cross-reactive functionalities through irreversible cross-links. Nevertheless, many 
parameters are required for the formation of these resistant covalent bonds since the process of 
hydrogel formation, when applied to bioencapsulation, should not compromise cell integrity 
and viability. Only mild conditions can be used with non-cytotoxic solvents and reagents which 
limit the choice to water soluble components and biocompatible cross-linkers.71 Moreover the 
aqueous solutions need to be buffered with the appropriate osmolality to provide viable 
environment for cells. Finally, the chemical reaction involved for the formation of the covalent 
network should not interfere with cell components or metabolic products. Several combinations 
of polymers with different binding methods responding to these requirements have been 
explored for cell encapsulation. 
 
 
Figure 1.5: Examples of junction sites for the formation of chemical hydrogels. Clockwise from top left: thiol + 
acrylate (Michael addition) 72,73; thiol + maleimide (Michael addition)74; furan + maleimide (diels alder)75; 2x 
acrylate (Photopolymerization)74, 76;  azide + alkyne (Huisgen 1,3-dipolar azide-alkyne “click reaction”)77. 
Modified poly(ethylene glycol) (PEG) with various functional groups have been used for the 
preparation of chemical hydrogel to encapsulate different types of cells. Fibroblast and 
keratinocytes were successfully immobilized in MS resulting from thiol-ene reaction between 
PEG diacrylate and thiolated gelatin.72,73 Using combination of PEG derivatives containing 
maleimide reactive functionality and acrylate or maleimide moieties afforded hydrogel suitable 
for the encapsulation of C2C12 myoblast.74 Photo-polymerization of fibrinogen-g-PEG 
acryloyl and PEG diacrylate provided hydrogels suitable for the encapsulation of BMSC.76 
Photo-polymerization of PEG diacrylate was also studied and led to the formation of MS usable 
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for the encapsulation Huh-7.5 cells.78 Numerous examples using other chemical polymers such 
as chitosan, dextran, hyaluronic acid or poly(vinyl alcohol) with chemical modification 
allowing the formation of chemical hydrogels have been investigated.79–82 This panel of 
chemical hydrogels have demonstrated good properties for the encapsulation of various cell 
types. 
Nevertheless, the slow kinetics of covalent bonds formation (in comparison with electrostatic 
interactions) can affect the shape of the resulting hydrogels and limit their applications. 
Generally, the rheological properties of the solution is also a parameter of great importance for 
the formation of chemical or physical hydrogels in the view of cell encapsulation.83 
 Hybrid hydrogels 
Combining the fast gelation of physical hydrogels with the high resistance of chemical 
hydrogels is the main purpose behind the development of hybrid hydrogels. Alginate based 
hybrid hydrogels have shown remarkable properties by merging the spontaneous formation of 
physical hydrogel in presence of divalent cations in combination with various covalent binding 
methods. One approach consists in the formation of multi-layer hydrogels such as alg-PLL-alg 
(APA)84 which incorporate cross-linking between adjacent layers of the MS. For instance, 
phenyl azide moieties appended to poly-L-lysine create covalent bonds with alginate when 
irradiated with UVA in a cell compatible protocol. The resulting hybrid MS showed high 
stability in alkaline buffer (pH 12) compared with purely physical MS (three years instead of 
one min). 
 
Figure 1.6: Representation of a multilayer alg-PLL-alg microsphere. 
Another approach using methacrylate polymers and PLL demonstrated the formation of 
covalent binding in the core or on the surface of the MS depending on the molecular weight of 
the crosslinker used. For this purpose the reactive polyanion, poly(methacrylic acid, sodium 
salt-co-2-[methacryloyloxy]ethyl acetoacetate) was co-encapsulated in calcium alginate (Ca-
alg) core followed by exposure to PLL of different size. The free amine groups of PLL reacted 
with the acetoacetate groups of the polyanion chain to form covalent bonds (enamine).85 
Approaches based on chemical cross-linking through complementary reactive groups attached 
to two oppositely charged polyelectrolytes were also investigated with promising results for 
cell microencapsulation.85,86 A two-component hydrogel composed of an interpenetrating 
polymer network of Ca-alg and covalently cross-linked vinyl sulfone-terminated multiarm 
poly(ethylene glycol) exhibited improved mechanical resistance compared to pure physical Ca-
alg MS. HuH7 cells were encapsulated in this system and viable over two weeks. 87–90 Another 
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two-component hydrogel was obtained from the mixture of Na-alg and Na-alg functionalized 
with cysteamine exhibiting again improved mechanical properties and good biocompatibility 
with the encapsulation of EDX cells over 30 days.91 (Figure 1.7) 
 
Figure 1.7 : Examples of alginate based hybrid hydrogels from multicomponents system. 
Pushing further the improvement of hydrogels, one-component hydrogels with both physical 
and chemical binding sites present on the precursor polymer were developed. This method has 
the advantage to overcome the introduction of a second polymer which facilitate the process of 
hydrogel preparation (Figure 1.8). 
 
Figure 1.8: Example of an alginate based one-component hybrid hydrogel system with thiols moieties incorporated 
on the structure of alginate for the formation of covalent bonds through disulfide bridges. 
The first reported application using this approach was the formation of Na-alg derivative with 
heterobifunctional thiol terminated PEG grafted on the carboxyl groups of alginate (Figure 1.8). 
The MS formed from this polymer exhibited improved mechanical properties combined with 
good biocompatibility with encapsulated material (Huh-7 cells).87 Alternative one-component 
hydrogel systems imply the grafting of azide-terminated PEG chains to Na-alg for concomitant 
ionotropic interaction with Ca2+ and chemical ligation through Staudinger reaction of the azide 
moieties with phosphine-containing components present in the gelation bath.92 Human 
pancreatic islets were successfully encapsulated using such systems.93  
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1.5 MICROENCAPSULATION TECHNIQUES 
Various methods for the formation of MS have been developed to answer the needs of the 
numerous applications using this technology. The need for large scale production of robust core 
material can be achieved by a panel of technologies including pan coating, air suspension 
coating, emulsification or spray drying which have showed great advantages for industrial 
production of encapsulated materials.94–96 Nevertheless due to their rough conditions and broad 
size distribution these methods can hardly be adapted to cell encapsulation. Alternatively, softer 
methods such as droplets extrusion or microfluidics have been successfully used for the 
formation of cell-containing MS. Droplets extrusion is the most widely used method for cell 
encapsulation as it relies on a simple instrumental setup. It consists of dripping a cell-containing 
solution of polymer through a needle into a gelation bath to shape MS containing cells 
entrapped in their core. The main limitations of this straightforward method are the need for 
low viscosity initial polymer solution and the large diameter of the resulting MS ranging from 
1.5 to 3 mm. The optimal size of MS used for cell encapsulation was estimated to range from 
100 to 500 μm granting high surface-to-volume ratio which ensures good transport of nutrient 
and oxygen to the encapsulated cells.97 In order to reduce the size of the beads while using 
droplet extrusion systems, different methods were developed. A simple instrumentation is the 
coaxial air-flow droplet generator.98 The principle is to blow air with constant flow toward the 
end of the needle used for the extrusion to shape droplets ranging from 200 to 1000 μm at the 
needle outlet. Another approach consists of using a vibrating nozzle. The vibration breaks the 
droplets from the nozzle affording so uniform smalls MS.99 Uniform beads in a good size range 
were also obtained by applying a high electrostatic field between the needle and the gelation 
bath. The size of the droplets can be tuned by controlling the electrostatic pulse.100–102 Finally 
a method called “jet breakage by rotating elements” can produce small sized MS with good 
homogeneity using kinetic force such as rotating nozzles, a rotating disk or a cutting wire.103  
 
Figure 1.9 : Principle of droplets formation by (left to right): coaxial air-flow, rotating disk (jet cutting), 
electrostatic potential and vibrating nozzle 
Recently promising results were reported using microfluidic technology for the encapsulation 
of living cells delivering MS with high homogeneity in size distribution.104–107 This technology 
produces MS from an aqueous precursor solution which is shaped to the desired droplet size 
with the help of an immiscible oil phase such as mineral oil, silicone oil, corn oil, hexadecane 
oil, or fluorinated oil.108  
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Figure 1.10: Principle of MS formation using microfluidics 
The hydrogel network is then further internally crosslinked by ionic gelation or 
photopolymerization which showed good compatibility for cell microencapsulation.109 This 
technology requires a sophisticated instrumental setup and a good control of the different 
parameters such as the pressure in the system, the viscosity of the solutions (oil and aqueous) 
and the design of the microfluidic chips (size and length of the channels). Nonetheless, droplets 
with very low polydispersity were obtained with microfluidics devices allowing the 
encapsulation of several types of cells.110–116 Moreover, single cell microencapsulation was 
achieved with this technology, which can be advantageous for various applications.117,118 Still, 
the production of a large amount of droplets by microfluidic systems within a short time scale, 
which is essential for clinical applications, remains a difficult task. The scaling up of such 
methods could however be a major breakthrough in the field of cell encapsulation.119 
1.6 PROPERTIES OF HYDROGELS FOR CELL MICROENCAPSULATION 
When intended for cell microencapsulation and transplantation, the hydrogel polymeric 
materials should display a panel of properties suitable to sustain long term cell viability and 
functionality. In particular, the immobilization matrix should protect the encapsulated cells 
from external mechanical stress and detrimental environment while ensuring the cross-diffusion 
of nutrients, oxygen, metabolic products and waste. Larger sized biomolecules (antibodies) and 
immune cells should not be able to cross the MS membrane. Below are presented the main 
parameters which play a crucial role in tuning the properties hydrogel materials.  
 Mechanical resistance 
The mechanical resistance of MS is a determining factor for the long term viability of the 
encapsulated cells in vivo. Low resistance MS are subject to disintegration leading to a loss of 
immunoprotection resulting in graft failure. The importance of mechanical stability in cell 
encapsulation has been emphasized in recent years, giving rise to various methods for its 
evaluation.120–123 The main characteristics contributing to the protection of the encapsulated 
cells from the environmental constraints are the deformability (stiffness) and the resistance to 
fracture (toughness) of the hydrogel. The forces to which MS are exposed in vivo can vary a 
lot with respect to the transplantation site and the animal model but no study gives precise 
Introduction 
12
information about the magnitude of these forces and the exact resistance requirements with 
respect to the model used. 
Nonetheless, the importance of mechanical resistance has been recognized and several methods 
have been developed to assess the mechanical properties of MS. The attributes such as physical 
resistance and deformation under compression can be quantitatively measured by means of a 
Texture Analyser.124–126 The MS are set under a probe which applies defined compression while 
monitoring the resistance of the material. Both the breaking load and the mechanical resistance 
to defined compressions can be determined with this instrument. Either a layer of several MS 
or a single MS can be evaluated with such system. Furthermore, the stiffness of the capsules 
can be measured by including cycles of compressions and monitoring the evolution of the 
resistance through multi-compression cycles. Importantly, this measurement provides valuable 
information regarding the ability of MS for shape recovery under repetitive deformations.  
Another method allowing qualitative evaluation of the hydrogel resistance consists in simply 
exposing the MS to a hypotonic solution such as water, leading to an increase of the osmotic 
pressure resulting in the swelling and potential disintegration of the MS.127 Such an experiment 
provides valuable information on the swelling properties of the MS, which is mostly relevant 
with physical hydrogels upon ion exchange and resulting in loss of cell protection. 
Permeability
One of the main purposes of cell encapsulation lies in the selective permeability of the hydrogel 
materials. More specifically, the hydrogel materials should block the contact of encapsulated 
cells with host immune cells and antibodies while allowing the diffusion of nutrients, oxygen 
and metabolic products. Even though the control of permselectivity is recognized as a crucial 
element in the field of cell encapsulation, different statements were reported concerning the 
optimal pore sizes to promote high performance of the encapsulated cells.128–131 On the one 
hand, one argues that the main role of the membrane is to protect encapsulated cells from direct 
contact with immune cells. If one considers only this role, a certain flexibility regarding the size 
of the pores is allowed as long as an inert polymer is used. On the other hand, a strict control of 
the pore size and the permeability may help reducing leakage of components to the outside of 
the capsule thus reducing immune reaction of the host. This last approach is mainly relevant  in 
the case of xenotransplantation.123
Measuring the permeability of hydrogels can be delicate and different methods have been 
developed for that purpose. The most important parameter describing the permeability 
regarding cell encapsulation is the molecular weight cut-off (MWCO) of the membrane. It 
represents the minimum size (molecular weight) of a compound excluded from the pores of the 
hydrogel. To measure MWCO, the common approach is the sized-based exclusion experiment 
which consists in measuring the diffusion of labeled compound such as dextran, pullulans or 
proteins of different sizes through the MS membrane. The observation of the diffusion can be 
achieved by different means such as the monitoring of fluorescent or radioactively tagged 
compounds.66,132–135 However, depending on the compound chosen to assess the MWCO the 
results has to be taken cautiously, as the size of polysaccharides for example cannot be directly 
compared to a protein of the same weight.136 Another method used with success is the inverse 
size-exclusion chromatography (ISEC). In this method, solutes of various sizes are eluted 
through a column filled with MS, allowing to measure their partition between the mobile phase 
and the stagnant MS phase.136 This technique can provide precise information on the pore size 
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and distribution but requires high volume of MS which can be challenging depending on the 
material and/or the method of production. The mesh size of the molecular network of the 
hydrogel can also be directly measured by cryo-scanning electron microscopy (cryo-SEM).137
Although it provides an accurate direct measurement, one has to keep in mind that the hydrogel 
molecular network might drastically change during the freezing process. 
1.7 PROPERTIES OF BIOLOGICAL COMPONENTS
To overcome the limitations of cell-based therapies, which mainly lie in the shortage of suitable 
cells for transplantation and the lack of long-term functionality of encapsulated cells, several 
parameters should be controlled, including the sources of cells, the site of transplantation and 
the biocompatibility toward the host.  
Source of cells
As mentioned before, a major advantage of cell encapsulation lies in the possibility to use non-
human cell sources in xenotransplantation protocols. This eventually leads to the question of 
the optimal alternative source of cells replacing human donors. One of the most contemplated
source of cells for this purpose is porcine cells. This model has already shown good 
compatibility for islets transplantation.138,139 More precisely, the use of neonatal pigs islet-like 
cells (NICCs) has demonstrated great advantages for this application, since NICCs are easily 
purified, exhibits low levels of T-cell response and a high resistance to ischemia and 
inflammation.140 Recent studies on NICCs led to the conclusion that islet clusters should be 
isolated from porcine during the first month of their life, and that the maturation of NICCs islets 
was optimal after 12 days of culture.141–143 In addition, recent progress in genome editing 
technologies, such as CRISPR/Cas9, allowed to precisely remove or insert genes anywhere in 
the genome.144 Genetically modified pigs were produced with numerous genetic modifications, 
allowing the removal of several porcine antigens (GalT/CMAH/b4GalNT2 triple gene KO) and 
incorporation of human genes regulating the immune response, the complement or the 
coagulation.144 Furthermore, the risk of xenozoonosis, i.e. the transmission of porcine infectious 
agents to humans, such as porcine endogenous retroviruses (PERV), was successfully blocked 
using the Crisp technology.145 Other source of transgenic islets cells were considered like the 
fish tilapia.146,147 Encouraging results were obtained with transplantation of encapsulated tilapia 
islets into mice in combination with immunosuppressive treatments, resulting in blood glucose 
level regulation for over 200 days.148 However, considering the significant difference between 
human and tilapia insulins, the use of tilapia islets for diabetes cell therapy might be 
compromised. Due to close physiological similarities between pigs and humans and the 
possibility to inactivate PERV, pig species currently appear as the most promising xenogeneic 
cell source for the treatment of diabetes through islets xenotransplantation.149
Site of transplantation
Several sites of transplantation have been considered for the deposition of encapsulated cells 
with good cell survival and functionality in different animals models.150,151 The optimal 
transplantation site needs to answer to several requirements such as sufficient vascularization 
to ensure the supply of oxygen and nutrients to the encapsulated cells, and good accessibility 
for the deposition and retrieval of the MS. The performance of different surgical sites was 
assessed by evaluating the survival of microencapsulated transplanted cells. A commonly used 
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site of transplantation showing an acceptable rate of success is the peritoneal cavity.59,152–154
This cavity has the main advantage of being very accessible for the deposition of MS and allows 
the transplantation of large amounts of material. Some studies however suggest that the 
vascularization/oxygenation in the peritoneal cavity is not optimal.59 Also, MS floating in the 
cavity can make their recovery delicate. An alternative approach was developed with the 
surgical creation of an omental pouch as a site for the deposition of encapsulated islets. This 
method allowed better oxygenation and a good functionality of the encapsulated cells.155–157  
Transplantation under the kidney has also been studied and exhibited good results with islets 
transplantation.158,159 The access to this site is easy and the high vascularization allows good 
viability of the cellular material. Even though transplantation of free islets in 
immunosuppressed models at this site exhibits good results, the limited space under the kidney 
could be a serious limitation when considering the transplantation of microcapsules which 
requires bigger volume to reach insulin independence. 
Subcutaneous locations are very accessible for transplantation and retrieval,160 but display low
blood supply. However, a study showed that the vascularization of these sites can be improved 
with prevascularization.161 Still, the physical constraints in these area are to be considered as a 
parameter affecting cell viability. The striated muscles also provide an easily accessible 
transplantation site with the advantage of being highly vascularized. Transplantation in mouse 
was done with good success taking profit of the high level of oxygen at this site. Nevertheless, 
transplantation in striated muscles has also been associated with strong fibrosis response.162,163
Finally, the portal vein is commonly used for islet transplantation providing efficient nutrition 
and blood supply. However, the risk of portal vein occlusion and the difficulty to retrieve MS 
from this site remain major limitations that have to be seriously considered in view of clinical 
applications.164
Biocompatibility
Despite the recent progresses which were achieved over the last two decades in the engineering 
of polymeric hydrogels for cell immobilization and in the harvesting of cell batches with 
suitable quality for transplantation, the success of clinical applications based on 
microencapsulated cells remains hampered by host biocompatibility defects.  While the 
physical and mechanical properties (resistance, stiffness, size, hydrophilicity) of the hydrogel 
MS can be modulated to promote viability and functionality of the encapsulated cells,165 the 
host acceptance remains a major challenge. 
Following the transplantation of encapsulated cells, the occurrence of pericapsular fibrotic 
overgrowth (PFO) is commonly observed, resulting in cell necrosis and ultimate loss of graft 
functionality.    
  Introduction 
15 
 
As depicted in Figure 1.11, the formation of fibrotic tissue surrounding the transplanted MS 
compromises the supply of nutrients and oxygen as well as the excretion of metabolic  
Figure 1.11 : Representation of pericapsular fibrotic overgrowth resulting in graft failure 
products.30,166–169 Recently, the biocompatibility of the encapsulation materials has been the 
subject of intensive investigation to answer the needs of transplantation. In particular, several 
approaches were developed to enhance the long-term functionality of encapsulated living 
cells.170 
1.7.3.1 Mechanisms of inflammation 
The inflammation occurring during the transplantation of MS follows complex patterns 
potentially involving numerous mechanisms.171–174 The processes of inflammation and fibrosis 
formation were described as three successive phases: the acute inflammation, the chronic 
inflammation and finally the long-lasting granulation tissue phase.171  
The acute inflammation occurs directly after the transplantation of the microcapsules. This 
phase is defined by the attraction of granulocytic neutrophil cells in the area of transplantation. 
These cells carry chemotactic cytokines and chemokines which are small proteins stimulating 
the recruitment of specific surrounding cells. This immune response cannot be avoided, as the 
surgery needed for the transplantation is a natural trigger of the acute inflammation which is an 
essential protective response in injured tissues.175 Nevertheless if these signals persist for 
several days, monocytes, macrophages and lymphocytes will accumulate in the area of 
inflammation. This progression of cell types present at the inflammation site is the turning point 
making the beginning of the chronic inflammation phase. Several factors have been associated 
with the prolongation of inflammatory signals occurring around the biomaterial after 
transplantation, leading to chronic inflammation. 
The adsorption/desorption of proteins on the surface of the encapsulation material is a well-
studied process that can be involved in the host inflammation response and highly depends on 
the nature of the material. The protein adsorption on the surface of the MS can trigger the 
inflammation mechanism in different ways. The adsorption of immunoglobulins (IgG, IgM and 
IgA) is the classical pathway leading to an immune response.176 Another way is the adsorption 
of proteins and conformational change.177,178 It has been studied that the denaturation of protein 
C3 when adsorbed at the surface of biomaterials can lead to the activation of the complement 
cascade mechanism of inflammation. This is triggered by the products resulting from the 
denaturation of C3, which are strongly chemotactic for leukocytes involved in inflammatory 
Nutrients 
Oxygen 
Fibrotic overgrowth 
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events. 179–181 Nevertheless the adsorption mechanism is mainly observed when using charged 
hydrophobic surfaces. In the case of alginate hydrogels with very low hydrophobicity this 
process remains limited.176 
Another parameter susceptible to trigger and sustain the inflammation response is the release 
of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs) from the MS. The inflammation potential of these molecules were emphasized in two 
studies focusing on alginate-based hydrogels. The quality of the alginate material, in particular 
its purity is a key parameter for biocompatibility. In case of high concentration of PAMPs such 
as peptidoglycan, lipoteichoic acid, and flagellin which are recognized by Toll-like receptors 
(TLR2, 5, 8 and 9), the host immune response is activated.182 The release of DAMPs from 
encapsulated islets have been monitored by the quantification of HMGB1, DNA and uric acid 
which were shown to activate MyD88-TLR receptors.183 In case inflammation signals are 
sustained in the same area, others cell types such as “vascularized fibrous tissue” fibroblasts 
and macrophages, foreign giant cells and polynuclear cells are recruited and the inflammation 
then turns to the long-lasting granulation tissue phase.184 
Several models were developed to assess the potential immune response toward encapsulation 
materials. One can mention the “whole blood model” which consists of placing empty 
hydrogels (without cell content) into human whole blood in presence of an anticoagulant (often 
lepirudin).  This model covers many parameter involved in the early stage inflammation like 
the complement system, effector of coagulation (except for the thrombine inhibited when 
lepirudin is used) and fibrinolysis cascades. Leukocytes and platelets are also present in whole 
blood allowing the study of their behavior. Various types of MS have been analyzed using this 
model.185,186 These studies highlighted the fact that pure alginate MS were much less susceptible 
to provoke an inflammatory response whereas multilayer systems such as alginate-PLL-
alginate, alginate-PLL, alginate-cellulose and sulfate-PMCG triggered the inflammation via 
different pathways involving adsorption mechanisms. Even though this method is an efficient 
non-invasive way to compare the inflammatory potential of many materials, one should keep 
in mind that the presence of cells in the MS would most likely change drastically the outcome. 
While in vitro assays allow for the screening of many encapsulation materials without the 
recourse to animal models, the complexity of foreign body inflammation response cannot be 
fully reproduced in vitro. 
1.7.3.2 Methodologies to reduce inflammation and fibrosis 
In recent years, several approaches were investigated to reduce the inflammatory reaction to 
transplanted encapsulated cells. The formation of fibrotic tissue induced by the transplantation 
of MS can be triggered by the nature of the encapsulation material and of the cell content. It has 
been shown that the purity of the material used for the encapsulation such as alginate can 
significantly influence its biocompatibility.182 Moreover the cellular core of the capsules is 
highly susceptible to trigger the inflammation reaction given that cells are known to produce 
danger-associated molecular patterns identified as a source of inflammation reaction.183 In 
particular, in the case of xenotransplantation, the cellular metabolites excreted from the MS are 
treated as foreign antigens by the host. The main reported approaches addressing PFO focus 
either on the modification of the MS surface, on the co-encapsulation of small molecular 
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modulators of the immune response, and/or on the modification of the cell content.  A selection 
of the strategies recently developed is listed in Table 2.
Remarkable results were obtained with the co-encapsulation of mesenchymal stem cells 
(MSCs) which are able to produce small molecular modulators able to mitigate the immune 
response and therefore decrease PFO. Using Ba-alg MS, the co-encapsulation of hepatocellular 
carcinoma cells HuH7 with mesenchymal cells demonstrated significant reduction of PFO in 
vivo. The same method was used for the co-encapsulation of islets and exhibited not only 
reduction of fibrosis but also an improved survival and functionality of the allograft up to 50 
days after treatment in diabetic mice. 187,188 Another approach focusing on surface modification 
was achieved by coating the MS with chitosan which appeared to reduce protein absorption to 
the material surface 189 and lead to an extension of the life-time of encapsulated islets in mice 
and canine models.190
A widely investigated approach addressing the issue of PFO focuses on the co-encapsulation 
of anti-inflammatory or immunosuppressive drugs with the effector cells. Several studies 
observed the enhancement of functionality of the encapsulated cells in relation with a reduction 
of fibrosis when small anti-inflammatory molecules were co-encapsulated.191–193 The screening 
of a panel of known anti-inflammatory drugs for co-encapsulation with rat islets highlighted 
the beneficial effect of curcumin to mitigate PFO and to maintain reduced blood glucose level 
over 60 days in mice model.191 A significant reduction of PFO was also observed with the co-
encapsulation of ketoprofen in polyester MS in vivo.194 However, the limitation of the co-
encapsulation strategy lies in the burst release effect which reduces the time during which the 
drug effect can be expected. More efficient systems might be achieved by covalent drug 
conjugation to the polymeric material for improved release kinetics (section 2).
Table 2 : Strategies to reduce PFO in the transplantation of alginate-based MS; h: human; m: mouse; IP: intra-
peritoneal; MSCs: mesenchymal stem cells; SC: sub-cutaneous; PFO: pericapsular overgrowth; PLO: poly(L-
ornithine); PLA: poly(lactic acid) 
Material MS content In vitro/ in vivo model Outcome
Na-alg/Ba2+
hMSCs : HUH7 (1:1) C57BL/6 miceIP infusion
1.4 fold reduction of 
PFO187
mMSCs / hHUH7 (2:1)
C57BL/6 mice
SC injection
2 fold reduction of 
PFO187
C57BL/6 mice
SC injection
2.1 fold reduction of 
PFO187
Stimulated mMSCs / 
m-islets (1:1)
C57BL/6 mice
IP infusion
6 fold reduction of PFO 
100% normoglycemic 
mice after 50 days 188
unstimulated mMSCs / 
m-islets (1:1)
C57BL/6 mice
IP infusion
2.5 fold reduction of 
PFO
71% normoglycemic 
mice after 50 days188
Na-alg/Ba2+ rat islets/curcumin 1 mg/mL
C57BL/6 mice
IP infusion
reduced blood glucose 
level over 60 days
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no fibrosis on almost 
all capsules retrieved 
after 60 days191
Na-alg/Ca2+
cationic 
coating
Rat 
islets/pentoxifylline 
(PTX) 400 μg/mL
Co-culture of 
encapsulated islets with 
mice lymphocytes
burst release of PTX
reduced attack of 
encapsulated islets by 
lymphocytes192
Na-alg/Ca2+
Porcine islets
MS coated with PEG-
rapamycin layer
BALB/c mice
IP infusion
reduced infiltration of 
fibrotic cells after 30 
days
no significant effect on 
blood glucose level 193
alg/PLO/alg/
Ca2+
PLA loaded with 
ketoprofen 
CD-1 mice
IP infusion
75% of KET released 
during the 1st day 
no sign of 
inflammation after 63 
days194
Na-alg/Ba2+
chitosan 
coating
porcine islets GalT KO mice
80% graft survival 
after 381 days 
2 fold reduction of 
PFO190
canine islets 
3 transplantations 
Pancreatectomized 
beagles
99% of capsules 
without PFO
231 days insulin 
independence190
The size and shape of the MS were also described as important parameters to influence the host 
immune response.195 In recent study it was shown that larger beads (1.5 mm) exhibited less 
immune reaction and fibrosis than smaller beads made of different materials in rats and primate 
models.196
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2 THESIS OBJECTIVES
A large number of patients could benefit from progress in cell transplantation therapies if 
polymeric materials presenting optimal properties for cell microencapsulation could be 
produced. Maintaining the intrinsic favorable properties of alginate hydrogels but improving 
their physical properties, mechanical behavior and biocompatibility is at the heart of this work.  
The main goal was to improve the longevity of encapsulated cells, in particular insulin 
producing cells, by reduction of PFO. Following the encouraging results observed with the co-
encapsulation of small molecular modulators of the host immune response (section 1.7.3.2), an 
alternative approach based on the covalent conjugation of anti-inflammatory or anti-fibrotic 
compounds to the alginate backbone was developed. Controlled and sustained delivery of the 
active ingredient at the MS transplantation site is expected by hydrolysis of the covalent linkage 
in vivo.
The long term in vivo stability of the hydrogel MS was addressed in parallel and several 
alginate-based hybrid hydrogels were developed to form stable MS. In order to maintain the 
carboxylic groups of Na-alg available for ionic interactions, the modification of the hydroxyl 
groups of the alg backbone was investigated to introduce thiol- or 1,2-dithiolane-containing 
poly(ethylene) glycol derivatives. Concomitant fast ionotropic gelation and slow covalent 
crosslinking (disulfide bridge of disulfide cluster formation) was targeted during MS 
production.  
Combining these two aspects was ultimately studied to produce functionalized hybrid alginate-
based hydrogels for islets transplantation. 
2.1 INHIBITION OF PERICAPSULAR FIBROTIC OVERGROWTH
The reduction of PFO might be achieved by inhibition of the inflammation cascade at different 
stages of the process. The most common inflammation modulators are the non steroidal anti-
inflammatory drugs (NSAIDs), which inhibit enzymes involved in the early stage of the 
inflammation pathway. More specific small molecular effectors such as inhibitors of fibroblast 
activation protein-? (FAP-?) were also considered. 
Inhibitors of fibroblast activation protein-?
Fibroblast activation protein-α (FAP-α) belongs to the post-proline dipeptidyl aminopeptidase 
family and shares high similarity with dipeptidyl peptidase IV (DPPIV).197 Involved in the 
control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue 
repair, and epithelial carcinogenesis, FAP-α plays a significant role during fibrosis formation. 
It is therefore reasonable to target the inhibition of this protein to prevent PFO. Several studies 
demonstrated that the selective inhibition of FAP-α protein can be achieved with small 
molecules containing the Gly-Pro sequence or analogues.198 Moreover, it was previously 
demonstrated in the group199 that cyano-Pro derivatives displayed effective FAP-? inhibition 
(Figure 2.1).200
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Figure 2.1 : Generic structure of FAP-α inhibitor (left) and derivative synthesized in the group (right) 
These structures were thus selected for further modification in view of their covalent grafting 
to the alg backbone.  
 Nonsteroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used drugs by 
millions of people worldwide for their ability to relieve patients from pain, fever and 
inflammation.201,202 Curcumin and ketoprofen are both non-steroidal anti-inflammatory agents 
exhibiting therapeutic effects which are mostly associated with the inhibition of the proteins 
COX-1 and COX-2 involved in the early stage inflammation cascade.203–205  
The encapsulation of free curcumin and ketoprofen in alginate based hydrogels was already 
investigated and appeared to decrease PFO in mice.191,194 These two molecules were thus 
selected for covalent conjugation to the alg backbone and further local controlled delivery from 
the MS. Due to their remarkable therapeutic virtues, many natural and synthetic derivatives of 
curcumin (curcuminoids) have been developed and displayed similar anti-inflammatory 
characteristics.206,207 Derivatives of ketoprofen have also been synthesized showing good 
results as anti-inflammatory prodrugs with hydrolysable ester bonds.208–210  
While burst release of co-encapsulated free drugs results in short term action, we expected that 
slow release from covalent adducts would inhibit the early and subsequent stages of 
inflammation on an extended period of time which would drastically reduce fibrosis formation 
and improve the lifetime of the encapsulated cells. In the case of curcumin, the phenols groups 
were considered for derivatization to produce a doubly functionalized prodrug for the grafting 
to alginate. In the case of ketoprofen, the carboxylic function was used for the derivatization in 
order to prodrug candidates. 
 
Figure 2.2 : Curcumin (left) and ketoprofen (right) chemical structures. The sites for derivatization are highlighted 
in blue 
By combining improved stability and resistance rising from new alginate based hybrid 
hydrogels with the properties of inhibition of PFO provided through controlled release of anti-
inflammatory/fibrotic compounds, the final objective of this research was to produce 
multifunctional alginate-based hydrogels for long-term cell therapy protocols. 
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Figure 2.3 : Representation of new multifunctional hydrogels 
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3 RESULTS AND DISCUSSION 
3.1 SYNTHESIS OF ANTI-FIBROTIC DERIVATIVES 
One of the main limitation regarding transplantation of encapsulated cells is the formation of 
fibrotic tissues around the MS leading to the death of the encapsulated material. To address this 
issue, this work focused on covalent binding of anti-fibrotic small molecules (drugs) on the 
structure of hydrogels allowing a controlled release in vivo which would mitigate fibrosis 
formation over long term improving the life time and functionality of the encapsulated material. 
The anti-fibrotic compounds considered for this work were thus chemically designed to display 
functionalities allowing covalent binding on the surface of the hydrogel either before or during 
the formation of the MS. For this purpose, polymers used for hydrogel formation were 
accordingly developed in parallel with the incorporation of new functionalities accessible for 
the integration of the drug derivatives (section 3.3). Since the formation of MS has to be 
performed in the presence of living cells, the reactions designed for the conjugation of the drugs 
at that stage have to be biorthogonal to avoid compromising cell viability. Hence the 
functionalities used for the formation of covalent binding during MS formation were 
maleimide, which can react with thiol groups through a 1,4-Michael addition, and lipoyl 
moieties that can produce clusters of disulfide bridges (Figure 3.1 left). In contrast, covalent 
binding of drugs on the polymer backbone before MS formation do not require specific 
biorthogonal conditions allowing more flexibility in the choice of the reaction used for this 
matter. Alkyne and amine moieties were thus synthetically added on the anti-fibrotic 
compounds for this purpose (Figure 3.1 right). 
 
Figure 3.1 : Strategies for the grafting of anti-fibrotic compounds on microspheres 
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Three small molecules presenting a potential anti-fibrotic effect were thus derivatized to present 
the desired functionalities on their chemical structure: FAP-α inhibitors, Curcumin and 
Ketoprofen. 
 Derivatives of FAP-α inhibitors  
The core of FAP-α inhibitor was modified with different moieties suitable for the formation of 
covalent bonds on the polymeric structure used for hydrogel formation. The structure 
responsible for the inhibition of FAP-α (Figure 3.2 right) was covalently linked through amide 
bond to maleimide, alkyne and two derivatives of lipoic acid (Figure 3.2 left). 
 
Figure 3.2 : Derivatization of FAP-α inhibitor 
Based on a synthetic procedure previously developed in the Group for Functionalized 
Biomaterials,199 the synthesis of the FAP-α inhibitor core started from L-proline which was 
converted into the activated cyano-pyrrolidine (4) derivative according to Scheme 1. 
L-proline was first protected as a tert-butyl carbamate and then converted into amide using 
coupling agents (HOBt and EDCI) to yield (S)-tert-Butyl 2-carbamoylpyrrolidine-1-
carboxylate (2). Dehydration in the presence of trifluoro acetic anhydride allowed formation of 
nitrile (3) in high yield. Treatment of 3 under reduced pressure with 2-bromoacetyl bromide 
resulted in one-pot deprotection/acylation of the amine moiety which to produce compound 4 
in reasonable yield. 
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Scheme 1: Synthesis of the cyano-pyrrolidine block. Reagents and conditions: i- Boc2O, Et3N, DCM, 23°C, 16 
hr; ii- HOBt, EDCI, NH3, THF, 23°C, 16 hr; iii- TFAA, Et3N, DCM, 0°C to 23°C, 16 hr; iv- 2-bromoacetylbromide, 
MeCN, reduced pressure, 23°C, 1 hr. 
In parallel, the isoindolinone block (Scheme 2) was prepared from commercially available 
methyl 2-bromo-5-methoxy-benzoic acid. First, cyanation was achieved by successive 
treatment with CuCN and excess of KCN to afford intermediate 5 in 86% yield. The nitrile 
moiety was reduced in presence of Raney Ni under H2 atmosphere which induced in situ 
cyclization to the isoindolinone derivative 6. The methyl ether was then cleaved in presence of 
methionine and MsOH followed by O-alkylation with tert-butyl bromoacetate to produce 
carbamate 7 in 72% yield (2 steps). Deprotonation of the lactam moiety with LiHMDS, 
followed by N-alkylation in presence of compound 4 delivered the expected target derivative 
8. Cleavage of the tert-butyl ester under mild conditions provided the corresponding carboxylic 
acid in quantitative yield. 
 
Scheme 2: Synthesis of FAP-α inhibitor free acid derivative. Reagents and conditions: i- 1) CuCN, DMF, 140°C, 
30 min, 2) KCN, H2O, 50°C, 1 hr; ii- Ni raney, H2, MeOH, 23°C, 16 hr; iii- 1) MsOH, methionine, 85°C, 16 hr, 2) 
tert-butyl bromoacetate, NaOH, TBAB, H2O, DMF/DCM, 23°C, 16 hr; iv- LiHMDS, 0°C, 18, THF, 23°C, 16 hr; 
v- SiO2, toluene, reflux, 60 min. 
The intermediate 9, presenting the FAP-α inhibitor core and a carboxyl group, was used as a 
building block for the introductions of the different functionalities considered for further 
conjugation to the hydrogel polymeric structure via amide formation. For the introduction of 
maleimide, a short linker was synthesized with an amine available for further coupling. 
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While the introduction of a tetra ethylene linker to maleimide was not met with success, a 
smaller spacer could be introduced (Scheme 3). Ethylenediamine was monoprotected in 
presence of Boc2O and the remaining free amine reacted with maleic anhydride in presence of 
triethylamine. The resulting succinic acid was treated with sodium acetate at 65°C to produce 
the maleimide core in 51% yield. Quantitative cleavage of the tert-butyl carbamate in acidic 
medium afforded the maleimide derivative 12 which was coupled with 9 in the presence of 
TBTU. 
 
Scheme 3: Synthesis of maleimide derivative and conjugation to FAP-α inhibitor. i- Boc2O, DCM, 16 hr; ii- 1) 
maleic anhydride, NEt3, ethanol, 0°C, 4 hr, 2) Na acetate, acetic anhydride, 65°C, 30 min; iii- TFA, DCM, 0°C, 
1 hr: iv- TBTU, DIPEA, 9, THF, 23°C, 16 hr 
The next derivative of FAP-α inhibitor was obtained through coupling with propargylamine to 
provide an alkyne moiety suitable for further “click reaction” with azide-containing substrates 
(Scheme 4). 
 
Scheme 4 : Synthesis of FAP-α inhibitor alkyne derivative. i- HOBt, EDCI, DIPEA, propargylamine, 23°C, 12 
hr. 
For the addition of a lipoic acid on the FAP-α inhibitor structure, N-Boc-ethylenediamine (10) 
was reacted with lipoic acid in presence of EDCI and HOBt to afford intermediate 15 in 75% 
yield. Acidic deprotection of the amine, followed by coupling with 9 provided an additional 
derivative of FAP-? presenting a lipoyl moiety for disulfide bridge cluster formation. 
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Scheme 5 : Conjugation of lipoic acid to FAP- α inhibitor. Reagents and conditions: i- Boc2O, 23°C, 12 hr; ii- 
lipoic acid, EDCI, HOBt, DIPEA, 23°C, 12 hr; iii- TFA, 0°C to 23°C 1.5 hr; iv- EDCI, HOBt, DIPEA, 9, 23°C, 
16 hr. 
Subsequent experiments revealed a very low solubility of compound 17 in aqueous solutions 
which was a major limitation for further conjugation to the hydrogel structure during MS 
formation. Therefore, a hydrophilic spacer was introduced as depicted in Scheme 6. 
Monotosylation of tetra(ethylene glycol) (TEG) was followed by the substitution of the tosyl 
group with sodium azide to afford intermediate 19 in good yield. Alternatively, TEG was 
subjected to ditosylation and substitution with sodium azide. The resulting diazide 21 was 
subjected to Staudinger reduction in biphasic medium to allow for mono-reduction and 
formation of derivative 22 in moderate yield. 
 
Scheme 6: Synthesis of linkers derived from tetra(ethylene glycol). Reagents and conditions: i- NaOH, TsCl, 0°C 
to 23°C, 1 hr; ii- NaN3, 90°C, 7 hr; iii- TsCl, Et3N, DMAP,0°C to 23°C, 16 hr; iv- NaN3, 90°C, 16 hr; v- toluene, 
aq. HCl 5%, PPh3, 0°C to 23°C, 6 hr. 
Lipoic acid was coupled to derivative 19, either after activation in the form of N-
hydroxysuccinimide (NHS) ester (23) or using HOBt/EDCI as coupling reagent.  During the 
activation step, polymerization of the lipoyl moiety in the presence of NHS led to moderate 
yield of the activated intermediate. Better yield was obtained when performing direct 
esterification of lipoic acid. The azide was then reduced in presence of triphenylphosphine and 
HCl 5% to yield compound 25 which was kept in solution to avoid polymerization. Conjugation 
to FAP-? inhibitor 9 was achieved in the presence of TBTU/HOBt to provide the targeted 
derivative 26 in 54% yield.  
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Scheme 7 : Derivatization of FAP-α inhibitor with lipoic acid using TEG spacer. Reagents and conditions: i- 
NHS, DCC, 0°C to 23°C, 12 hr; ii- 19, HOBt, EDCI, DIPEA, 23°C, 12 hr; iii- NEt3, 23°C, 12 hr; PPh3, THF, aq. 
HCl 5%, 23°C, 17 hr.; v- TBTU, HOBt, DIPEA, 9, 23°C, 16 hr. 
The investigation regarding conjugation of these FAP-α inhibitor derivatives on the structure 
of alginate-based hydrogels are not described here as they were not met with success and 
therefore discontinued. 
Curcumin derivatives
Curcumin is known to exhibit several bioactivities including anti-inflammatory properties 
which have been associated with the inhibition of various inflammation pathways such as the 
protein COX-2.207 However, its potential is hindered by low solubility in aqueous media and 
rapid metabolism resulting in limited potency and poor absorption. Nevertheless, the potential 
of curcumin has been widely recognized and several derivatives (curcuminoids) have already 
been designed to address these limitations.211–213
The initial attempts focusing on direct functionalization of the hydroxyl groups of curcumin by 
esterification were not met with success due to the formation of many side products, resulting 
in very low yield of the desired compounds. Therefore, an alternative strategy relying on the 
use of benzaldehyde derivatives such as vanillin as precursors for the formation of the 1,3-
diketone moiety of curcumin was chosen. 
The insertion of lipoyl and alkyne functions on vanillin was done by esterification on the 
hydroxyl group in presence of DMAP and DCC with lipoic acid and 4-pentynoic acid. 
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Scheme 8: Synthesis of vanillin derivatives. Reagents and conditions: i- DMAP, DCC, 23°C, 12 hr; ii- DMAP, 
DCC, 0°C to 23°C, 12 hr. 
The introduction of a hydrophilic spacer was conducted by mono-esterification of TEG with 
lipoic acid, followed by activation of the remaining alcohol as a mesylate and nucléophilic 
substitution in the presence of vanillin. Only moderate yields were achieved throughout the 
sequence but the amount of material obtained was sufficient to perform the targeted conjugation 
assays.  
  
Scheme 9: Synthesis of vanillin derivatives with TEG-L.A. linker. Reagents and conditions: i-lipoic acid, EDCI, 
DMAP, 10 hr; ii- MsCl, NEt3, 0°C to 23°C 16 hr; iii- K2CO3, KI, 90°C, 12 hr. 
Two equivalents of the vanillin derivatives were then allowed to react in a double condensation 
reaction with acetylacetone in presence of boron oxide, tributyl borate n-butylamine affording 
the corresponding curcuminoids (32, 33 and 34) in moderate yields (Scheme 10). 
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Scheme 10: Synthesis of curcuminoids. Reagents and conditions i- BO3, 2,4-pentanedione, 27 or 28 or 31, 
tributyl borate, n-butylamine, HCl (0.5 M) 80°C to 23°C, 3 hr. 
Ketoprofen derivatives
Ketoprofen is a widely used and studied nonsteroidal anti-inflammatory drug. As per curcumin, 
its anti-inflammatory propriety is associated with the inhibition of proteins COX-1 and COX-
2.204 Derivatization of ketoprofen can easily be done using the reactivity of its carboxy lic acid.  
Scheme 11: Synthesis of ketoprofen derivatives. Reagents and conditions: i- N-Boc-ethanolamine, DMAP,  DCC, 
0°C to 23°C, 12 hr; ii- TFA, 23°C, 2 hr; iii- 4-pentynoic acid, HOBt, EDCI, DIPEA, 23°C, 12 hr; iv- lipoic acid, 
HOBt, EDCI, DIPEA, 23°C, 12 hr 
  Results and Discussion 
31 
 
A small linker was introduced on the structure of ketoprofen by esterification with N-Boc-
ethanolamine (52) in presence of DCC and DMAP yielding intermediate 35. The amine was 
then deprotected in presence of trifluoroacetic acid and was allowed to react either with 
pentynoic acid or lipoic acid to afford the respective desired derivatives of ketoprofen in good 
yields (37 and 38). 
To increase the solubility of the lipoyl containing derivative, ketoprofen was first coupled to 
TEG derivative (22), followed by Staudinger reduction of the terminal azide to provide 
intermediate 40 in 39% yield. The conjugation to lipoic acid through amide bond formation 
afforded KET-TEG-LA (41) in 70% yield.  
Scheme 12: Synthesis of KET-TEG-L.A. Reagents and conditions: i- ketoprofen, EDCI, HOBt, DIPEA, 23°C, 12 
hr; ii- PPh3, H2O, 23°C, 12 hr; iii- lipoic acid, HOBt, EDCI, DIPEA, 23°C, 12 hr 
The final strategy developed for the conjugation of ketoprofen to the backbone of alginate 
involved PEGylation of of the drug for direct grafting on the hydroxyl groups of Na-alg. The 
PEGylation of ketroprofen was done starting from N-Boc mono-protected PEG2000 displaying 
either a free hydroxyl group or amine. The coupling on ketoprofen was achieved either by 
esterification on the hydroxyl or the formation of amide bond on the amine. The deprotection 
was done in acidic conditions yielding PEGylated ketoprofen with a free amine available for 
further conjugation on alginate backbone (section 3.4). 
 
Scheme 13: Synthesis of PEGylated ketoprofen derivatives. Reagents and conditions: i- ketoprofen, [DCC, 
DMAP] or [HOBt, EDCI, DIPEA] 23°C, 12 hr; ii-HCl 4N, 23°C, 2 hr. 
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3.2 ANTI-FIBROTIC ACTIVITY AND BIOCOMPATIBILITY 
The anti-fibrotic potential of the derivatives presented above was evaluated by quantification 
of different genes involved in fibrotic response, in myofibroblasts (collaboration with the group 
of Prof. Léo Bühler at the University Hospital in Geneva). Primary human fibroblasts were 
stimulated with the pro-fibrotic transforming growth factor beta 1 (TGFβ1) to differentiate into 
myofibroblasts, the effector cells of fibrosis. Only the derivatives of curcumin, ketoprofen and 
FAP-alpha inhibitor containing tetraethylene glycol (26, 34 and 41) exhibited suitable solubility 
in aqueous media to perform this assay. 
 
 
 
Figure 3.3: Structure of the drug derivatives used for the anti-fibrotic assay. 
The mRNA expression of three genes was quantified by RT-PCR and normalized with respect 
to the expression of the gene RPL0 after incubation with different concentration of the anti-
fibrotic derivatives for 24 hours. The expression of α-smooth muscle actin (α-SMA) which is a 
marker for myofibroblast highly increased in presence of TGFβ1. However, the two other 
monitored genes: alpha-1 type I collagen (COL1A1) and the matrix metalloproteinase-1 (MMP-
1) remained unchanged. 
Incubation with curcumin derivative at a concentration of 0.125, 0.25 and 0.5 mg/mL did not 
inhibit the expression of α-SMA which was only slightly reduced when incubated with a 
concentration of 1 mg/mL. COL1A1 expression was not affected but the expression of MMP1, 
which is an anti-fibrotic molecule, was notably reduced already with a concentration of 0.125 
mg/mL. Hence the anti-fibrotic effect of the curcuminoid 34 was considered as not sufficient 
to expect a significant mitigation of fibrosis when covalently linked to the hydrogel. 
On the other hand, good inhibition of α-SMA was observed when the primary human fibroblasts 
were incubated with the two other drugs derivatives. A concentration 0.5 mg/mL of compound 
41 or 0.125 mg/mL of compound 26 was sufficient to observe significant inhibition of α-SMA. 
Moreover, a concentration of 0.5 mg/mL resulted in a small increased expression of MMP-1 
associated with the inhibition of COL1A1 for both active compounds. 
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Figure 3.4: mRNA expressions of α-SMA, COL1A1& MMP1 in presence of the drug derivatives 26, 34 and 41 
(n=3). 
The biocompatibility of these derivatives with encapsulated living material was confirmed 
monitoring the functionality of rats islets co-encapsulated in Ca-alg MS with the drug 
derivatives (26, 34 and 41). Islets and Na-alg solution (1000 IEq/mL of polymer solution) were 
mixed and extruded into a gelation bath containing CaCl2. The release of insulin from the 
resulting MS was then measured in different conditions (basal, stimulated in 16.7 mM glucose 
solution and stimulated with theophylline) and normalize with respect to the total amount of 
insulin (Figure 3.5). Non-encapsulated (free) islets were monitored as reference. 
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Figure 3.5: Insulin secretion of rats islet co-encapsulated in Ca-alg MS with compounds 26, 34 and 41 (n=3). 
While when co-encapsulated with curcumin derivative (34) the functionality of the 
encapsulated islets was slightly reduced, the presence of the two other drug derivatives did not 
significantly affect islets functionality and thus their viability. 
Among the three drug derivatives tested, FAP-α inhibitor derivative 26 and ketoprofen 
derivative 41 exhibited a superior anti-inflammatory potential. Nevertheless, the experiments 
focusing on the development of grafting methods of anti-fibrotic derivatives on the polymeric 
structure of the hydrogels (section 3.4) were performed predominantly on ketoprofen and 
curcumin derivatives which have the benefit of being already approved by the FDA and require 
less synthetical steps (better overall yield) when compared to the synthesis of FAP-α inhibitors 
derivatives. 
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3.3 ALGINATE DERIVATIVES FOR THE ENGINEERING OF HYDROGELS 
As presented in section 1.4, Na-alg present excellent gelling properties in the presence of 
divalent cations and high cell compatibility. Na-alg thus appears as a perfect candidate for the 
development of new hybrid hydrogels. Hybrid hydrogels can either rise from a mixture of two 
polymers each bringing their contribution to the formation of physical and chemical interactions 
or by developing a polymeric structure possessing both properties. An interesting approach for 
the development of such system is thus the introduction of new functionalities capable to 
perform covalent crosslinking on the backbone of Na-alg. Different strategies were investigated 
to introduce new functionalities on the alginate backbone with the drive to produce one-
component hybrid hydrogel presenting the ability to form rapid ionic interactions thanks to the 
properties of alginate and additional covalent bindings to reinforce the network. For this 
purpose, most existing strategies based their approach on the derivatization of the reactive 
carboxyl groups present on alginate.92,92,93,214–220 Although this approach allows direct 
derivatization of the polymer either via esterification or amide bond formation, each component 
added at this position prevents the carboxyl group to take part in the formation of physical 
hydrogel. In this scenario, high grafting degree (GD), representing the ratio of alginate units 
functionalized, is not practicable. To avoid this downside, alternative approaches were 
developed allowing selective derivatization of the hydroxyl groups present on the backbone of 
Na-alg which are not required for the formation of physical hydrogel. Consequently, 
functionalization at this position even with high GD should not affect the formation of physical 
hydrogel.  
In our group, the first method allowing functionalization of the hydroxyl of alginate backbone 
in C3 and C2 positions of respectively the mannuronic and guluronic residues of alginate with 
the use of succinic anhydrate was developed by Dr. F. Borcard. Na-alg was first converted into 
the corresponding tetrabutylammonium (TBA) salt to improve solubilization in organic 
solvents such as DMSO for further chemical transformations (Scheme 14). The hydroxyl 
groups of Na-alg were then allowed to react with succinic anhydride forming an ester bond and 
generating an easily accessible new carboxylic moiety available for further functionalization. 
The next step was amide bond formation in the presence of amine terminated heterobifuntional-
PEG derivatives allowing the introduction of new reactive functionalities on the backbone of 
alginate available for covalent cross-binding.91 (Scheme 14 left)  
 
Scheme 14 : Strategies developed for the functionalization of the hydroxyl moieties of Na-alg  
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Due to limitations arising from this method (see chapter 3.3.1), another approach was developed 
in our group, allowing the functionalization of the hydroxyl group of alginate using CDI 
chemistry. With this approach, hydroxyl groups are activated by the formation of imidazolide-
alginate intermediate enabling the grafting of amine terminated heterobifuntional-PEG 
derivatives through a carbamate linkage.197 (Scheme 14 right) The main advantage of this 
approach lies in the formation of a carbamate bond, more robust than ester bond formed when 
succinic anhydride was used to functionalized the hydroxyl group of alginate. 
The evaluation of different hydrogels prepared by these two derivatization methods was done 
to define the optimal chemical composition in view of cell microencapsulation and potential for 
further incorporation of anti-fibrotic compounds (chapter 3.4). For this purpose, the mechanical 
properties of the resulting hydrogel along with their stability in different media were evaluated. 
The best candidates were finally evaluated for their biocompatibility in vitro and in vivo.  
 Alginate-PEG-(triazole)-SH  
The first approach focused on the introduction of thiol moieties on Na-alg for the formation of 
disulfide bridge cross-linking during MS production. The thiol moieties were introduced on the 
alginate backbone via succinic anhydride chemistry followed by amide formation in the 
presence of heterobifunctional PEG 1000 and 2000 α-amine ω-thiol (PEG1000/2000-SH) 
(Figure 3.6). Depending of the reaction conditions, chemical modifications of Na-alg result in 
partial degradation of the polysaccharide backbone which affect the viscosity of the resulting 
polymeric solutions. Therefore, the formation of well-shaped MS requires to adjust the 
concentration of precursor solutions to reach viscosity range compatible with the extrusion 
setup used for MS production (50 to 600 mPa·s). 
 
Figure 3.6 : Alg-PEG-SH derivative and hybrid hydrogel microsphere formation 
First, the alginate derivative with thiol-terminated PEG 1000 (alg-PEG1000-SH) with a GD of 
2.2% (determined by 1H NMR) was evaluated. To produce the MS, solutions of the polymer (2 
and 2.5 wt. %) in 3-(N-morpholino) propanesulfonic acid (MOPS) (10 mM, pH = 7.4) with a 
viscosity of respectively 191 and 310.5 mPa·s were extruded into a gelation bath containing 
CaCl2 (100 mM). 
Both polymer solutions led to the formation of MS which appeared to be much more opaque 
than MS formed from similar systems which do not contain a triazole moieties on the PEG 
grafting units (Figure 3.7).91 
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alg-PEG1000-SH 2 wt. % alg-PEG1000-SH 2.5 wt. % 
  
Figure 3.7: Microspheres produced from alg-PEG1000-SH (GD=2.2%) 
The size of the MS measured at day 1 and day 7 following the extrusion revealed substantial 
shrinking of the MS over one week in the gelation bath (Table 3). This suggests that the density 
of the hydrogel matrix increases after MS formation due to the slow formation of the covalent 
bonds (disulfide bridges). 
Table 3: Sizes of microspheres alg-PEG 1000 2.2% [μm] (n=10). 
  Alg-PEG 1000 2% Alg-PEG 1000 2.5% 
Day 1  943.8± 92.9 802.1 ± 164.6 
Day 7  464.8 ± 44.6 451.1 ± 68.2 
The mechanical resistance properties of the MS were evaluated with a texture analyzer (Figure 
3.9). The maximal resistance for one compression at 90% of the initial size reached 12.6 and 
15.5 [N/mm3] for the MS formed from respectively the solutions at 2 and 2.5 wt. % of the alg-
PEG1000-SH derivative. For comparison, MS formed from unmodified Na-alg (3 wt%) 
displayed a mechanical resistance of 2.4 [N/mm3]. In addition, the resistance response occurs 
early in the compression curve, which supports the idea that the hydrogel possesses a dense 
network. Repetitive compressions at 90% of the initial size (Figure 3.9 top right) shows that 
despite their high density, the MS present outstanding elastic properties. After 10 compressions, 
the shape recovery still exceeds 60%.  
The stability of the hydrogel network was assessed by qualitative analysis of the resistance of 
the ionic and covalent interactions. The MS were placed either in tris(2-carboxyethyl) 
phosphine hydrochloride (TCEP) (0.5 M) to reduce disulfide bridges or in sodium citrate 
solutions (100 mM) which have the ability to replace the calcium ions and dissolve the physical 
hydrogel. The MS formed form alg-PEG1000-SH demonstrated good stability in TCEP but 
dissolved in sodium citrate. This observation was associated with the hypothesis that the amount 
of thiol grafted on alginate (GD = 2.2%) was not sufficient to maintain the network of the MS 
without ionotropic crosslinking; thus studies with alginate derivatives presenting higher GD 
were performed. 
Alg-PEG 1000 and 2000 with respective GD of 6.7 and 5.7 % were produced. MS were formed 
from the extrusion of polymer solutions at different concentrations in MOPS (Figure 3.8). Due 
to the high viscosity and low homogenity of alg-PEG2000-SH solutions, the extrusion protocol 
resulted in non-spherical massive pieces of hydrogel instead of round-shaped hydrogel (Figure 
3.8). 
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3 wt. % 
 
Figure 3.8: Microspheres formed from alg-PEG1000-SH 6.7% (top) and alg-PEG2000-SH 5.7% (bottom)  
The opacity of both alg-PEG1000-SH and alg-PEG2000-SH MS indicate again a dense 
configuration of the hydrogel matrix. In addition, only alg-PEG2000-SH at 1.8 wt.% resulted 
in spherical shapes. The size of the MS measured 1 and 7 days after their formation (Table 4) 
were similar. The fact that these MS did not shrink (unlike to the ones with a lower GD) can be 
associated with a higher congestion of polymers within the hydrogel rising form the presence 
of additional PEGs chain due to the higher GD. 
Table 4: Microspheres size [μm] and viscosity of alg-PEG1000-SH and alg-PEG2000-SH solutions (n=10). 
  PEG 1000 
1.8 wt. % 
PEG 1000 
2 wt. % 
PEG 1000 
2.5 wt. % 
PEG 2000 
2.5 wt. % 
day 1 621.0 ± 90.8 502.3 ± 85.1 578.9 ± 71.3 563.6 ± 74.2 
day 7 618.9 ± 90.8 467.8 ± 85.1 520.3 ± 80.6 565.9 ± 103.7 
Viscosity 312.1 mPa·s 301.1 mPa·s 1839 mPa·s 959.9 mPa·s 
Interestingly, the resistance of the MS was lower than the one measured for the MS with lower 
degree of grafting. It reached 6 [N/mm3] for alg-PEG1000-SH and 4.4 [N/mm3] for alg-
PEG2000-SH. Both are still more resistant than pure Ca-alg hydrogel. 
The measure of repetitive compressions revealed also larger decrease of the relative resistance 
over the cycles of compression. The MS are weakening after several compression to stabilize 
around 40 % of their initial resistance. No notable difference was observed between the alg-
PEG1000-SH and alg-PEG2000-SH within the same concentration. Unfortunately, despite the 
higher grafting degree of heterobifunctional PEG thiol terminated, these MS were still unstable 
in sodium citrate solution. 
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Figure 3.9: Mechanical resistance of microspheres prepared from Na-alg-PEG-SH. Low grafting degree (top); 
high grafting degree (bottom). Single compression to 90% of the initial size (left); repetitive compression (right) 
(n=10). 
Finally, transplantation of MS produced from alg-PEG1000-SH (GD 6.7%; 1.8 wt.%) resulted 
in the dissolution of the hydrogel within 15 days. We hypothesized that the ester linkage used 
for the conjugation to the alginate backbone was labile in vivo. Further studies were thus 
performed on alginate derivatives presenting a carbamate linkage as grafting functionality (see 
Scheme 14, right).  
Since MS of high opacity were only observed when formed with PEGylated alginate derivatives 
displaying 1,2,3-triazole moiety, it was envisaged that this chemical motif was responsible for 
this characteristic. A potential explanation of this observation is the formation of hydrogen 
bonds with the triazole moieties as illustrated in Figure 3.10 which could explain the formation 
of an opaque hydrogel structure.221  
 
Figure 3.10: Hydrogen bonding between triazole groups present on PEG derivatives 
Although these hydrogen bonding interactions may strengthen the hydrogel network, their 
formation is not well controlled and could already occur in the polymer solution, before contact 
with the gelation bath, resulting in non-homogeneous solutions and compromising the integrity 
of the resulting MS. Moreover, these interactions also reduce the flexibility of the PEG-SH 
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extremities, which may compromise the formation of the desired disulfide bridges. Most 
importantly, the main purpose of hybrid hydrogel which is to combine ionic and covalent 
binding is lost in this case. To avoid this scenario, alginate derivatives containing linear PEGs 
(exempt of triazole) were evaluated. 
 Alg-PEG-SH and Alg-PEG-LA derivatives containing linear PEGs 
The next systems focused on alginate derivatives containing thiol or 1,2-dithiolane 
functionalities for the formation of simple disulfide bridges or disulfide clusters, respectively 
(Figure 3.11).222,223 
 
Figure 3.11: MS formation from alg-PEG-SH or alg-PEG-LA with carbamate grafting unit 
The synthesis procedure depicted in Scheme 14 allowed the formation of alg-PEG1000-SH 
with several GD: 5.90%, 7.05%, 8.07% and 12.9%. MS were produced by extrusion of a 3 wt. 
% solution of the polymers (MOPS 10 mM, pH 7.4) into a gelation bath containing CaCl2 
(Figure 3.12). As expected, the opacity which was previously observed in the presence of 
triazole moieties, was largely reduced, supporting the hypothesis that hydrogen bonding 
interactions were responsible for this opacity. 
  
  
Figure 3.12: Microspheres from alg-PEG1000-SH 5.90% (top left) 7.05% (top right), 8.07% (bottom left), 12.9% 
(bottom right) 
As the viscosity of the polymer solution decreased with the increase of the GD, we observed a 
clear dependence of the size and shape of the resulting MS on the value of the GD (Table 5).  
The shape and the size of the MS were highly dependent on the GD of the polymer. 
Interestingly, the size of these MS did not significantly evolve over 7 days in the gelation bath. 
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Table 5: Size of MS [μm] produced from alg-PEG1000-SH at day 1 and day 8 and viscosity of the polymer solution 
with respect to the degree of grafting (n=10). 
Degree of grafting 5.9 % 7.05 % 8.07 % 12.9 % 
Day 1 934.00 ± 100.81 909.00 ± 111.09 532.90 ± 55.06 491.37 ± 31.95 
Day 8 913.07 ± 105.56 940.89 ± 122.89 540.50  ± 46.42 468.47 ± 34.32 
Viscosity (3 w. %) 209.0 mPa·s 121.6 mPa·s 64.57 mPa·s 42.62 mPa·s 
A drastic decrease of mechanical resistance and shape recovery was observed with the increase 
of grafting degree (annexes Figure 6.2). This singularity has been associated with a structural 
deformation of the hydrogel network caused by the increase of PEG chains within the hydrogel.  
In light of the above, batches of alginate derivatives functionalized with thiol and lipoyl 
moieties through PEG1000 and 2000 spacers were prepared and evaluated (Table 6). The results 
concerning the synthesis and the evaluation of these polymers were published in “Synthesis 
Strategies to Extend the Variety of Alginate-Based Hybrid Hydrogels for Cell 
Microencapsulation” Biomacromolecules 2017.197  
Table 6: Characteristics of alg-PEG derivatives wt. % in MOPS 
Product Viscosity (mPa·s) Degree of grafting [%] 
Alg-PEG1000-SH (3 wt. %) 209 5.2 
Alg-PEG1000-LA (3 wt. %) 161 6.7 
Alg-PEG2000-SH (4 wt. %) 53 13.0 
Alg-PEG2000-LA (4 wt. %) 161 21.0 
Na-alg (3 wt %) 245 - 
Na-alg (4 wt %) 586 - 
In view of the viscosity of the polymer solutions, the initial concentration was adjusted to 
produce well-shaped MS (3 wt. % for alg-PEG1000 derivatives and 4 wt. % for alg-PEG2000 
derivatives). Two solutions of Na-alg (3 and 4 wt. %) were also characterized and used for the 
formation of Ca-alg MS, for comparison. Both alginate derivatives (thiol and 1,2-dithiolane) 
functionalized with the smaller PEG chain (PEG 1000) exhibited an increase of resistance when 
compressed at 90% of their initial size when compared to pure Ca-alg beads prepared from a 3 
wt. %. Resistance values of 3 and 5 N/mm3 were measured for respectively alg-PEG1000-SH 
and alg-PEG1000-LA MS while Ca-alg MS was measured at 2.4 N/mm3. However, the alginate 
derivatives functionalized with longer PEG chain (PEG 2000) exhibited less resistance 
displaying only 1.2 and 2 N/mm3 for alg-PEG2000-SH and alg-PEG2000-LA MS, which is 
below the resistance of Ca-alg MS prepared form a 4 wt. % solution (2.6 N/mm3). Nevertheless, 
shape recovery performance upon repeated compression to 90% of the initial diameter exhibited 
great improvement with respect to Ca-alg MS for both length of PEG and both functionalities 
grafted on the alginate backbone (Figure 3.13).  
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Figure 3.13: Shape recovery after10 successive compressions to 90% of the initial diameter of alg-PEG1000-
SH/LA, alg-PEG2000-SH/LA and Ca-alg MS (n=10). 
When compared to Ca-alg MS, the improvement of the shape recovery performance was more 
pronounced for thiol-containing derivatives than for 1,2-dithiolane derivatives. While the 
elasticity seemed to be slightly enhanced in the presence of the longer PEG derivatives, we 
decided to investigate alg-PEG1000-SH/LA MS for cell microencapsulation, as their 
mechanical resistance was superior. 
Mouse insulinoma cells MIN6 were used as model cells. The MIN6 cells were mixed in the 
polymers solution and extruded in a gelation bath containing CaCl2 producing monodisperse 
MS with homogenous cell distribution. The MS were kept in cell culture medium for the 
subsequent analyses. 
Alg-PEG1000-SH Alg-PEG1000-LA 
Day 3 Day 15 Day 3 Day 15 
    
Figure 3.14: Microscopy image of MIN6 cells encapsulated in alg-PEG1000-SH and alg-PEG1000-LA at day 1 
and day 15. Top panel: light microscopy, middle panel: staining of live cells with FDA (green), bottom panel: 
staining of dead cells with PI (red). “Reprinted (adapted) with permission from Synthesis Strategies to Extend the 
Variety of Alginate-Based Hybrid Hydrogels for Cell Microencapsulation. Biomacromolecules. Copyright 2017.” 
Cell viability was assessed by fluorescein diacetate and propidium iodide (FDA/PI) staining 
according to the protocol established by Jones et al.224 3, 10 and 15 days after encapsulation. 
While MIN6 cells viability at day 3 post-encapsulation was close to 100%, a decrease was 
observed after one week but stabilized around 70% viability from day 7 post-transplantation. 
This behavior is often observed for the encapsulation of cells in hydrogel matrices. After a 
decrease in viability over the first days post-encapsulation, a stabilization is then generally 
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observed as cells seem to adapt to their new environment on a longer time scale. Therefore, 
over this time period, the chemical composition of the hydrogels did not induce cytotoxicity.  
Alg-PEG1000-SH Alg-PEG1000-LA 
  
Figure 3.15: Quantification of viable and non-viable encapsulated MIN6 cells by FDI/PI staining at day 3, 10 and 
15 expressed as % of the total cell area (n = 6). “Reprinted (adapted) with permission from Synthesis Strategies 
to Extend the Variety of Alginate-Based Hybrid Hydrogels for Cell Microencapsulation. Biomacromolecules. 
Copyright 2017.” 
Interestingly, it was observed that the integrity of the MS depended on the nature of the 
chemical functionality used for covalent cross-linking. While alg-PEG1000-SH MS remained 
intact over 15 days, alg-PEG1000-LA MS showed some dissolution in vitro after 10 days 
(Figure 3.16). This was confirmed by observation under light-microscopy, which revealed out-
diffusion of cells and translucent MS. 
 
Figure 3.16: Light-microscopy image of MIN6 cells encapsulated in alg-PEG1000-LA at day 10. “Reprinted 
(adapted) with permission from Synthesis Strategies to Extend the Variety of Alginate-Based Hybrid Hydrogels 
for Cell Microencapsulation. Biomacromolecules. Copyright 2017.” 
This observation indicates that disulfide cluster cross-linking is less stable in culture conditions 
than disulfide bridge cross-linking. Even though this characteristic is disadvantageous when 
considering cell encapsulation for long term cell therapy as it could lead to an acute rejection 
to the graft and hyper-immunization of the host which could impact on his chances for a 
subsequent transplants, some applications could benefit from the dissolution of the hydrogel 
and the research toward the development of alg-PEG-LA MS was continued.  
To assess the compatibility of these polymers in vivo, cell free MS were transplanted into the 
peritoneal cavity of immune-competent mice and were retrieved after 30 days. Interestingly 
both hydrogels were stable and retrievable. Moreover, the MS exhibited no sign of fibrosis 
which indicate good biocompatibility of the material with the host. 
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Figure 3.17: Macroscopic inspection at 30 days after intraperitoneal transplantation. Some MS are indicated by 
arrows. “Reprinted (adapted) with permission from Synthesis Strategies to Extend the Variety of Alginate-Based 
Hybrid Hydrogels for Cell Microencapsulation. Biomacromolecules. Copyright 2017.” 
In summary, new alginate derivatives were obtained by functionalization of the hydroxyl 
groups of Na-alg with heterobifunctional PEG derivatives through carbamate linkage. The MS 
obtained with these derivatives presented improved mechanical properties when compared to 
pure Ca-alg MS, in particular for shape recovery following multiple compressions. The nature 
of the functionality added on the biopolymer had a direct influence on the physical properties 
of the resulting MS, and also impacts their stability in different environments. The unexpected 
stability of alg-PEG-LA MS in the in vivo experiment may be due to the environement (pH and 
solutes) of the intraperitoneal site which provides suitable conditions for the stability of 
disulfide clusters whereas the encapsulation of MIN6 cells in vitro lead to dissolution of the 
same MS. A superior elasticity was observed for the derivatives with thiol moieties than with 
1,2-dithiolane moieties. Moreover, MS displaying disulfide bridge covalent cross-linking 
present higher durability in culture medium than MS with disulfide clusters. Finally good 
biocompatibility was observed for both polymers with the encapsulated material and the host. 
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3.4  CONJUGATION OF ANTI-INFLAMMATORY COMPOUNDS TO ALGINATE-
BASED HYDROGELS 
Different strategies were considered for the grafting of the anti-inflammatory compounds on 
the backbone of alginate derivatives with respect to their structure. As exposed before, the 
strategies involving lipoyl and maleimide moieties were developed for the conjugation of the 
drugs during formation of the microspheres whereas alkyne and amine moieties were 
introduced on the drug structures in view of grafting on the alginate before hydrogel formation. 
To control the conjugation of the anti-fibrotic compounds during hydrogel formation, the 
following approaches focused on the derivatives displaying lipoyl moieties and alg-PEG-LA. 
 Conjugation through disulfide cluster formation 
As depicted in Figure 3.18, the first approach involved the combination alginate derivatives and 
drug derivatives, both functionalized with 1,2-dithiolane moieties, during MS formation.  
Taking advantage of the fluorescent properties of curcuminoids, derivative 34 (see Scheme 10) 
was selected for the conjugation assay. 
 
Figure 3.18: Conjugation of anti-inflammatory compounds displaying lipoyl moiety on the structure of hydrogel 
through formation of disulfide clusters. 
To monitor the fluorescence of the curcuminoid core, the excitation and emission spectra of 
compound 34 in MOPS buffer were recorded at different concentrations on an infinite 200 PRO 
TECAN multiplate reader. 
The excitation band of derivative 34 was remarkably wide and not very well-shaped. 
Nonetheless, the difference between the excitation and the emission bands was sufficient to 
allow monitoring by fluorescence. Moreover, optimization of the parameters allowed the 
detection of fluorescence at low concentration (around 4.56 nM) (Figure 3.19). 
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Figure 3.19: Excitation (left) and fluorescent emission (right) spectra of compound 34 for the indicated 
concentration in MOPS solution 10 mM. 
MS were prepared by extruding a solution of alg-PEG2000-LA (4 wt. % in MOPS 10 mM) 
containing derivative 34 (1 mg/mL), into a gelation bath containing CaCl2. Since dithiothreitol 
(DTT) has been reported to favor disulfide cluster formation, the same experiment was repeated 
in the presence of DTT (0.5 eq. relative to the PEG chains).  The same procedure was done in 
parallel with Na-alg (2 wt. %, without DTT). 
Alg-PEG2000-LA Alg-PEG2000-LA + DTT 
Bright field Fluorescent Bright field Fluorescent 
    
Alginate LV 
Bright field Fluorescent 
  
Figure 3.20: Microspheres prepared in presence of curcuminoid 34 under bright field and fluorescence 
microscopy: excitation CFP (436/12) emission YFP (500/20) 
The MS exhibited a good morphology and were imaged by fluorescence microscopy on a 
LEICA DMI6000 B with CFP/YFP filters corresponding to the excitation and emission bands 
previously measured (Figure 3.20). All MS samples (1 mL of MS in 3 mL of MOPS solution) 
were monitored over a period of 25 days. At specific time points, both the supernatant and the 
MS were analyzed by fluorescence microscopy (Figure 3.21). 
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Figure 3.21: Fluorescence of the supernatant (left). Fluorescence of the microspheres (right). 
As shown in Figure 3.21, the amount of curcuminoid released from alg-PEG2000-LA MS over 
the first two days was much higher than the release from Ca-alg MS. The presence of DTT 
during MS formation reduces slightly the release of compound 34, which is an indication of the 
beneficial effect of DTT regarding the formation of disulfide clusters. Nevertheless, 
experiments reproduced with unmodified curcumin (without lipoyl moieties) exhibited similar 
release behaviors which does not support evidence of formation of disulfide clusters including 
the drug (annexes Figure 6.4). Moreover the measure of fluorescence of the microsphere by 
microscopy did not show a different behavior over the timespan of the experiment. Similar 
decrease of fluorescence was observed for all the MS over 25 days. 
Since monitoring of the release of curcuminoid 34 by fluorescence did not provide direct 
evidence of the grafting of the drug on the structure of the hydrogel, subsequent investigations 
were focused on alternative strategies providing direct evidence of conjugation to the polymer 
prior the formation of the hydrogel. 
3.5 GRAFTING OF PEGYLATED KETOPROFEN ON ALGINATE 
The last conjugation approach focused on the grafting of PEGylated anti-inflammatory drugs 
(in particular, ketoprofen) to the alginate backbone prior to MS formation. Na-alg was first 
treated with formic acid to form the carboxylic acid which was then deprotonated in presence 
of TBAOH yielding TBA-alg (46). TBA-alg was then solubilized in DMSO, treated with 1,1′-
carbodiimidazole (CDI) and reacted with either PEG-ester-KET (44) or PEG-amide-KET (45) 
to yield the corresponding functionalized alginate derivatives which were then purified by 
dialysis. 
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Scheme 15: Synthesis of alginate derivative with PEGylated ketoprofen (ester/amide). Reagents and conditions: 
i- HCOOH, TBAOH; ii-1) CDI, DMSO, 30 min, 2) 44 or 45, H2O, 23°C, 2 hr. 
The grafting degrees of alg-PEG-(ester/amide)-KET (47 and 48) were evaluated by 
deconvolution method of 1H-NMR spectra. Different grafting degrees were obtained by varying 
the equivalence of the PEGylated ketoprofen. A GD of 7% was obtained with 0.1 eq. and a GD 
up to 20% with 0.2 eq. of the PEGylated drug. Direct confirmation of the covalent conjugation 
of PEGylated ketoprofen on the backbone of alginate was obtained by Diffusion Ordered 
Spectroscopy (DOSY) NMR. This method measures the relaxation time of the protons which 
is associated with the diffusion of the molecules. Since the diffusion itself depends on the sizes 
of the molecules, it is possible to differentiate the protons of molecules of different sizes. The 
characteristic peak of PEGylated ketoprofen (not grafted) and alg-PEG-KET were thus 
compared and exhibited different relaxation time confirming the covalent grafting of the 
PEGylated drug to the backbone of alginate (Figure 3.22). Moreover, DOSY experiment 
allowed the observation of the diffusion of the protons of alginate in correlation with the protons 
of PEG (annexes Figure 6.5). 
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Figure 3.22: DOSY spectra of alg-PEG-KET (green) and un-grafted H2N-PEG-KET (red). 
MS were produced with the two polymers (47 and 48) by extruding 1 mL of 3 wt % solutions 
of alg-PEG-ester-KET (7% GD) and 1.2 mL of 2.5 wt % alg-PEG-amide-KET (7% GD) in 
MOPS, into a gelation bath containing CaCl2, yielding MS with irregular morphology and wide 
size distribution (Figure 3.23). 
  
Figure 3.23: MS of alg-PEG-amide-ket (left) and alg-PEG-ester-ket (right) 
To monitor the release of ketoprofen from the hydrogel, 1 mL of MS was placed in 3 mL 
gelation bath (MOPS, 100 mM CaCl2) and aliquots of the supernatants were replaced at regular 
time points for 1 week (0.5, 1, 3, 6, 24, 48, 72, 96, 168 h). The amount of ketoprofen released 
was then quantified by LC-MS analysis of aliquots. The MS including ketoprofen through ester 
linkage (47) showed regular release of the drug during the time of the experiment whereas the 
release of ketoprofen linked through amide bonds was very slow with only traces of the drug 
detected in the supernatant over the time of the experiment (Figure 3.24). This observation 
emphasized the difference between the two types of bonds (amide and ester) used for the 
binding of ketoprofen, the ester bond being much more labile than amide in MOPS buffer. 
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Figure 3.24: Cumulative release of ketoprofen form alginate-PEG-ester-KET and alginate-PEG-amide-KET 
microspheres at physiological pH (7.4) (n=3). 
The production of MS with good morphology and size distribution was obtained by mixing Na-
alg (1.5 wt. %) with the alginate derivatives (alg-PEG-ester-KET (47) or alg-PEG-amide-KET 
(48), both at 3.5 wt. %, with a GD of 20%) with weight:weight ratio of 2:1 before extrusion. 
For the sake of simplicity, the mixture of polymers are named alg-A-KET (for Na-alg:47 / 2:1) 
and alg-B-KET (for Na-alg:48 / 2:1) from this point forward. The extrusion of both mixture of 
polymers in a gelation bath containing CaCl2 yielded monodisperse well-shaped MS. Using 
similar ratios, mouse insulinoma MIN6 cells were encapsulated by mixing the polymer 
solutions with the cells (3 x 106 cells/mL of polymer solution) before extrusion. 
The corresponding results were published in: “Antifibrotic Effect of ketoprofen-Grafted 
Alginate Microcapsules in the Transplantation of Insulin Producing Cells” Bioconjug. Chem. 
2018.225 
The MS obtained from the mixtures of polymers exhibited a good morphology with an average 
diameter between 500 and 600 μm. Homogeneous cell distribution was observed in both 
conditions. In parallel, MS from pure Na-alg were prepared with the same extrusion protocol, 
leading to similar characteristics (Figure 3.25). 
  
t [hr] STD (amide) 
[nmol] 
STD (ester) 
[nmol] 
0.5 0,0018 0,0987 
1 0,0015 0,0357 
3 0,0015 0,0048 
6 0,003 0,0072 
24 0,0024 0,0072 
48 6.00E-04 0,0024 
72 0,0027 0,0072 
94 6.00E-04 0,0144 
120 0,0015 0,0189 
144 0,0018 0,0153 
180 0,0024 0,0072 
336 0,0033 0,0159 
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Figure 3.25: Empty microspheres (top) and MIN6 cells encapsulated (bottom) in alginate (left) alg-B-KET 
(middle) and alg-A-KET (right) 
Since the drug release is known to be controlled by hydrolysis of the linkage to ketoprofen 
(ester or amide), the modification of the environment acidity is expected to influence the release 
rate of ketoprofen.210 Therefore release of ketoprofen from the empty (cell-free) MS was studied 
in MOPS solution containing CaCl2 (100 mM), adjusted to pH 3.0, 7.4, or 11. The amount of 
ketoprofen release was quantified by LC-MS analysis of the supernatant, which was withdrawn 
and replaced at regular time points over 2 weeks (0.5, 1, 3, 6, 24, 48, 72, 96, 168, and 336 h). 
At pH 7.4, MS incorporating ketoprofen through an ester linkage (alg-A-KET) showed regular 
release of the drug over 2 weeks, the covalent conjugation preventing burst effect within the 
first hours following microsphere formation. The rate of release was enhanced in basic 
conditions while acidic conditions slowed down the kinetics, which confirmed the hypothesis 
that hydrolysis controls the release rate of ketoprofene (Figure 3.26 left).210 Under the same 
conditions, MS incorporating ketoprofen with an amide linkage (alg-B-KET) released only 
traces of the drug over 2 weeks (data not shown). The MS remained stable over 2 weeks under 
all pH conditions, showing the resistance of the electrostatic network toward a large range of 
pH. Since the release of ketoprofen over 14 days, was still monitored, one can expect the drug 
to have a long term anti-inflammatory impact around the MS when transplanted.  
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Figure 3.26: (left) In vitro cumulative ketoprofen release from alg-A-KET at the indicated pH value, under slow 
mechanical agitation (n=3). (right) ketoprofen release from microencapsulated MIN6 cells in alg-A-KET 
microspheres compared to empty alg-A-KET in the same conditions (n=3). 
The release of ketoprofen in presence of MIN6 cells was then evaluated. 0.5 mL of MS 
containing cells were maintained in DMEM complete medium (1 mL) and aliquots of the 
medium (0.5 mL) were withdrawn and replaced with fresh culture medium over 2 weeks. As 
displayed on Figure 3.26 (right), the presence of MIN6 cells within the hydrogel induced faster 
release of the drug over the first 7 days. This observation might be due to the presence of 
hydrolytic enzymes of ester linkage in the encapsulated cells. Again, only traces of ketoprofen 
were observed in the supernatant of alg-B-KET MS for both conditions (data not shown). These 
data evidenced that the approach based on the covalent functionalization of hydrogel with drugs 
allows longer term release when compared to co-encapsulation strategy.194
Quantification of the anti-fibrotic effect
In order to evaluate the anti-inflammatory potential of these hydrogels at the implantation site 
and its ability to mitigate pericapsular fibrotic overgrowth in vitro, empty and MIN6 cell 
containing MS of alg-A-KET, alg-B-KET and Ca-alg were transplanted into the peritoneal 
cavity of immune-competent mice and follow-up for a period of 30 days. Even though the 
release of ketoprofen from alg-B-KET was very low in vitro, the potential of this derivative 
toward mitigation of fibrosis formation was tested in vivo since the environment might induce 
ketoprofen release. After 30 days in the peritoneal cavity of the mice, the MS were retrieved
and analyzed. Layers of fibrotic tissue of varying thickness were observed under light 
microscopy. A quantification of the cellular overgrowth revealed a lower amount of fibrotic 
tissue surrounding the empty MS containing ketoprofen; notably Alg-B-KET exhibited 
significant reduction of fibrosis (Figure 3.27). Interestingly, when observing the MS containing 
MIN6 cells, alg-A-KET exhibited significant decrease of fibrotic overgrowth compared to alg-
B-KET which can be attributed to the higher release rate observed for ester bonds (Figure 3.24). 
A nonsignificant decrease of fibrosis was observed when compared to pure Na-alg. Similar
results were observed with the analysis of MS retrieved at earlier time points (15 days) where 
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significant reduction of fibrotic tissue was observed around the ketoprofen-containing MS 
(Annexes, Figure 6.6). 
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Figure 3.27 : (left) Bright-field microscopy images of MS retrieved from the peritoneum after 30 days of 
transplantation. Cell-free MS (upper panels) and with MIN6 cells (lower panels). (Right) Pericapsular fibrotic 
overgrowth quantified using ImageJ and expressed as a percentage of fibrotic overgrowth. Fibrotic overgrowth 
for cell-free MS (white bars) and for microspheres containing MIN6 cells (striped bars). All values are means ± 
standard deviation (SD) of at least 5 MS. **p < 0.01, ***p < 0.001. “Reprinted (adapted) with permission from 
Antifibrotic Effect of Ketoprofen-Grafted Alginate Microcapsules in the Transplantation of Insulin Producing 
Cells. Bioconjug. Chem. Copyright 2018.” 
The anti-fibrotic effect of ketoprofen-containing hydrogels was further evaluated by implanting 
the three types of MS under the kidney capsule and analysing of the collagen deposition by 
microscopy using Goldner’s Trichrome coloration after 4 weeks. The histological slice revealed 
fibrotic responses around the MS with fibrous collagen deposition (green) for all types of MS 
(Figure 3.28). The amount of collagen was quantified by computational imaging (Definiens 
software). Pure alginate empty MS did not induce an important fibrotic response, exhibiting a 
minimal pericapsular collagen deposition while a slightly higher amount of fibrotic tissue was 
observed in presence of alg-A-KET and alg-B-KET. On the other hand, pure Ca-alg MS 
containing MIN6 cells induced a strong fibrotic response with high collagen deposition. This 
observation is probably associated with the diffusion of DAMPs from the encapsulated cells 
triggering an inflammatory response from the foreign host body. This effect appeared to be 
significantly reduced around both ketoprofen-containing MS. Alg-A-KET exhibited the best 
results with less collagen deposition, which might again rise from the higher release rate of 
ketoprofen observed in vitro for this type of hydrogel. 
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Figure 3.28: Quantification of collagen deposition around empty and MIN6 cells containing MS at 4 weeks after 
transplantation under the kidney capsule. (left) Sections of formalin-fixed and paraffin-embedded kidneys were 
colored with Goldner’s Trichrome. cell-free MS (upper panels) and MS with MIN6 cells (lower panels). (right) 
Quantification of collagen deposition performed with Definiens software. Cell-free MS (white bars) and with MIN6 
cells (striped bars). All values are means ± standard deviation (SD) of 5 slides per condition. **p < 0.01, ***p < 
0.001. “Reprinted (adapted) with permission from Antifibrotic Effect of Ketoprofen-Grafted Alginate 
Microcapsules in the Transplantation of Insulin Producing Cells. Bioconjug. Chem. Copyright 2018.” 
The difference of fibrotic response which was observed between the peritoneal cavity and the 
kidney capsule might be explained by the higher vascularization of the environment located 
under the kidney capsule (see section 1.7.2). The significant anti-fibrotic effect, observed under 
the kidney capsule, due to the slow release of ketoprofen at the implantation site has the 
potential to improve the functionality of microencapsulated insulin producing cells as the high 
vascularization of this site of transplantation ensures efficient delivery of oxygen and 
nutriments to the cells. 
 Biocompatibility with encapsulated material 
The viability of the encapsulated MIN6 cells was assessed at the end of both experiments 
(transplantation in the peritoneal cavity and under the kidney capsule) by insulin staining 
(Figure 3.29). Immunostaining allowed the detection of insulin in MIN6 cells for each condition 
after the transplantation, which confirmed the viability and good functionality of the 
encapsulated MIN6 cells 30 days after transplantation. 
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Figure 3.29: Insulin staining of encapsulated MIN6 cells 30 days after transplantation “Reprinted (adapted) with 
permission from Antifibrotic Effect of Ketoprofen-Grafted Alginate Microcapsules in the Transplantation of 
Insulin Producing Cells. Bioconjug. Chem. Copyright 2018.”  
These results support that the long term functionality of transplanted encapsulated living cells 
(MIN6) could be enhanced with the use of ketoprofen containing hydrogels (alg-A-KET or alg-
B-KET) by reduction of the fibrotic response when compared to pure alginate MS. 
Within the context of cell therapy toward the treatment of T1D, the encapsulation of neo-natal 
pig islets having the ability to produce insulin was explored, as this source of cells has the 
potential to overcome the limitations associated with human cells. For this purpose, neo-natal 
pig islets were encapsulated in Ca-alg and alg-A-KET (10000 IEQ / ml of polymer). The islets 
viability was monitored with FDI/PI at day 1 and day 7. As shown on Figure 3.30 the viability 
of islets was not affected by the encapsulation in Ca-alg and alg-A-KET MS.  
  
  Results and Discussion 
55 
 
Free Alginate Alg-A-KET 
 
Figure 3.30: Microscopy image of neo natal pig islets, free, encapsulated in alginate and in alg-A-KET at day 7. 
Top panel: light microscopy, middle panel: staining of live cells with FDA (green), bottom panel: staining of dead 
cells with PI (red). 
The functionality of encapsulated neo-natal pig islets was then assessed by monitoring the 
secretion of insulin in different conditions (basal, stimulated in 16.7 mM glucose and with 
theophylline), 3 and 7 days after encapsulation (Figure 3.31). Resulting data suggested that the 
secretion of insulin in response to stimulation remains regulated after encapsulation in Alg-A-
KET, as compared with free islets but the quantity of insulin released is slightly reduced. This 
behavior should be oversee when considering transplantation of MS for glucose regulation in 
diabetic models.  
Day 3 Day 7 
  
Figure 3.31: Glucose-stimulated insulin release for nonencapsulated neonatal pig islets (Free) and encapsulated 
in microspheres of alginate and alg-A-KET. Insulin release at basal glucose concentration (2.8 mM) upon 
stimulation at glucose concentration of 16.7 mM (n=3). 
Overall, hydrogels formed from a mixture of Na-alg and ketoprofen functionalized alginate 
(alg-A-KET, alg-B-KET) appear as attractive materials for the encapsulation and 
transplantation of insulin producing cells. These new systems exhibited very promising 
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properties concerning the ability to reduce the formation of pericapsular overgrowth and to 
sustain the viability/functionality of encapsulated cells. The next objective of the study was to 
evaluate their mechanical properties, since this parameter impacts the long term durability of 
the transplanted systems. 
Mechanical resistance
The resistance of alg-A-KET and alg-B-KET MS was evaluated by single and repeated 
compression to 90% of their initial diameter. In comparison with pure Ca-alg MS, the 
mechanical resistance of alg-(A/B)-KET was slightly lower exhibiting 1.48 and 1.79 [N/mm3] 
for alg-A-KET and alg-B-KET compared to 2.4 [N/mm3] for Ca-alg. The decrease of this 
mechanical properties may be attributed to the addition of extra polymer chain (PEG 2000) 
inducing steric hindrance within the hydrogel structure and not contributing to the hydrogel 
network. 
The elasticity of these MS was also slightly reduced due to the presence of PEG within the 
hydrogel structure, exhibiting a decrease of shape recovery when compared to Ca-alg MS of 
the same size (Figure 3.32).
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Figure 3.32: Shape recovery of alginate, alg-A-KET and alg-B-KET upon 10 successive compression to 90% of 
the initial diameter of the beads (n=10). 
As these new polymers presented highly promising properties regarding their biocompatibility, 
the next investigations focused on the reinforcement of the hydrogel structure in order to 
increase both the mechanical resistance and the shape recovery performance.
3.6 THREE COMPONENTS SYSTEM
In order to combine the beneficial effect of ketoprofen containing alginate derivatives with 
reinforced hydrogel structures through covalent bonds, a recently developed hybrid hydrogel 
system was considered. This system, developed in the “Group for Functionalized Biomaterials” 
at EPFL (PhD thesis work of L.Szabó), involves the combination of two alginate derivatives 
functionalized with complementary heterobifunctional PEG polymers presenting reactive thiol 
or acrylate end moieties. When the hydrogel is produced in the presence of divalent cations, the 
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spontaneous 1,4-addition of thiol to acrylate functionality allows for the formation of a network 
of strong sulfur-carbon covalent linkages in addition to the electrostatic network, with the 
potential to reinforce the MS structure. Therefore, the combination of this system with alginate 
derivative 47 was assessed by mixing alg-PEG-SH, alg-PEG-acrylate and alg-PEG-ester-
ketoprofen (47) in equivalent weight ratios (3C-alg) (Figure 3.33). 
 
Figure 3.33: Representation of three components hybrid hydrogel formation with alg-PEG-SH, alg-PEF-acrylate 
and alg-PEG-ester-ketoprofen. 
The three polymers were solubilized in MOPS buffer, alg-PEG-acrylate (3 wt. %), alg-PEG-
thiol (3 wt. %), alg-PEG-ester-ket (47) (GD 20%, 2.5 wt. %) and mixed together (wt. ratio = 
1:1:1) until homogenization of the resulting solution was achieved. The MS were then produced 
by extrusion of the solution into a gelation bath containing CaCl2 yielding large MS (above 1 
mm). Ca-alg MS of the same size were produced for comparison. 
3C-alg  Alginate 
  
Figure 3.34: (left) images of microspheres prepared from a mixture of three polymers (3C-alg), (right) alginate 
MS. 
Although, the shape and size distribution of the MS were not optimized, several parameters 
were assessed. Ketoprofen release from 3C-alg MS was evaluated from a sample containing 1 
mL of MS in 3 mL of gelation bath (MOPS, 100 mM CaCl2). Aliquots of the supernatant were 
analyzed at regular time points over 2 weeks (0.5, 1, 3, 24, 48, 96, 120, 144, 168, 336 h). The 
quantification of ketoprofen released was performed by LC-MS analysis of the aliquots (Figure 
3.35).  
  Results and Discussion 
58 
 
0 50 100 150 200 250 300 350
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
1,1
1,2
1,3
1,4
1,5
1,6
nm
ol
es
Time (hr)
 3C-alg
 
t (hr) 0.5 1 3 24 48 96 120 144 168 336 
STD (3 comp.) [nmol] 0,09 0,036 0,048 0,036 0,009 0,024 0,027 0,006 0,027 0,018 
Figure 3.35: In vitro cumulative ketoprofen release from 3C-alg in MOPS solution pH 7.4 (n=3). 
3C-alg MS displayed regular release of ketoprofen during the time of the experiment with a 
profile similar than the one observed with alg-A-KET (Figure 3.24).  
The mechanical resistance of 3C-alg MS was then evaluated at 1, 7 and 14 days after MS 
formation by single and repeated compression to 90% of their initial diameter. During this 
period, no significant size evolution was observed (Table 7). 
Table 7: Sizes of microspheres 3C-alg at day 1, 7 and 14 (n=10) 
 Alginate 3 components 
Day 1 1030±123 1175±123 
Day 7 986±118 1091±124 
Day 14 1107±108 986±146 
The resistance of 3C-alg MS to a single compression evolved from only 0.71 [N/mm3] at day 1 
(against 1.60 [N/mm3] for Ca-alg MS of the same size) to 1.17 [N/mm3] after one week 
incubation in gelation bath. Interestingly pure Ca-alg MS resistance decreased after 7 days in 
the same conditions to 1.27 [N/mm3]. After two weeks both MS kept a stable resistance (1.10 
[N/mm3] and 1.27 [N/mm3]). Similarly, the shape recovery of 3C-alg MS improved 
significantly during the first 7 days of incubation and stayed stable for the following week 
exhibiting 50 % recovery whereas Ca-alg MS displayed only 30% recovery at their best (Figure 
3.36). The improvements of the mechanical properties of this system during the first week of 
incubation can be associated with the kinetics of the formation of the covalent network, which 
require several days to be completed.  
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Figure 3.36: Shape recovery after 10 successive compressions to 90% of the initial diameter of 3C-alg and Ca-
alginate microspheres (n=10). 
These preliminary assays performed on 3C-alg MS showed that the shape recovery performance 
was significantly enhanced by the combination of a network of covalent bonds with the 
electrostatic network. In addition, sustained ketoprofen release was observed over two weeks 
as for the Na-alg/alg-A-KET hydrogel initially developed. In view of these promising results, 
the encapsulation of neo-natal pig islets in 3C-alg hydrogel systems and their transplantation 
into immune competent mice are currently investigated.  
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4 CONCLUSION 
Cell-based therapies relying on the transplantation of xenogeneic cells into semi-permeable 
hydrogels have the potential to reduce or even avoid the use of chronic immunosuppression and 
to overcome the shortage human donor materials. The success of such an approach strongly 
relies on the properties of the material used for cell encapsulation. Since the pioneering 
developments of Bisceglie27 and Chang,28  significant progress was achieved to improve the 
performance of the material used for cell encapsulation, notably with the development of 
alginate-based hydrogels which provide spontaneous MS formation in the presence of divalent 
cations and high compatibility toward human and animal cells. Still, several limitations remain, 
especially when in vivo long term durability and functionality are required. Therefore, this 
thesis project was devoted to the development of alginate-based hydrogels able to overcome 
some of the current shortcomings, including the formation of pericapsular overgrowth and the 
lack of long term durability. For this purpose, several strategies were explored for the 
conjugation of anti-inflammatory compounds to alginate-based hydrogel networks and for the 
incorporation of covalent cross-linkings to reinforce the polymeric matrix. 
First, new alginate-based hybrid hydrogels formed by functionalization on the hydroxyl group 
of Na-alg with heterobifunctional PEG derivatives containing end thiols or 1,2-dithiolane 
functionalities were characterized. The importance of the covalent link between the PEG linker 
and Na-alg was emphasized, leading to the development of a new synthetic route for the 
functionalization of the hydroxyl groups of Na-alg through carbamate bonds. The MS obtained 
from the derivatives of Na-alg containing either thiols or lipoyl moieties presented improved 
mechanical properties, in particular the shape recovery performance following multiple 
compressions, when compared with pure Ca-alg MS. It was then demonstrated that the length 
of the linear PEG linkers used for the introduction of the thiols or 1,2-dithiolanes had an 
influence on the mechanical properties of the resulting hydrogels. Shorter PEG (PEG 1000) 
linkers led to the formation of MS with higher resistance than PEG 2000. The potential of these 
hydrogels toward microencapsulation was demonstrated with the encapsulation of MIN6 cells 
which exhibited good viability in both MS types over two weeks. Good bioacceptance of the 
cell-free MS was also observed in preliminary in vivo studies. The so-developed hydrogels 
present several advantageous features for biomedical applications: i) the MS are obtained from 
a one-component polymer system containing the functionalities for both electrostatic and 
covalent cross-linking; ii) the conditions for MS production avoid the use of additional chemical 
cross-linkers, as the convalent bonds are spontaneously formed in aqueous medium, 
concomitantly to the formation of the electrostatic interactions. The functionalization strategy 
allows for the introduction of immune response modulators, which was explored in the second 
part of this project.    
Three anti-fibrotic compounds were selected for their protential conjugation to the hydrogel 
network through covalent crosslinking (Curcumin, Ketoprofen and FAP-α inhibitor) to improve 
the biocompatibility of the MS by mitigation of the fibrotic response. In a first attempt, it was 
envisaged to take advantage of the chemical functionalities already present on functionalized 
alginate derivatives such as thiol and lipoyl moieties to bind the anti-inflammatory compounds 
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during MS production. Since the covalent conjugation and further release of anti-inflammatory 
compounds could not be evidenced through this approach, we turned to an alternative strategy 
relying on the direct conjugation of the anti-fibrotic compounds on the backbone of Na-alg prior 
to MS formation. For this approach, ketoprofen was PEGylated with either an ester or amide 
linkage. The resulting PEGylated drugs were grafted on the hydroxyl groups of Na-alg, 
resulting in alg-A-KET and alg-B-KET whose chemical structures were confirmed by DOSY-
NMR. In combination with Na-alg, these polymers led to the formation of functionalized MS 
which were assessed for drug release, encapsulation of insulin producing cells and 
transplantation in immune competent mice. In particular, their ability to mitigate pericapsular 
fibrotic overgrowth was analyzed, in comparison with pure alginate-derived MS. Although only 
traces of ketoprofen were released from the hydrogel containing an amide linkage to ketoprofen, 
regular and sustained drug release was observed up to 14 days from the hydrogel containing an 
ester bond to ketoprofen. In presence of MIN6 cells, the release was accelerated during the first 
days following the encapsulation, which probably resulted from the action of cell esterase. The 
potential to inhibit the PFO was evaluated with the transplantation of both type of MS in 
immune-competent mice. For cell-free MS, a reduction of the pericapsular overgrowth was 
observed around the functionalized hydrogels when compared to pure alginate 30 days after 
transplantation. Moreover, the high increase of fibrotic tissue formation observed in the 
transplantation of encapsulated MIN6 cells in pure Ca-alg MS was significantly reduced around 
functionalized MS, in the same condition. 
Hence, mitigation of PFO around cell-containing MS was achieved by controlled release of 
ketoprofen from the hydrogel matrix, resulting from the in vivo hydrolysis of the chemical bond 
used to conjugate the drug to PEG spacer. One of the main advantage of this approach is the 
long-term release providing the active compound over several days at the transplantation site 
which is highly advantageous for the mitigation PFO whereas simple co-encapsulation of anti-
inflammatory compounds results in burst release of the drugs within the first hours limiting 
critically the duration of the anti-fibrotic action of the drugs. Furthermore, a variety of small 
molecular immune response modulators could be used with this strategy, including the 
possibility to combine several drugs for synergistic effects.  
Finally, in order to combine the anti-fibrotic effect of alg-PEG-KET derivatives with a 
reinforced hydrogel matrix, the combination of alg-PEG-SH and alg-PEG-acrylate with alg-A-
KET (3C-alg) was explored. Preliminary results showed that the release of ketoprofen was still 
sustained from this hydrogel including new functionalities in its structure. In addition, the 
mechanical properties of the MS were strengthened after an incubation time confirming the late 
formation of covalent bonds between acrylate and thiols. 
These promising results will be the basis for further investigations, including: 
- The development of other complementary alg-PEG derivatives for the production of 
hydrogel microspheres simultaneously stabilized by both ionotropic gelation and 
covalent cross-linking (thiol-maleimide and azide-alkyne combinations) 
- The covalent conjugation of other immune response modulators on the hydrogel 
polymeric materials for sustained controlled delivery at the transplantation site 
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- The standardization of xenogeneic cells source for microencapsulation, including the 
stimulation of their secretion capacity by co-culture systems 
- The validation of the capacity of the cell-transplant products in vivo with a longer 
follow-up period (6 months to one year)  
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5 EXPERIMENTAL SECTION 
5.1 MATERIALS AND METHODS 
Na-alg Kelton HV (lot no. 61650A, [η] = 813 mL g−1 in 0.1 M NaCl, T = 25 °C, G/M = 0.6) 
was obtained from Kelco (San Diego, USA, CA). Linear PEG (TBOC-PEG2000-OH and 
TBOC-PEG2000-NH2) were obtained from Jenkem Technology (Beijin, China). Other 
commercial reagents (Fluka, Sigma, Switzerland; TCI Europe, Zwijndrecht, Belgium) were 
used without further purification. Unless special mention, all reactions were performed under 
argon atmosphere (1 atm). Anhydrous solvents were obtained by filtration (Puresolv MD 5, 
Innovative Technology, Oldham, UK). Glassware was dried for 12 h in an oven (T > 100 °C) 
or under vacuum with a heat gun (T > 200 °C). Reactions were monitored by TLC (Merck silica 
gel 60F254 plates, Merck, Darmstadt, Germany). Detection was performed by UV light, 
KMnO4, Ninhydrin or I2. Purifications were performed by flash chromatography on silica gel 
(Merck N° 9385 silica gel 60, 240-400 mesh). NMR spectra were recorded on Bruker Avance 
III-400, Bruker Avance-400 or Bruker DRX-400 spectrometers at room temperature (rt) (400 
MHz) (Bruker, Billerica, MA, USA). 1H frequency is at 400.13 MHz, 13C frequency is at 100.62 
MHz. Chemical shifts are expressed in parts per million (ppm) and coupling constants (J) in 
hertz (Hz). Solvents used for NMR spectroscopy were deuterated chloroform (CDCl3, Acros), 
deuterated methanol (CD3OD, Acros) and deuterated water (D2O). Mass spectra were obtained 
on a Nermag R-10-10C spectrometer with chemical ionization (NH3) and mode m/z (amu) [% 
relative base peak (100%)] (Nermag, Santa Clara, CA, USA). IR spectra were recorded on a 
Jasco FT/IR-4100 spectrometer outfitted with a PIKE technology MIRacleTM ATR accessory 
as neat films compressed onto a Zinc Selenide window. The spectra are reported in cm-1. Mass 
spectra were obtained by using a Waters ACQUITY H-class UPLC/MS ACQ-SQD by electron 
ionization (EI positive and negative) or a Finnigan TSQ7000 by electrospray ionization (ESI+). 
The accurate masses were measured by ESI-TOF using a QTOF Ultima from Waters. 
Quantitative MS analyses were performed on and Agilent Accurate Mass Q-TOF LCMS mass 
spectrometer coupled to an Agilent 1290 series UHPLC system (Agilent Technologies, USA). 
The separation was achieved using an ACQUITY UPLC® BEH C18 1.7μm column, 2.1 mm x 
50 mm (Waters) heated at 30°C. 
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5.2  TETRA(ETHYLENE GLYCOL) DERIVATIVES 
Scheme 16: Synthesis of linkers derived from tetra(ethylene glycol). Reagents and conditions: i- NaOH, TsCl, 
0°C to 23°C, 1 hr; ii- NaN3, 90°C, 7 hr; iii- TsCl, Et3N, DMAP,0°C to 23°C, 16 hr; iv- NaN3, 90°C, 16 hr; v- HCl 
5%, PPh3,0°C to 23°C 6 hr. 
Tetraethylene glycol p-toluenesulfonate (18) 
 
The following protocol was adapted from the procedure reported by Ligeour et al.226 
Tetra(ethylene glycol) (43.3 mL, 250 mmol, 10 equiv) was dissolved in THF (10 mL) and the 
solution was cooled to 0°C. Aq. NaOH 50% (4.8 mL, 60 mmol, 2.4 equiv) was added and a 
solution of TsCl (4.77 g, 25 mmol, 1 equiv) in THF (15 mL) was introduced dropwise. The 
reaction mixture was stirred for 1 hr at 23°C. The solvent was then removed in vacuo and the 
residue was dissolved in chloroform. The solution was washed with water (3 x 30 mL), brine 
(30 mL), dried over MgSO4 and concentrated in vacuo. The product was purified by FCC 
(EtOAc) to afford compound 1 as a colorless oil (6.100 g, 17.51 mmol, 70%). The analytical 
data were in agreement with literature report.  
1H NMR (400 MHz, CDCl3) δ 7.76 (dt, J = 8.5, 1.1 Hz, 2H, CHar), 7.31 (d, J = 8.1 Hz, 2H, 
CHar), 4.13 (tt, J = 4.8, 3.9, 1.1 Hz, 2H, CH2-OTs), 3.74 – 3.51 (m, 14H, CH2-O), 2.41 (s, 3H, 
CH3). 
MS (ESI/QTOF) m/z: [M+Na]+ Calcd for C15H24NaO7S+ 371.11; Found 371.33  
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1H NMR spectrum of 18 
 
Tetraethylene glycol azide (19)  
 
The following protocol was adapted from the procedure reported by Tellers et al.227 Sodium 
azide (0.51 g, 7.85 mmol, 1.2 equiv) was added to a solution of TEG monotosyl (18) (2.28 g, 
6.54 mmol, 1 equiv) in DMF (10mL). The reaction mixture was stirred for 7 hr at 90°C. The 
solvent was removed in vacuo and the residue was dissolved in water (15 mL). The solution 
was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine 
(10 mL), dried over MgSO4 and concentrated in vacuo to afford TEG mono-azide (19) as a 
colorless oil (0.940 g, 4.29 mmol, 66%). The analytical data were in agreement with literature 
report. 
1H NMR (400 MHz, CDCl3) δ 3.72 – 3.59 (m, 12H, CH2-O), 3.56 (dd, J = 5.4, 3.7 Hz, 2H, 
CH2-OH), 3.35 (t, J = 5.0 Hz, 2H, CH2-N3). 
MS (ESI/QTOF) m/z: [M+Na]+ Calcd for C8H17N3NaO4+ 242.11; Found 242.25 
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1H NMR spectrum of 19 
 
Tetraethylene glycol di(p-toluenesulfonate) (20) 
 
The following protocol was adapted from the procedure reported by Goswani et al.228 
Tetra(ethylene glycol) (8.9 mL, 51.5 mmol, 1 equiv) was dissolved in DCM (100 mL) under 
neutral atmosphere (Ar). The solution was cooled to 0°C and TsCl (29.4 g, 154 mmol, 3 equiv), 
Et3N (21.5 mL, 154 mmol, 3 equiv) and DMAP (315 mg, 2.57 mmol, 0.05 equiv) were 
successively added. The reaction mixture was stirred for 16 hr at 23°C. The reaction mixture 
was washed with water (3 x 50 mL). The organic phase was dried over MgSO4 and concentrated 
in vacuo. The product was purified by FCC (PE:EtOAc = 7:3) to afford TEG ditosyl (20) as a 
yellowish oil (22.38 g, 44.53 mmol, 86%). The analytical data were in agreement with literature 
report. 
1H NMR (400 MHz, CDCl3) δ 7.83 – 7.77 (m, 4H, CHar), 7.35 (d, J = 8.2 Hz, 4H, CHar), 4.19 
– 4.13 (m, 4H, 2 x TsO-CH2), 3.76 – 3.65 (m, 4H, 2 x TsO-CH2-CH2), 3.57 (q, J = 1.3 Hz, 8H, 
CH2-O), 2.45 (s, 6H, 2 x CH3). 
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1H NMR spectrum of compound 20 
 
Tetraethylene glycol di(azide) (21) 
 
The following protocol was adapted from the procedure reported by Goswami et al.228 TEG 
ditosyl (20) (22.4 g, 44.5 mmol, 1 equiv) was dissolved in DMF (50 mL) and NaN3 (6.95 g, 
107 mmol, 2.4 equiv) was added. The reaction mixture was stirred for 16 hr at 90°C. The solvent 
was removed in vacuo and the residue was dissolved in water (30 mL). The solution was 
extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (2 x 
20 mL), dried over MgSO4 and concentrated in vacuo to afford TEG diazide (21) as a yellowish 
oil (37.34 mmol, 9.12 g, 84%). The analytical data were in agreement with literature report. 
1H NMR (400 MHz, CDCl3) δ 3.63 (td, J = 8.3, 7.2, 3.4 Hz, 12H, CH2-O), 3.34 (dq, J = 10.7, 
5.5 Hz, 4H, 2 x CH2-N3). 
IR (cm-1): 2871, 2104, 1294, 1125. 
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1H NMR spectrum of compound 21 
 
1-Amino, 11-azido-3,6,9-trioxaundecane (22)  
 
The following protocol was adapted from the procedure reported by Goswami et al.228 TEG 
diazide (21) (9.12 g, 37.3 mmol, 1 equiv) was dissolved in toluene (45 mL) and aq. HCl 5% 
(45 mL) was added. The solution was cooled to 0°C and PPh3 (9.79 g, 37.3 mmol, 1 equiv) was 
added portion wise. The reaction mixture was then allowed to warm up to 23°C and stirred for 
6 hr. The aqueous phase was recovered and co-evaporated with toluene under vacuo to afford 
amine-TEG-azide (22) as an opaque oil (4.55 g, 20.85 mmol, 56%). The analytical data were 
in agreement with literature report. 
1H NMR (400 MHz, CDCl3) δ 8.27 (s, 2H, NH2), 3.83 (t, J = 5.1 Hz, 2H, CH2-NH2), 3.75 – 
3.63 (m, 10H, CH2-O), 3.44 (t, J = 5.0 Hz, 2H, CH2-CH2-N3), 3.23 (t, J = 5.0 Hz, 2H, CH2-N3).  
MS (ESI/QTOF) m/z: [M+H]+ Calcd for C8H19N4O3+ 219.14; Found 219.24 
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1H NMR spectrum of 22 
 
 
5.3 DERIVATIZATION OF LIPOIC ACID WITH TETRA(ETHYLENE GLYCOL) 
DERIVATIVES 
 
Scheme 17: Derivatization of lipoic acid with tetra(ethylene glycol) derivatives. Reagents and conditions: i- NHS, 
DCC, 0°C to 23°C, 12 hr; ii- HOBt, EDCI, DIPEA, 23°C, 12 hr, iii- NEt3, 23°C, 12 hr, iv- PPh3, THF, aq. HCl 
5%, 23°C, 17 hr.  
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Lipoic Acid NHS-ester (23) 
 
The following protocol was adapted from the procedure reported by Benito‐Alifonso David et 
al.229 To a stirred solution of lipoic acid (15 g, 72.7 mmol, 1 equiv) in THF (60 mL) was added 
N-hydroxysuccinimide (10 g, 87.2 mmol, 1.2 equiv) portion wise. The solution was cooled to 
4°C and a solution of DCC (18 g, 87.2 mmol, 1.2 equiv) in THF (25 mL) was added dropwise. 
The reaction mixture was allowed to warm up to 23°C and stirred for 12 hr. The solution was 
filtered through a pad of celite and solvent was removed in vacuo. The product was purified by 
FCC (EtOAc:PE = 1:2) to afford 23 as a yellow solid (9.14 g, 30.12 mmol, 41%). The analytical 
data were in agreement with literature report. 
1H NMR (400 MHz, CDCl3) δ 3.58 (dq, J = 8.2, 6.4 Hz, 1H, CH-S), 3.24 – 3.07 (m, 2H, 
CH2-S), 2.91 – 2.78 (m, 4H, 2 x CH2 (15, 16)), 2.63 (t, J = 7.4 Hz, 2H, CH2COO), 2.47 (dtd, J 
= 13.1, 6.6, 5.4 Hz, 1H, CH2 (3’)), 1.92 (dq, J = 12.6, 6.9 Hz, 1H, CH2 (3’’)), 1.84 – 1.65 (m, 
4H, 2 x CH2 (6, 8)), 1.64 – 1.51 (m, 2H, CH2, (7)). 
1H NMR spectrum of 23 
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Lipoic acid-TEG-azide (24) 
 
The following molecule was obtained through two different protocols. The former is adapted 
from the procedure reported by Benito‐Alifonso David et al.229 Amine-TEG-azide (22) (200 
mg, 785 μmol, 1 equiv) was dissolved in DMF (5 mL). Lipoic acid NHS-ester (23) (476 mg, 
1.57 mmoles, 2 equiv) and NEt3 (120 μL, 864 μmol, 1.1 equiv) were added were added and the 
solution was stirred at 23°C for 12 hr. The solvent was removed in vacuo and the residue was 
dissolved in DCM (10 mL) and washed with aq. sat. NH4Cl (3 x 10 mL) brine (10 mL). The 
organic phase was reduced in vacuo and the product was purified by FCC (DCM:MeOH = 1:0 
? 8:1) to afford 24 as a yellow oil (268 mg, 0.66, mmol, 84%).The analytical data were in 
agreement with literature report. 
Lipoic acid (227 mg, 1.1 mmol, 1.2 equiv) was dissolved in DMF (3 mL) and EDCI (202 mg, 
1.05 mmol, 1.15 equiv), HOBt (281 mg, 1.83 mmol, 2 equiv) and DIPEA (454 μL, 2.75 mmol, 
3 equiv) were added to the solution. The reaction mixture was stirred for 10 min before the 
addition of a solution of amine-TEG-azide (5) (233 mg, 916 μmol, 1 equiv) in DMF (3 mL). 
The solution was stirred for 12 hr at 23°C. DMF was removed in vacuo. The residue was 
dissolved in water (7 mL) and extracted with DCM (3 x 5 mL). The combined organic phases 
were washed with sat. aq. NaHCO3 (3 x 5 mL) and brine (5 mL). The solvent was removed in 
vacuo to afford 7 as a yellow oil (349 mg, 0.86 mmol, 94%).  
1H NMR (400 MHz, CDCl3) δ 6.06 (d, J = 6.5 Hz, 1H, NH), 3.87 – 3.37 (m, 17H, CH2-O + 
CH-S), 3.28 – 3.09 (m, 2H, CH2 16), 2.48 (dq, J = 12.4, 6.3 Hz, 1H, 15’), 2.21 (t, J = 7.5 Hz, 
2H, CH2-CO), 1.93 (dd, J = 13.0, 6.7 Hz, 1H, 15’’), 1.70 (tdd, J = 15.3, 9.2, 5.2 Hz, 4H,2 x CH2 
11, 13), 1.50 (ddd, J = 14.3, 8.2, 5.6 Hz, 2H, CH2 12). 
13C NMR (101 MHz, CDCl3) δ 172.83 (CO), 70.86 (CH2 TEG), 70.77 (CH2 TEG), 70.71 (CH2 
TEG), 70.40 (CH2 TEG), 70.21 (CH2 TEG), 70.04 (CH2 TEG), 56.56 (CH-S), 50.82 (CH2 
TEG), 40.36 (15), 39.29 (CH2 TEG), 38.60 (16), 36.53 (CH2-CO), 34.79 (13), 29.05 (12), 25.50 
(11). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C16H30N4NaO4S2+ 429.1601; Found 429.1606 
IR (cm-1): 3283, 2921, 2872, 2098, 1649, 1537, 1288, 1100 
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1H NMR spectrum of 24 
13C NMR spectrum of 24 
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Lipoic acid-TEG-amine (25) 
 
The following protocol was adapted from the procedure reported by from Yuan Guo et al230. 
To a solution of azide-TEG-LA (24) (210 mg, 517 μmol, 1 equiv) in THF (15 mL) was added 
PPh3 (190 mg, 724 μmol, 1.4 equiv). The reaction mixture was stirred for 1 hr at 23°C before 
the addition of aq. HCl 5% (1 mL). The reaction mixture was stirred for 16 hr at 23°C. THF 
was then removed in vacuo and water (8 mL) was added to the aqueous phase. The aqueous 
phase was then washed with a mixture EtOAc:PE = 1:1 (3 x 5 mL) and co-evaporated with 
toluene in vacuo to afford 25 as a yellow oil which was used without further purification. The 
analytical data were in agreement with literature report. 
HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C16H33N2O4S2+ 381.1876; Found 381.1877. 
Etylenediamine derivatizazion 
 
Scheme 18: Derivatization of lipoic acid with ethylene diamine. Reagents and conditions: i- Boc2O, 23°C, 12 hr; 
ii- lipoic acid, EDCI, HOBt, DIPEA, 23°C, 12 hr; iii- TFA, 0°C to 23°C 1.5 hr. 
tert-Butyl 2-hydroxyethylcarbamate (52) 
 
The following protocol was adapted from the procedure reported by Becht et al.231 To a solution 
of ethanolamine (2.98 g, 16.4 mmol, 1.2 equiv) in anhydrous DCM (16 mL) was added 
dropwise a solution of Boc2O (2.92 mL, 13.6 mmol, 1 equiv) in anhydrous DCM (5 mL). The 
solution was stirred for 12 hr at 23°C. The reaction mixture was washed with sat. aq. NaHCO3 
(3 x 15 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The product 
was purified by FCC (EtOAc:PE = 1:1) to afford 52 as a transparent oil (1.86 g, 11.54 mmol, 
85%). The analytical data were in agreement with literature report. 
1H NMR (400 MHz, CDCl3) δ 5.11 (s, 1H, NH), 3.66 (t, J = 5.1 Hz, 2H, CH2-O), 3.25 (t, J = 
5.1 Hz, 2H, CH2-N), 2.97 (s, 1H, OH), 1.42 (s, 9H, 3 x CH3). 
MS (ESI/QTOF) m/z: [M+Na]+ Calcd for C8H19N4O3+ 184.09; Found 184.12 
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1H NMR spectrum of 52 
 
N-Boc-ethylenediamine (10) 
 
The following protocol was adapted from the procedure reported by Liu et al.5.A solution of 
Boc2O (7.26 g, 33.28 mmol, 1 equiv) in DCM (300 mL) was added dropwise to a solution of 
ethylenediamine (12 g, 199.70 mmol, 6 equiv) in DCM (100 mL). The solution was stirred for 
12h at 23°C. The volume of the solution was reduced to 20 mL. The mixture was then with sat. 
aq. Na2CO3 (2 x 100 mL). The organic layer was dried over MgSO4 and concentrated in vacuo 
to afford N-Boc-Ethylenediamine (10) as a colorless oil (5.23 g, 32.64 mmol, 98%). 
1H NMR (400 MHz, CDCl3) δ 5.05 (s, 1H, NH), 3.11 (q, J = 6.0 Hz, 2H, CH2-NHBoc), 2.74 
(t, J = 5.9 
Hz, 2H, CH2-NH2), 1.39 (s, 9H, 3 x CH3). 
MS (ESI/QTOF) m/z: [M+H]+ Calcd for C7H17N2O2+ 161.13; Found 161.07 
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1H NMR spectrum of 10 
 
Lipoic acid-N-Boc-ethylenediamine (15) 
 
EDCI (869 mg, 4.54 mmoles, 1.15 equiv), HOBt (964 mg, 7.89 mmoles, 2 equiv) and DIPEA 
(1.96 mL, 11.8 mmoles, 3 equiv) were added to a solution of lipoic acid (814 mg, 3.94 mmoles, 
1 equiv) in DMF (10 mL). The reaction mixture was stirred for 15 min under argon atm and N-
Boc-ethylenediamine (10) (758 mg, 4.73 mmoles, 1.2 equiv) in DMF (4 mL) was added. The 
mixture was stirred for 12 hr at 23°C. DMF was then removed in vacuo and the residue was 
purified by FCC (EtOAc:PE = 8:2) to afford 15 as a yellow oil (1.02 g, 2.94 mmol, 74%). 
1H NMR (400 MHz, CDCl3) δ 3.57 (dq, J = 8.7, 6.4 Hz, 1H, CH-S), 3.35 (td, J = 6.4, 5.5, 4.3 
Hz, 2H, CH2-NHBoc), 3.27 (d, J = 6.1 Hz, 2H, CH2-NH), 3.23 – 3.06 (m, 2H, CH2-S), 2.46 
(dtd, J = 10.2, 6.6, 5.4 Hz, 1H, (13’)), 2.19 (t, J = 7.3 Hz, 2H, CH2 (6)), 1.98 – 1.84 (m, 1H, 
(13’’)), 1.68 (dtd, J = 15.1, 7.9, 7.2, 4.9 Hz, 4H, 2 x CH2 (8, 10)), 1.44 (s, 11H, CH2 (9) + 3 x 
CH3). 
13C NMR (101 MHz, CDCl3) δ 173.53 (CO), 56.39 (CHS), 40.24 (CH2 x 2 + CH2 (12)), 38.48 
(CH2S), 36.40 (6), 34.62 (8), 28.37 (3 x CH3 Boc), 25.34 (10). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C15H28N2NaO3S2+ 371.1434; Found 371.1431 
IR (cm-1): 3333, 2930, 1701, 1644, 1518, 1254, 1165 
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1H NMR spectrum of 15 
13C NMR spectrum of 15 
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Lipoic acid-ethylenediamine (16) 
 
Product 15 (363 mg, 1.04 mmol, 1 equiv) was dissolved in DCM (5 mL) and the solution was 
cooled to 0°C. TFA (1.24 mL, 16.6 mmol, 16 equiv) was added dropwise and the reaction 
mixture was allowed to warm up to 23°C for 1.5 hr. The volatiles were removed in vacuo and 
product 16 was directly engaged in the next step. 
N-Boc-(2-Aminoethyl)maleimide (11) 
 
The following protocol was adapted from the procedure reported by Liu et al.5 A solution of 
maleic anhydride (2.67 g, 27.20 mmol, 1 equiv) in ethanol (200 mL) was added dropwise to a 
solution of N-Boc-ethylenediamine (10) (5.23 g, 32.64 mmol, 1.2 equiv) and triethylamine 
(4.55 mL, 32.64 mmol, 1.2 equiv) in ethanol (230 mL), cooled to 0°C. The reaction mixture 
was stirred for 4 hr. The solvent was removed in vacuo and the residue was dissolved in acetic 
anhydride (55 mL). Sodium acetate (2.23 g, 27.20 mmol, 1 equiv) was added and the solution 
was stirred at 60-70°C for 30 min. The reaction mixture was cooled to 23°C and water (50 mL) 
was added. The solution was extracted with EtOAc (3 x 60 mL). The combined organic layers 
were washed with sat. aq. NaHCO3 (2 x 25 mL), dried over MgSO4 and concentrated in vacuo. 
The product was purified by FCC (EtOAc:PE = 1:3) to afford 11 as a white solid (4.03 g, 16.79 
mmol, 51%). The analytical data were in agreement with literature report. 
1H NMR (400 MHz, CDCl3) δ 6.71 (s, 2H, CH-CH), 4.71 (s, 1H, NH), 3.66 (m, 2H, CH2-N), 
3.33 (m, 2H, CH2-NH), 1.40 (s, 9H, 3 x CH3). 
MS (ESI/QTOF) m/z: [M+K]+ Calcd for C11H16KN2O4+ 279.07; Found 279.26 
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1H NMR spectrum of 11 
 
N-(2-Aminoethyl) maleimide Trifluoroacetate Salt (12) 
 
The following protocol was adapted from the procedure reported by Liu et al.5 To a solution of 
11 (4.03 g, 16.79 mmol, 1 equiv) in DCM (40 mL), cooled to 0°C, was added trifluoroacetic 
acid (20.15 mL) and the reaction mixture was stirred for 1 hr. DCM was evaporated in vacuo 
and the residue was dissolved in methanol (12 mL). Precipitation with diethyl ether (200 mL), 
followed by filtration afforded 12 as a white solid (3.956 g, 16.54 mmol, quant.). The analytical 
data were in agreement with literature report.  
1H NMR (400 MHz, D2O) δ 6.93 (s, 2H, CH=CH), 3.87 (t, J = 5.8 Hz, 2H, CH2), 3.26 (t, J = 
5.8 Hz, 2H, CH2). 
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1H NMR spectrum of 12 
 
5.4 FAP-ALPHA INHIBITOR BLOCK 1 
The synthesis of FAP-α inhibitor backbone was performed following the procedure described 
in Passemard. S doctoral thesis199 with minor modifications. 
 
Scheme 19: Synthesis of the cyano-pyrrolidine block. Reagents and conditions. i- Boc2O, Et3N, DCM, 23°C, 16 
hr; ii- HOBt, EDCI, NH3, THF, 23°C, 16 hr; iii- TFAA, Et3N, DCM, 0°C to 23°C, 16 hr; iv- 2-bromoacetylbromide, 
MeCN, reduced pressure, 23°C, 1 hr 
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(S)-tert-Butyl 2-carbamoylpyrrolidine-1-carboxylate (1) 
 
To a cooled suspension (0°C) of L-proline (10 g, 86.86mmol, 1 equiv) in chloroform (330 mL), 
Boc2O (19.90 mL, 91.20 mmol, 1.05 equiv) and NEt3 (15.75mL, 112.92 mmol, 1.3 equiv) were 
added dropwise. The reaction mixture was stirred for 16 hr at 23°C. The solution was washed 
with aq. HCl 1N (3 x 100 mL). The organic phase was dried over MgSO4 and evaporated in 
vacuo to afford 1 as a white solid (18.2 g, 84.55 mmol, 97%). The product was used for the 
next step without purification. 
(S)-tert-Butyl 2-carbamoylpyrrolidine-1-carboxylate (2) 
 
To a solution of 1 (15 g, 69.69 mmol, 1 equiv) in THF (500 mL) were added HOBt (10.73 g, 
69.69 mmol, 1 equiv) and EDCI (15.36 g, 80.14 mmol, 1.15 equiv). The solution was stirred at 
23°C for 30 min and aq. ammonia 25 % (5.72 mL, 76.65 mmol, 1.1 equiv) was added dropwise. 
The mixture was stirred for an additional 16 hr at 23°C. The volatiles were evaporated in vacuo 
and the residue was dissolved in EtOAc (200 mL). The solution was washed with sat. aq. 
NaHCO3 (200 mL), brine (200 mL), dried over MgSO4 and evaporated in vacuo to afford 2 as 
a yellowish oil (9.2 g, 42.94 mmol, 61%). 
1H NMR (400 MHz, CDCl3) δ 5- 4.62 (s, 1H, COOH), 4.40 - 4.17 (m, 1H, N-CH), 3.65 - 3.23 
(m, 2H, N-CH2), 2.14-1.80 (m, 4H, CH2-CH2), 1.56 – 1.33 (m, 9H, 3 x CH3). 
ESI-MS m/z: [M + Na]+ Calcd for C10H18N2NaO3+ 237.12; Found 237.08 
(S)-tert-Butyl 2-cyanopyrrolidine-1-carboxylate (3) 
 
To a cooled suspension (0°C) of 2 (9 g, 42.00 mmol, 1 equiv) and NEt3 (25.52 mL, 189.02mmol, 
4.5 equiv) in DCM (200 mL), was added TFAA (11.68 mL, 84.01, 2 equiv) dropwise. The 
solution was allowed to warm up to 23°C and was stirred for 12 hr. The reaction mixture was 
washed with water (100 mL), aq. 0.5 M HCl (100 mL) and sat. aq. NaHCO3 (100 mL). The 
organic phase was dried over MgSO4 and evaporated in vacuo to afford 3 as a yellowish oil 
(38.22 mmol, 7.5 g, 91 %). 
1H NMR (400MHz, CDCl3) δ 4.58 – 4.40 (m, 1H, N-CH), 3.61 – 3.14 (m, 2H, N-CH2), 2.30–
1.94 (m, 4H, CH2-CH2), 1.48 (m, 9H, 3 x CH3). 
ESI-MS m/z: [M + Na]+ Calcd for C10H16N2NaO2+ 219.11; Found 219.08 
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1H NMR spectrum of 3 
 
(S)-1-(2-bromoacetyl) pyrrolidine-2-carbonitrile (4) 
 
To a solution of 3 (7.5 g, 38.22 mmol, 1 equiv) in MeCN (75 mL) was added 2-
bromoacetylbromide (6.66 mL, 76.43 mmol, 2 equiv) and the pressure of the flask was reduced 
to 500 mbar. The mixture was stirred for 1 hr at 23°C and the volatiles were removed in vacuo. 
The product was purified by FCC (Pe:EtOAc = 6:4) to afford 4 as a yellowish oil (4.9 g, 
19.99mmol, 52%). 
1H NMR (400 MHz, CDCl3) δ 4.91 – 4.69 (m, 1H, N-CH), 3.83 (s, 2H, Br-CH2), 3.76 – 3.56 
(m, 2H, N-CH2), 2.35 – 2.15 (m, 4H, CH2-CH2).  
ESI-MS m/z: [M + Na]+ Calcd for C7H9BrN2NaO+ 238.99; Found 239.03 
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1H NMR spectrum of 4 
 
  
  Experimental section 
85 
 
5.5 FAP-ALPHA INHIBITOR BLOCK 2 
 
 
Scheme 20 : Synthesis of FAP-α inhibitor derivative. Reagents and conditions: i- 1) CuCN, DMF, 140°C, 30 
min, 2) KCN, H2O, 50°C, 1 hr; ii- Ni raney, H2, MeOH, 23°C, 16 hr; iii- 1) MsOH, methionine, 85°C, 16 hr, 2) 
tert-butyl bromoacetate, NaOH, TBAB, H2O, DMF/DCM, 23°C, 16 hr; iv- LiHMDS, 0°C, 18, THF, 23°C, 16 hr; 
v- SiO2, toluene, reflux, 60 min; vi- HOBt, EDCI, DIPEA, propargylamine, 23°C, 12 hr; vii- TBTU, DIPEA, 14, 
THF, 23°C, 16 hr ; viii- EDCI, HOBt, DIPEA, 12, 23°C, 16 hr ; ix- TBTU, HOBt, DIPEA, 8, 23°C, 16 hr  
Methyl 2-cyano-5-methoybenzoate (5) 
 
CuCN (4.75 g, 53.05mmol, 1.3 equiv) was added to a solution of methyl 2-bromo-5-
methoxybenzoate (10 g, 40.80 mmol, 1 equiv) in DMF (40 mL) and the reaction mixture was 
stirred for 30 min at 140°C. The mixture was cooled to 23°C and cold water (60 mL) was added. 
The resulting precipitate was filtered and dissolved in water (80 mL). KCN (7.97 g, 122.41 
mmol, 3 equiv) was added and the mixture was stirred for 1 hr at 50°C. The resulting solid was 
filtered, washed with water and dissolved in CHCl3 (100 mL). The solution was dried over 
MgSO4 and concentrated in vacuo to afford 5 as a white solid (6.7 g, 35.04 mmol, 86%). 
1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.6 Hz, 1H, CHar (6)), 7.62 (s, 1H, CHar (3)), 7.13 
(d, J = 11.3 Hz, 1H, CHar (1)), 4.00 (s, 3H, CH3-OCO), 3.91 (s, 4H, CH3-O). 
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ESI-MS m/z: [M + Na]+ Calcd for C10H9NNaO3+ 214.05; Found 214.04 
1H NMR spectrum of 5 
 
6-Methoxy-2,3-dihydro-1H-isoindol-1-one (6) 
 
To a solution of 5 (6.7 g, 35.04 mmol, 1equiv) in MeOH (120 mL) under argon atm was added 
Raney Ni (5 mol %). The argon atm was then replaced by H2 atm and the mixture was stirred 
for 16 hr at 23°C. The catalyst was removed by filtration on a pad of celite. Volatiles were 
removed in vacuo and the crude product was triturated in a minimal amount of EtOAc:isooctane 
= 1:1 at 60°C. The mixture was cooled to 23°C and the resulting precipitate was filtered and 
washed with cold EtOAc:isoOctane = 1:2 to afford 6 as a white solid (3.82 g, 23.41 mmol, 67 
%). 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.36 (m, 2H, 3, 2 x CHar (6, 3)) 7.16 (dd, J = 8.4, 2.4 
Hz, 1H, CHar (1)), 6.88 (s, 1H, NH), 4.42 (s, 2H, CH2), 3.89 (s, 3H, CH3). 
ESI-MS m/z: [M + H]+ Calcd for C9H10NO2+ 164.07; Found 164.08 
1H NMR spectrum of 6 
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6-Hydroxy-2,3-dihydro-1H-isoindol-1-one (6b) 
 
Methionine (42.13mmol, 6.29 g, 1.8 equiv) was added to a solution of 6 (23.41 mmol, 3.82 g, 
1 equiv) in MsOH (468.21 mmol, 30.38 mL, 20 equiv) and the mixture was stirred at 85 °C for 
16 hr. After cooling to 0 °C, cold water (5°C) was added and the mixture was stirred at 5°C for 
1 hr. The resulting solid was recovered by filtration, washed with aq. 1% HCl, water and dried 
to afford 6b as a white solid (16.76mmol, 2.5 g, 72%). This product was directly engaged in 
the next step. 
tert-Butyl [(3-oxo-1,2-dihydro-1H-isoindol-5-yl)oxy] (7) 
 
Compound 6b (2.5 g, 16.76 mmol, 1equiv) was dissolved in DMF:DCM = 1:1 (30 mL). Tert-
butyl bromoacetate (0.81 g, 18.43, 1.1 equiv), TBAB (0.27 g, 0.84 mmol, 0.05 equiv) and aq. 
50% NaOH (1.88 g, 23.47 mmol, 1.4 equiv) were added successively. The mixture was stirred 
for 16 hr at 22 °C and the product was extracted with DCM (3 x 10 mL). The combined organic 
phases were dried over MgSO4 and concentrated in vacuo. Purification by FCC (PE:EtOAc = 
1:1) afforded 7 as a white solid (3.45 g, 13.12 mmol, 78%). 
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1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.3 Hz, 1H, CHar (6)), 7.28 (d, J = 2.5 Hz, 1H, 
CHar (3)), 7.22 (dd, J = 8.3, 2.5 Hz, 1H, CHar (1)), 6.40 (s, 1H, NH), 4.58 (s, 2H, OCH2), 4.39 
(s, 3H, CH2N), 1.49 (s, 9H, 3 x CH3). 
ESI-MS m/z: [M + Na]+ Calcd for C14H17NNaO4+ 286.11; Found 286.17 
1H NMR spectrum of 7 
 
(S)-tert-Butyl 2-((2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-yl)oxy) 
acetate (8) 
 
LiHMDS (1M) (4.32 mL, 4.32 mmol, 1.5 equiv) was added to a cooled (0°C) solution of 7 
(756.8 mg, 25.88 mmol, 1 equiv) in THF (9 mL). After 30 min, a solution of 4 (811.8 mg, 3.74 
mmol, 1.3 equiv) in THF (9 mL) was added dropwise. The mixture was allowed to warmup to 
23°C and stirred for 10 hr. Volatiles were removed in vacuo and the residue was purified by 
FCC (EtOAc:PE = 4:1) to afford 8 as a white solid (683.5 mg, 1.71 mmol, 59%). 
1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.3 Hz, 1H, CHar (19)), 7.27 (d, J = 8.3 Hz, 1H, 
CHar (16)), 7.19 (dd, J = 8.3, 2.5 Hz, 1H, CHar (14)), 4.79 – 4.72 (m, 1H, CHC≡N), 4.57 (s, 2H, 
CH2 (11)), 4.44 (d, J = 16.4 Hz, 1H, CH2N (20)), 4.18 (dd, J = 27.5, 16.1 Hz, 1H, N-CH2 (9)), 
3.79 – 3.45 (m, 2H, CH2 (2’)), 2.43 – 2.03 (m, 4H, CH2 (1’), CH2 (5’)), 1.49 (s, 9H, 3 x CH3). 
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13C NMR (100MHz, CDCl3) δ 168.8 (8), 167.6 (21), 166.9 (12), 158.2 (15), 134.9 (18), 132.9 
(17), 124.0 (19), 120.8 (14), 118.7 (6), 107.4 (16), 82.7 (26), 65.8 (11), 50.5 (20), 46.6 (4), 46.0 
(2), 44.6 (9), 29.9 (5), 28.1 (27, 28, 29), 25.3 (1) 
HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C21H26N3O5+ 400.1872; Found 400.2500 
1H NMR spectrum of 8 
 
(S)-2-((2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-yl)oxy)acetic acid (9) 
 
Compound 8 (57 mg, 0.14 mmol, 1 equiv) was added to a suspension of silica (0.71 g) in toluene 
(3 mL). The mixture was stirred at reflux for 1 hr. Celite (150 mg) was added to the reaction 
mixture and a solution of DCM:MeOH = 4:1 (10 mL) was poured in the reaction mixture. The 
solids were filtered and rinsed with DCM:MeOH = 4:1 (20 mL). The filtrate was concentrated 
under reduced pressure to afford the free carboxylic acid (9) as a white solid in quantitative 
yield. This product was directly engaged in the next step. 
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(S)-2-((2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-yl)oxy)-N-(2-(2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)acetamide (13) 
 
A solution of compound 9 (61 mg, 0.18 mmol, 1 equiv) in THF (5 mL) was cooled to 0°C. 
DIPEA (0.03 mL, 0.21 mmol, 1.2 equiv) and TBTU (69.35 mg, 0.216 mmol, 1.2 equiv) were 
added successively and the mixture was stirred for 30 min under Ar atm. A solution of 14 (54.2 
mg, 0.21 mmol, 1.2 equiv) and DIPEA (0.03 mL, 0.21 mmol, 1.2 equiv) in THF (3 mL) was 
added. The mixture was allowed to warmup to 23°C and stirred for 12 hr. The solvent was 
removed in vacuo and the residue was dissolved in DCM (10 mL), washed with aq. HCl 1% (2 
x 5 mL), NaHCO3 (2 x 5 mL), brine (5 mL) and dried over MgSO4. DCM was removed in 
vacuo and the product was purify by FCC (EtOAc:MeOH = 9:1). Further purification was 
obtained by precipitation in MeOH:DCM = 5:1 and n-pentane to afford (S)-2-((2-(2-(2-
cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-yl)oxy)-N-(2-(2,5 dioxo-2,5-dihydro-
1H-pyrrol-1-yl)ethyl)acetamide (13) (44 mg, 0.095 mmol, 44 %) as a white solid. 
1H NMR (400MHz, CDCl3) δ 7.45 (d, J = 8.3 Hz, 1H, CHar(16)), 7.31 (d, J = 2.4 Hz, 1H, 
CHar(19)), 7.23 (dd, J = 8.3, 2.5 Hz, 1H, CHar(15)), 6.73 (s, 2H, CH-CH (1, 2)), 4.76 – 4.71 (m, 
1H, CH-CN (31)), 4.56 - 4.52 (s, 2H, CH2 (12)), 4.48 (m, 2H, CH2-N (23)), 4.38 (d, J = 17.0 
Hz, 1H, CH2-N (24)), 3.75 (dt, J = 6.3, 3.7 Hz, 1H, CH2-N (28’)), 3.72 – 3.67 (m, 2H, CH2-N 
(8)), 3.62 (td, J = 8.6, 8.0, 3.0 Hz, 1H, CH2-N (28”)), 3.51 – 3.45 (m, 2H, CH2-N (9)), 2.25 (m, 
4H, CH2-CH2 (29, 30)). 
13C NMR (100 MHz, CDCl3) δ 171.2 (3, 5), 169.5 (11), 167.3 (25), 157.8 (20), 135.4, (14), 
134.2 (1, 2), 132.8 (17), 124.2 (16), 120.1 (15), 118.0 (18), 108.3 (19), 67.2 (12), 50.7 (23), 
46.7 (31), 45.9 (28), 44.5 (24), 38.0 (9), 36.9 (8), 29.7 (30), 25.1 (29). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C23H23N5NaO6+ 488.1546; Found 488.1546 
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1H NMR spectrum of 13 
13C NMR spectrum of 13 
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(S)-2-((2-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-yl)oxy)-N-(prop-2-yn-
1-yl)acetamide (14) 
 
EDCI (31 mg, 0.31mmol, 2 equiv) HOBt (31.3 mg, 0.20 mmol, 1.3 equiv) and DIPEA (0.081 
mL, 0.47mmol, 3 equiv) were added to a solution of 9 (54 mg, 0.16 mmol, 1 equiv) in DMF (5 
mL). The reaction mixture was stirred for 15 min under Ar atm. Propargylamine (0.03mL, 0.47 
mmol, 3 equiv) was added and the mixture was stirred for 12 hr at 23°C. DMF was removed in 
vacuo and the residue was purify by FCC (DCM:MeOH = 50:1 ? 25:1) to afford (S)-2-((2-(2-
(2 cyanopyrrolidin-1-yl)-2-oxoethyl)- 3-oxoisoindolin-5-yl)oxy)-N-(prop-2-yn-1-yl)acetamide 
(14) as a white solid (30 mg, 0.079mmol, 55 %). 
1H NMR (400 MHz, CDCl3)δ 7.41 (d, J = 8.4 Hz, 1H, CHar (15 )), 7.36 (d, J = 2.5 Hz, 1H, 
CHar (18 )), 7.17 (dd, J = 8.2, 2.5 Hz, 1H, CHar (16 )), 6.77 (s, 1H, 13), 4.76 (d, J = 7.2 Hz, 1H, 
CH-CN), 4.73 – 4.61 (m, 1H, 9’, 20), 4.57 (s, 2H, CH2-O (11)), 4.47 (d, J = 16.5 Hz, 1H, CH2-
CCH (24)), 4.22 – 4.13 (m, 1H, CCH), 3.79 – 3.54 (m, 2H, NCH2 (2)), 2.47 – 2.03 (m, 3H, 
CH2-CH2 (1, 5)). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C20H20N4NaO4+ 403.1377; Found 403,1382 
1H NMR spectrum of 14 
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N-(2-(2-((2-(2-((S)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-
yl)oxy)acetamido)ethyl)-5-(1,2-dithiolan-3-yl)pentanamide (17) 
 
Compound 9 (0.200 g, 0.58 mmol, 1 equiv) was dissolved in DMF (10 mL) and DIPEA (0.29 
mL, 1.75 mmol, 3 equiv), EDCI (128 mg, 0.670 mmol, 1.15 equiv)and HOBt (179 mg, 1.17 
mmoles, 2 eq.) were added successively. The reaction mixture was stirred for 30 min under Ar 
atm. A solution of 16 (199 mg, 0.699 mmol, 1.2 equiv) in DMF (7 mL) was added and the 
reaction mixture was stirred for 12 hr. The solvent was then removed in vacuo and the residue 
was dissolve in DCM (10 mL) and washed with water (3 x 10 mL), brine (1 x 10 mL) and dried 
over MgSO4. The DCM was then removed in vacuo and the product was purified by FCC 
(DCM:MeOH = 20:1) to afford 17 as a pale yellow solid (0.106 g, 0.18 mmol, 30%) 
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.4 Hz, 1H, CHar), 7.32 (d, J = 2.5 Hz, 1H, CHar), 
7.21 (dd, J = 8.3, 2.5 Hz, 1H, CHar), 6.28 – 6.21 (m, 1H, NH), 4.74 (dd, J = 7.5, 2.8 Hz, 1H, 
CH-CN), 4.66 (d, J = 16.5 Hz, 1H, (25’)), 4.57 (d, J = 16.6 Hz, 1H, (35’)), 4.53 (s, 2H, (1)), 
4.45 (d, J = 16.5 Hz, 1H, (25’’)), 4.22 (d, J = 16.6 Hz, 1H, (35’’)), 3.74 – 3.61 (m, 2H, (29)), 
3.56 – 3.39 (m, 4H, (7+8)), 3.19 – 3.04 (m, 2H, CH2-S), 2.42 (dtd, J = 12.9, 6.6, 5.3 Hz, 1H, 
(17’)), 2.34 – 2.20 (m, 4H, (33 + 34)), 2.16 (t, J = 7.5 Hz, 2H, (12)), 1.87 (dq, J = 12.7, 6.9 Hz, 
1H, (17’’)), 1.63 (qd, J = 7.7, 7.2, 2.4 Hz, 4H, (15 + 13)), 1.49 – 1.34 (m, 2H, (14)). 
13C NMR (101 MHz, CDCl3) δ 174.05(CO), 169.00 (CO), 168.70 (CO), 166.91 (CO), 157.64 
(O-Car), 135.45 (Car), 133.30 (Car), 124.33 (Car), 120.33 (Car), 118.23 (CN), 108.28 (Car), 67.64 
(1), 56.54 (CHS), 50.58 (25), 46.75 (CH-CN), 46.08 (29), 44.65 (35), 40.33 (17), 39.92 (7), 
39.82 (8), 38.57 (CH2S), 36.34 (12), 34.68 (15), 29.94 (33), 28.94 (14), 25.42 (13), 25.39 (34). 
HRMS m/z: [M+H]+ Calcd for C27H36N5O5S2+ 574.2152; Found 574.2151 
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1H NMR spectrum of 17 
13C NMR spectrum of 17 
 
  Experimental section 
95 
 
N-(1-((2-(2-((S)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)-3-oxoisoindolin-5-yl)oxy)-2-oxo-
6,9,12-trioxa-3-azatetradecan-14-yl)-5-(1,2-dithiolan-3-yl)pentanamide (26) 
 
Compound 9 (0.200 g, 0.58 mmol, 1 equiv) was dissolved in DMF (5 mL) and DIPEA (0.29 
mL, 1.75 mmol, 3 equiv), TBTU (0.374 g, 1.17 mmol, 2 equiv) and HOBt (0.107 g, 0.699 
mmol, 1.2 equiv) were added successively. The reaction mixture was stirred for 30 min under 
Ar atm and a solution of 25 (0.266 g, 0.7 mmol, 1.2 equiv) in DMF (6 mL) was added. The 
reaction mixture was stirred for 12 hr and the solvent were removed in vacuo. The residue was 
purify by FCC (EtOAc ? DCM:MeOH = 10:1). To afford the desired product (26) as a 
yellowish oil (0.220 g, 0.316 mmol, 54%) 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.3 Hz, 1H, CHar), 7.41 (d, J = 2.5 Hz, 1H, CHar), 
7.20 (dd, J = 8.3, 2.5 Hz, 1H, CHar), 7.05 (d, J = 8.9 Hz, 1H, NH (29)), 6.21 (s, 1H, NH (31)), 
4.81 – 4.77 (m, 1H, CH-CN), 4.72 (d, J = 16.4 Hz, 1H, (19’)), 4.62 (d, J = 18.3 Hz, 3H, (2’) + 
(NOC-CH2-O)), 4.51 (d, J = 16.4 Hz, 1H, (19’’)), 4.26 (d, J = 16.5 Hz, 1H, 2’’), 3.84 – 3.55 
(m, 17H, CH2 TEG + CH-S + CH2 (9)), 3.47 (q, J = 5.2 Hz, 2H, CH2 (30)), 3.25 – 3.10 (m, 2H, 
CH2-S), 2.54 – 2.44 (m, 1H, CH2 (36’)), 2.41 – 2.24 (m, 4H, (1 + 5)), 2.22 (t, J = 7.5 Hz, 2H, 
CH2 (40)), 1.94 (dq, J = 12.7, 6.9 Hz, 1H, CH2 (36’’)), 1.79 – 1.63 (m, 4H, 2 x CH2 (37, 39)), 
1.56 – 1.43 (m, 2H, CH2 (38)). 
13C NMR (101 MHz, CDCl3) δ 172.95 (CO), 167.86 (CO), 166.93 (CO), 157.72 (CO), 135.50 
(Car), 133.50 (Car), 124.33 (Car), 119.79 (Car), 118.20 (Car), 109.07 (Car), 70.68 (CH2 TEG), 
70.66 (CH2 TEG), 70.51 (CH2 TEG), 70.36 (CH2 TEG), 70.08 (CH2 TEG), 69.85 (CH2 TEG), 
67.94 (OC-CH2-O), 56.61 (CH-S), 50.60 (19), 46.78 (CH-C≡N), 46.13 (N-CH2-CO), 44.68 
(2), 40.39 (36), 39.30 (30), 39.00 (CH2-NH), 38.62 (32), 36.50 (40), 34.80 (37), 30.01 (1), 29.08 
(38), 25.53 (39), 25.43 (5). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C33H47N5NaO8S2+ 728.2758; Found 728.2759. 
IR (cm-1): 2924, 2363, 1758, 1670, 1430, 1216, 1285 
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1H NMR spectrum of 26 
 
13C NMR spectrum of 26 
 
  Experimental section 
97 
 
5.6 CURCUMIN DERIVATIVES 
 
Scheme 21: Synthesis of curcumin derivatives. Reagents and conditions: i- DMAP, DCC, 23°C, 12 hr; ii- DMAP, 
DCC, 0°C to 23°C, 12 hr; iii- K2CO3, KI, 90°C, 12 hr; iv- BO3, 2,4-pentanedione, 29 or 30 or 33, tributyl borate, 
n-butylamine, HCl (0.5 M) 80°C to 23°C, 3 hr. 
4-Formyl-2-methoxyphenyl pent-4-ynoate (28) 
 
To a solution of 4-pentynoic acid (387 mg, 3.94 mmol, 1.2 equiv) in DCM (5 mL) cooled to 
0°C was added vanillin (500 mg, 3.29 mmol, 1 equiv), DMAP (80.3 mg, 657 μmol, 0.2 equiv) 
and DCC (1.08 g, 5.26 mmol, 1.6 equiv). The reaction was allowed to warmup to 23°C and 
stirred overnight. The reaction mixture was then filtered on Buchner. The filtrate was 
recovered and purified by FCC (EtOAc:PE = 17:5) to yield 4-formyl-2-methoxyphenyl pent-
4-ynoate (28) as a white solid (0.483 g, 2.08 mmol, 63%). 
1H NMR (400 MHz, CDCl3) δ 9.94 – 9.92 (m, 1H, CHO), 7.50 – 7.44 (m, 2H, CHar), 7.22 (dd, 
J = 7.9, 1.4 Hz, 1H, CHar), 3.91 – 3.85 (m, 3H, CH3), 2.90 – 2.80 (m, 2H, CH2), 2.63 (ddt, J = 
7.3, 5.8, 2.4 Hz, 2H, CH2), 2.03 (s, 1H, ≡CH). 
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13C NMR (101 MHz, CDCl3) δ 191.04 (COH), 169.25 (CO), 151.90 (Car), 144.80 (Car), 135.30 
(Car), 124.72 (CHar), 123.38 (CHar), 110.85 (CHar), 81.98 (C≡CH), 69.43 (C≡CH), 56.09 (CH3), 
33.13 (CH2), 14.45 (CH2). 
HRMS (APPI/QTOF) m/z: [M + H]+ Calcd for C13H13O4+ 233.0808; Found 233.0809 
IR (cm-1): 3275, 1762, 1692, 1273, 1127, 1608 
 
1H NMR spectrum of 28 
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13C NMR spectrum of 28 
 
4-Formyl-2-methoxyphenyl 5-(1,2-dithiolan-3-yl)pentanoate (27) 
 
To a solution of vanillin (0.5 g, 3.29 mmol, 1 equiv) in DCM (5 mL) was added lipoic acid (814 
mg, 3.94 mmol, 1.2 equiv), DMAP (20.1 mg, 164 μmol, 0.05 equiv) and DCC (1.08 g, 5.26 
mmol, 1.6 equiv). The reaction mixture was stirred overnight at 23°C and water (7 mL) was 
added to the reaction mixture. The aqueous phase was extracted with DCM (3 x 5 mL). The 
organic phases were combined, washed with brine (10 mL), dried over MgSO4 and the solvent 
was removed in vacuo. The product was purified by FCC (EtOAc:PE = 1:1) to afford 4-formyl-
2-methoxyphenyl 5-(1,2-dithiolan-3-yl)pentanoate (27) as a yellowish oil (0.406 g, 1.19 mmol, 
36%). 
1H NMR (400 MHz, CDCl3) δ 9.94 (s, 1H, CHO), 7.51 – 7.45 (m, 2H, CHar), 7.21 (d, J = 7.8 
Hz, 1H, CHar), 3.90 (s, 3H, CH3), 3.68 – 3.56 (m, 1H, CH 17), 3.25 – 3.06 (m, 2H, CH2 20), 
2.63 (t, J = 7.4 Hz, 2H, CH2-CO), 2.48 (dtd, J = 13.0, 6.6, 5.3 Hz, 1H, CH2 21’), 1.93 (dq, J = 
12.7, 6.9 Hz, 1H, CH2 21’’), 1.86 – 1.69 (m, 4H, 2 x CH2 14, 16), 1.59 (m, 2H, CH2 15). 
13C NMR (101 MHz, CDCl3) δ 191.17 (CHO), 170.99 (CO), 152.09 (Car), 145.11 (Car), 135.31 
(Car), 124.90 (Car), 123.53 (Car), 110.91 (Car), 56.48 (CHS), 56.23 (CH3), 40.39 (20), 38.63 (21), 
34.73 (16), 33.87 (CH2-CO), 28.76(15), 24.76 (14). 
  Experimental section 
100 
 
HRMS m/z: [M + Na]+ Calcd for C16H20NaO4S2+ 363.0695; Found 363.0699 
 
1H NMR spectrum of 27 
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13C NMR spectrum of 27 
 
Lipoic acid-TEG-hydroxyl (29) 
 
The following protocol was adapted from the procedure reported by Zhu et al.232. Lipoic acid 
(1 g, 4.85 mmol, 1 equiv) and tetra(ethylene glycol) (3.36 mL, 19.4 mmol, 4 equiv) were 
dissolved in anhydrous DCM (75 mL). EDCI (2.79 g, 14.5 mmol, 3 equiv) and DMAP (88.8 
mg, 727 μmol, 0.15 equiv) were added and reaction mixture was stirred for 10 hr at 23°C. The 
reaction was quench with the addition of aq. NH4Cl (100 mL) and extracted with DCM (3 x 50 
mL). The combined organic phase were washed with water (3 x 100 mL) and concentrated in 
vacuo. The product was then purified by FCC (PE:EtOAc = 1:1) to afford Lipoic acid-TEG-
OH (29) as a yellow oil (1.161 g, 3.03 mmol, 63%). The analytical data were in agreement with 
literature report. 
1H NMR (400 MHz, CDCl3) δ 4.28 – 4.19 (m, 2H, CH2-OCO), 3.77 – 3.64 (m, 12H, CH2-O), 
3.63 – 3.60 (m, 2H, CH2-OH), 3.56 (m, 1H, CH-S), 3.25 – 3.07 (m, 2H, CH2-S), 2.52 – 2.41 
(m, 1H, CH2 (15’)), 2.35 (t, J = 7.4 Hz, 2H, CH2-COO), 1.91 (dq, J = 12.7, 6.9 Hz, 1H, CH2 
(15’’)), 1.76 – 1.60 (m, 4H, 2 x CH2 (11, 13)), 1.56 – 1.39 (m, 2H, CH2 (12)). 
1H NMR spectrum of 29 
  Experimental section 
102 
 
 
Lipoic acid-TEG-Mesyl (30) 
 
The following protocol was adapted from the procedure reported by Zhu et al.232. Compound 
29 (1 g, 2.61 mmol, 1 equiv) was dissolved in dry DCM (15 mL) and cooled to 0°C. NEt3 (400 
μL, 2.88 mmol, 1.1 eq.) and methanesulfonyl chloride (223 μL, 2.88 mmol, 1.1 eq.) were added 
to the solution under stirring. The reaction was allowed to warmup to 23°C and stirred 
overnight. The reaction mixture was diluted with the addition of DCM (50 mL) and washed 
with aq. HCl 5% (3 x 20 mL), aq. sat. NaHCO3 (3 x 20 mL) and water (20 mL). The organic 
phase was then reduced in vacuo and the product was purified by FCC (EtOAc:PE = 1:1) to 
afford the desired product 30 as a yellow oil (0.325 g, 0.71 mmol, 27%). 
1H NMR (400 MHz, CDCl3) δ 4.41 – 4.35 (m, 2H, CH2-OCO), 4.23 (dd, J = 5.8, 3.8 Hz, 2H, 
CH2-OMs), 3.80 – 3.74 (m, 2H, CH2-CH2OMs), 3.72 – 3.63 (m, 10H, CH2-O), 3.57 (dd, J = 
8.3, 6.3 Hz, 1H, CH-S), 3.24 – 3.09 (m, 2H, CH2-S), 3.08 (s, 3H, CH3), 2.46 (dd, J = 12.6, 6.3 
Hz, 1H, CH2 (15’)), 2.35 (t, J = 7.4 Hz, 2H, CH2-COO), 1.91 (dd, J = 13.0, 6.7 Hz, 1H, CH2 
(15’’)), 1.76 – 1.58 (m, 4H, 2 x CH2 (11, 13)), 1.47 (m, 2H, CH2 (12)). 
1H NMR spectrum of 30 
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Lipoic acid-TEG-Vanillin (31) 
 
A solution of 30 (224 mg, 486 μmol, 1 eq.) in DMF (0.97 mL) was added dropwise to a 
suspension of vanillin (76.8 μL, 535 μmol, 1.1 eq.) K2CO3 (101 mg, 729 μmol, 1.5 eq.) and KI 
(8 mg, 48.6 μmol, 0.1 eq.) in DMF (6 mL). The reaction mixture was heated to 90°C and stirred 
for 12 hr. After cooled to 23°C the solid residues were filtered and the filtrate was concentrated 
in vacuo. The product was purified by FCC (EtOAc:PE 7:3 ? 1:0) to yield 31 as a yellowish 
solid (174 mg, 0.337 mmol, 69%). 
1H NMR (400 MHz, CDCl3) δ 9.85 (s, 1H, CHO), 7.47 – 7.37 (m, 2H, 2 x CHar), 7.01 (d, J = 
8.1 Hz, 1H, CHar), 4.27 (t, J = 5.1 Hz, 2H, CH2 (2)), 4.24 – 4.20 (m, 2H, CH2 (6)), 3.92 (d, J = 
5.7 Hz, 6H, CH3 + CH2-(2)), 3.76 – 3.62 (m, 10H, CH2-O), 3.56 (dd, J = 8.2, 6.2 Hz, 1H, CH-
S), 3.23 – 3.06 (m, 2H, CH2 (16)), 2.46 (dq, J = 12.5, 6.3 Hz, 1H, CH2 (15’)), 2.34 (t, J = 7.4 
Hz, 2H, CH2-COO), 1.90 (dq, J = 13.6, 6.9 Hz, 1H, CH2 (15’’)), 1.67 (m, 4H, 2 x CH2 (11, 
13)), 1.54 – 1.40 (m, 2H, CH2 (12)). 
13C NMR (101 MHz, CDCl3) δ 190.97 (CHO), 173.47 (CO), 153.90 (Car), 149.95 (Car), 130.31 
(Car), 126.69 (CHar), 111.93 (CHar), 109.36 (CHar), 70.97 (CH2), 70.70 (CH2), 70.65 (CH2), 
70.59 (CH2), 69.40 (CH2), 69.20 (CH2), 68.52 (CH2), 63.46 (CH2), 56.36 (CH), 56.01 (CH3), 
40.24 (CH2), 38.50 (CH2-S), 34.61 (13), 33.96 (CH2COO), 28.76 (12), 24.63 (11). 
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HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C24H37O8S2+ 517.1924; Found 517.1940. 
IR (cm-1): 2942, 2356, 1260 
1H NMR spectrum of 31 
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13C NMR spectrum of 31 
 
Di(lipoic acid)-curcumin (32) 
 
Boron oxide (12.5 μL, 441 μmol, 1 equiv) was added to a solution of 2,4-pentanedione (45.2 
μL, 441 μmol, 1 equiv) in DMF (5 mL) and the solution was heated to 80°C under stirring. 
After 30 min a solution of compound 27 (300 mg, 881 μmol, 2 equiv) and tributyl borate (476 
μL, 1.76 mmol, 4 equiv) in DMF (6 mL) and a solution of N-butylamine (17.4 μL, 176 μmol, 
0.4 equiv) in DMF (0.5 mL) were added dropwise successively. After 2 hr during which the 
reaction became red-orange, aq. HCl 0.5 M (5 mL) was added and the reaction mixture was 
allowed to cool to 23°C for 1 hr under stirring. The solvent was then removed in vacuo and the 
residue was dissolved in water (10 mL) and extracted with EtOAc (3 x 10 mL). The organic 
phases were combined and washed with aq. LiCl 5% (2 x 10 mL). EtOAc was removed in vacuo 
and the product was purified by FCC (PE:EtOAc = 8:2) to afford di(lipoic acid)-curcumin (32) 
as a dark yellow solid gel. (102 mg, 0.14 mmol, 31%). 
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1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 15.8 Hz, 2H, CH-Car), 7.21 – 7.03 (m, 6H, CHar), 
6.57 (d, J = 15.8 Hz, 2H, 2 x CH-C=O), 5.86 (s, 1H, O=C-CH-C=O), 3.88 (s, 6H, 2 x CH3), 
3.68 – 3.56 (m, 2H, 2 x CH-S), 3.26 – 3.08 (m, 4H, 2 x CH2-S), 2.62 (t, J = 7.3 Hz, 4H, 2 x 
CH2-CO), 2.56 – 2.44 (m, 2H, 2 x (37’)), 2.01 – 1.89 (m, 2H, 2 x (37’’)), 1.85 – 1.67 (m, 8H, 2 
x (35) + 2 x (33)). 
13C NMR (101 MHz, CDCl3) δ 183.26 (CO), 171.45 (CO), 151.55 (Car), 141.48 (Car), 140.14 
(CH), 134.06 (Car), 124.39 (CH), 123.43 (CHar), 121.25 (CHar), 111.58 (CHar), 56.51 (CH-S), 
56.09 (CH3), 40.40 (37), 38.64 (CH2-S), 34.75 (35), 33.91 (CH2-COO), 28.79 (34), 24.84 (33). 
HRMS m/z: [M + H]+ Calcd for C37H45O8S4+ 745.1992; Found 745.1974. 
IR (cm-1): 3326, 2923, 1625, 1575 
1H NMR spectrum of 32 
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13C NMR spectrum of 32 
 
Di(pentyne)-curcumin (33) 
 
Boron oxide (29.4 μL, 1.04 mmol, 1 equiv) was added to a solution of 2,4-pentanedione (107 
μL, 1.04 mmol, 1 equiv) in DMF (6 mL) and the solution was heated to 80°C under stirring. 
After 30 min a solution of compound 28 (483 mg, 2.08 mmol, 2 equiv) and tributyl borate (1.12 
mL, 4.16 mmol, 4 equiv) in DMF (6 mL) and a solution of N-butylamine (41.1 μL, 416 μmol, 
0.4 equiv) in DMF (0.5 mL) were added dropwise successively. After 2 hr during which the 
reaction became red-orange, aq. HCl 0.5 M (5 mL) was added and the reaction mixture was 
allowed to cool to 23°C for 1 hr under stirring. The solvent was then removed in vacuo and the 
residue was dissolved in water (10 mL) and extracted with EtOAc (3 x 10 mL). The organic 
phases were combined and washed with aq. LiCl 5% (2 x 10 mL). EtOAc was removed in vacuo 
and the product was purified by FCC (PE:EtOAc 1:0 ? 13:7) and further purified with a second 
FCC (PE:DCM:MeOH = 10:10:1) to afford di(pentyne)-curcumin (33) as a yellow solid (0.153 
g, 0.29 mmol, 28%). 
1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 15.8 Hz, 2H, CH-Car), 7.20 – 7.04 (m, 6H, CHar), 
6.57 (d, J = 15.8 Hz, 2H,2 x CH-C=O), 5.86 (s, 1H, O=C-CH-C=O), 3.88 (s, 6H, 2 x CH3), 2.86 
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(dd, J = 8.3, 6.6 Hz, 4H, 2 x CH2-C=O), 2.65 (td, J = 7.6, 7.1, 2.7 Hz, 4H, 2 x CH2-C), 2.04 (t, 
J = 2.6 Hz, 2H, 2 x C≡CH). 
13C NMR (101 MHz, CDCl3) δ 183.22 (CO), 169.78 (CO), 151.51 (CarO), 141.36 (CarO), 
140.08 (CH), 134.20 (Car), 124.48 (Car), 123.39 (CH), 121.21 (Car), 111.64 (Car), 101.94 (O=C-
CH-C=O), 82.25 (C≡CH), 69.45 (C≡CH), 56.09 (CH3), 33.30 (CH2), 14.64 (CH2). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C31H28NaO8+ 551.1676; Found 551.1677 
IR (cm-1): 3289, 1755, 1587, 1512, 1631, 1125, 1250, 1300, 1026, 963, 913, 845, 1419 
1H NMR spectrum of 33 
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13C NMR spectrum of 33 
 
Di(lipoic acid-TEG)-curcumin (34) 
 
Boron oxide (33.7 μL, 1.19 mmoles, 1 equiv) was added to a solution of 2,4-pentanedione (122 
μL, 1.19 mmoles, 1 equiv) in DMF (6 mL) and the solution was heated to 80°C under stirring. 
After 30 min a solution of compound 31 (1.23 g, 2.38 mmoles, 2 equiv) and tributyl borate 
(1.28 mL, 4.76 mmoles, 4 equiv) in DMF (6 mL) and a solution of N-butylamine (47.1 μL, 476 
μmol, 0.4 equiv) in DMF (0.5 mL) were added dropwise successively. After 2 hr during which 
the reaction became red-orange, aq. HCl 0.5 M (5 mL) was added and the reaction mixture was 
allowed to cool to 23°C for 1 hr under stirring. The solvent was then removed in vacuo and the 
residue was dissolved in water (10 mL) and extracted with EtOAc (3 x 10 mL). The organic 
phases were combined and washed with aq. LiCl 5% (2 x 10 mL). EtOAc was removed in vacuo 
and the product was purified by FCC (PE:EtOAc 1:0 ? 13:7). Further purification was obtained 
with a second FCC (PE:EtOAc = 1:0 ? 1:1) to yield di(lipoic acid-TEG)-Curcumin (34) as a 
yellow-orange solid (0.501 g, 0.456 mmol, 38%). 
1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 15.8 Hz, 2H,2 x CH=CH), 7.16 – 7.04 (m, 4H, 
CHar), 6.91 (d, J = 8.3 Hz, 2H, CHar), 6.49 (d, J = 15.8 Hz, 2H, 2 x CH=CH), 5.82 (s, 1H, 
O=C-CH-C=O), 4.22 (dd, J = 5.4, 3.5 Hz, 8H, 4 x CH2-O), 3.91 (m, 12H, 2 x CH3 + 2 x CH2-
CH2-O), 3.77 – 3.62 (m, 20H, CH2 TEG), 3.61 – 3.51 (m, 2H, 2 x CH-S), 3.23 – 3.05 (m, 4H, 
  Experimental section 
110 
 
2 x CH2-S), 2.45 (dd, J = 12.6, 6.2 Hz, 2H, 2 x CH2’-CH-S ), 2.34 (t, J = 7.4 Hz, 4H, 2 x CH2-
CO), 1.89 (dd, J = 13.0, 6.7 Hz, 2H, CH2’’-CH-S), 1.72 – 1.61 (m, 8H, 2 x CO-CH2-CH2 + 2x 
CH2-CH-S), 1.46 (ddd, J = 18.3, 9.2, 6.6 Hz, 4H, 2 x CH2-CH2-C=O). 
13C NMR (101 MHz, CDCl3) δ 183.36 (CO), 173.61 (CO), 150.46 (Car), 149.72 (Car), 140.50 
(CH), 128.49 (Car), 122.60 (CHar), 122.22 (CH), 113.15 (CHar), 110.39 (CHar), 101.49 (OC-
CH-CO), 71.00 (CH2), 70.78 (CH2), 70.73 (CH2), 70.68 (CH2), 69.62 (CH2), 69.28 (CH2), 
68.51 (CH2), 63.58 (CH2), 56.46 (CH-S), 56.07 (CH3), 40.35 (CH2), 38.61 (CH2), 34.72 
(CH2), 34.05 (CH2), 28.87 (CH2), 24.72 (CH2). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C53H76NaO16S4+ 1119.3908; Found 
1119.3920 
IR (cm-1): 2924, 2366, 2346, 1732, 1617, 1582, 1511, 1456, 1265, 1139, 954 
1H NMR spectrum of 34 
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13C NMR spectrum of 34 
 
5.7 KETOPROFEN DERIVATIVES 
 
Scheme 22 : Synthesis ketoprofen derivatives with short (ethyl) linkers. Reagents and conditions: i- N-Boc-
ethanolamine, DMAP,  DCC, 0°C to 23°C, 12 hr; ii- TFA, 23°C, 2 hr; iii- 4-pentynoic acid, HOBt, EDCI, DIPEA, 
23°C, 12 hr; iv- lipoic acid, HOBt, EDCI, DIPEA, 23°C, 12 hr 
Ketroprofen-N-boc-ethanolamine (35) 
 
A stirred solution of N-Boc-ethanolamine (52) (0.288 g, 1.79 mmol, 1 equiv) and ketoprofen 
(0.5 g, 1.97 mmol, 1.1 equiv) in DCM (10 mL) was cooled to 0°C. DMAP (21.8 mg, 0.18 
mmol, 0.1 equiv) and DCC (0.406 g, 1.97 mmol, 1.1 equiv) were added successively. The 
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reaction mixture was stirred at 0°C for 20 min, warmup to 23°C and stirred for 12 hr. EtOAc 
(20mL) was added and the solution was filtered on through a pad of celite. The solvent was 
removed in vacuo and the product was purified by FCC (EtOAc:PE = 1:3 ? 1:0) to yield 
ketoprofen-N-Boc-ethanolamine (35) as a transparent oil (0.649 g, 1.633 mmol, 83%). 
1H NMR (400 MHz, CDCl3) δ 7.77 – 7.34 (m, 10H, CHar), 4.07 (ddd, J = 7.5, 5.2, 2.8 Hz, 
2H, O-CH2), 3.75 (q, J = 7.2 Hz, 1H, CH), 3.34 – 3.19 (m, 2H, N-CH2), 1.48 (d, J = 7.2 Hz, 
3H, CH-CH3), 1.34 (s, 9H, 3 x CH3(Boc)). 
13C NMR (101 MHz, CDCl3) δ 196.59 (CO), 174.08 (CO), 155.84 (CO), 140.90 (Car), 
138.09 (Car), 137.55 (Car), 132.70 (Car), 131.54 (Car), 130.20 (2 x Car), 129.30 (Car), 129.26 
(Car), 128.71 (Car), 128.46 (2 x Car), 64.21 (O-CH2), 45.45 (CH), 39.73 (N-CH2), 28.48 (3 x 
CH3 (Boc)), 18.54 (CH3). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C23H27NNaO5+ 420.1781; Found 420.1783. 
IR (cm-1): 711, 1156, 1272, 1282, 1509, 1691, 2984, 3383 
1H NMR spectrum of 35 
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13C NMR spectrum of 35 
 
Ketoprofen-ethanolamine (36) 
 
To a solution of Ketoprofen-N-Boc-ethanolamine (35) (500 mg, 1.26 mmoles, 1 equiv) in DCM 
(8 mL), TFA (0.93 mL, 12.6 mmol, 10 equiv) was added dropwise. The reaction mixture was 
stirred for 2 hr until completion of the reaction. The volatiles were removed in vacuo and the 
residue dissolved in EtOAc (10 mL) and washed with aq. sat. K2CO3 (3 x 10 mL). The organic 
layer was then evaporated in vacuo to afford the desire product (36) (0.36 g, 1.20 mmol, quant.). 
1H NMR (400 MHz, CDCl3) δ 7.82 – 7.39 (m, 9H), 3.65 (t, J = 5.1 Hz, 2H, O-CH2), 3.40 – 
3.32 (m, 1H, CH), 1.53 (d, J = 7.2 Hz, 2H, HN-CH2). 
13C NMR (101 MHz, CDCl3) δ 195.90 (CO), 173.93 (CO), 140.97 (Car), 137.16 (Car), 136.42 
(Car), 131.83 (Car), 130.70 (Car), 129.24 (2 x Car), 128.30 (Car), 128.17 (Car), 127.89 (Car), 127.51 
(2 x Car), 61.27 (O-CH2), 45.96 (CH), 41.67 (HN-CH2), 17.79 (CH3). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C18H19NNaO3+ 320.1257; Found 320.1265. 
IR (cm-1): 800, 1013, 1108, 1257 
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1H NMR spectrum of 36 
13C NMR spectrum of 36 
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Ketoprofen-ethanolamine-pentyne (37) 
 
4-Pentynoic acid (191 mg, 1.95 mmoles, 1.2 equiv) was dissolved in DMF (4 mL). Ketoprofen-
ethanolamine (36) (483 mg, 1.62 mmoles, 1 equiv), HOBt (498 mg, 3.25 mmoles, 2 equiv), 
EDCI (374 mg, 1.95 mmoles, 1.2 equiv) and DIPEA (805 μL, 4.87 mmoles, 3 equiv) were 
added. The reaction mixture was stirred at 23°C for 12 hr. The solvent was removed in vacuo 
and the residue was dissolved in EtOAc (10 mL), washed with water (2 x 10 mL) and brine (1 
x 10 mL). The organic phase was dried over MgSO4 and concentrated in vacuo. The product 
was purified by FCC on silica gel (EtOAc:PE = 1:1) to afford ketoprofen-ethanolamine-pentyne 
(37) as a white solid (220 mg, 0.58 mmol, 36%). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.40 (m, 9H, CHar), 6.15 (d, J = 6.4 Hz, 1H, NH), 4.27 
– 4.07 (m, 2H, O-CH2), 3.83 (q, J = 7.2 Hz, 1H, CH), 3.48 (q, J = 5.4 Hz, 2H, HN-CH2), 2.49 
– 2.41 (m, 2H, ONHC-CH2), 2.33 (td, J = 7.2, 1.0 Hz, 2H, ≡C-CH2), 1.91 (t, J = 2.6 Hz, 1H, 
≡CH), 1.55 (d, J = 7.2 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 196.85 (CO), 173.98(CO), 171.38 (CO), 141.08 (Car), 138.14 
(Car), 137.28 (Car), 132.91 (Car), 131.57 (Car), 130.28 (2 x Car), 129.31 (Car), 129.18 (Car), 128.64 
(Car), 128.52 (2 x Car), 83.01 (C≡CH), 69.33 (C≡CH), 63.90 (CH), 45.46 (CH2), 38.85 (CH2), 
35.18 (CH2), 18.30 (CH2), 14.92 (CH3). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C23H23NNaO4+ 400.1519; Found 400.1523. 
IR (cm-1): 701, 920, 1175, 1281, 1537, 1656, 1730, 3296 
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1H NMR spectrum of 37 
 
13C NMR spectrum of 37 
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Lipoic acid Ketoprofen-ethanolamine (38) 
 
Lipoic acid (213 mg, 1.03 mmoles, 1 eq.) was dissolved in DMF (5 mL). Ketoprofen-
ethanolamine (36) (413 mg, 1.24 mmoles, 1.2 eq.), HOBt (316 mg, 2.06 mmoles, 2 eq.), EDCI 
(237 mg, 1.24 mmoles, 1.2 eq.) and DIPEA (511 μL, 3.09 mmoles, 3 eq.) were added. The 
reaction mixture was stirred at 23°C for 12 hr. The solvent was removed in vacuo and the 
residue was dissolved in EtOAc (10 mL). The solution was washed with water (2 x 10 mL) and 
brine (1 x 10 mL). The organic phase was dried over MgSO4 and concentrated in vacuo. The 
product was purified by FCC on silica gel (EtOAc:PE  = 0:1 ? 1:1) to afford the desired product 
(38) as a yellowish solid (0.213 g, 0.44 mmol, 43%). 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.37 (m, 9H, CHar), 4.12 (t, J = 5.4 Hz, 2H, (CH2-NHC)), 
3.68 – 3.58 (m, 1H (CH-CH3)), 3.54 (dd, J = 8.1, 6.1 Hz, 1H, (CH-S)), 3.48 (qd, J = 5.5, 3.7 
Hz, 2H, (CH2-OCO)), 3.23 – 3.06 (m, 2H, CH2-S), 2.45 (dtd, J = 13.0, 6.6, 5.4 Hz, 1H, CH2 
(30’)), 2.24 (t, J = 7.4 Hz, 2H, CH2-CON), 1.89 (dq, J = 13.6, 6.9 Hz, 1H, CH2 (30’’)), 1.73 – 
1.57 (m, 4H, 2 x CH2 (25, 26)), 1.55 (d, J = 7.2 Hz, 3H, (CH3)), 1.49 – 1.34 (m, 2H, CH2 (27)). 
13C NMR (101 MHz, CDCl3) δ 196.58 (CO), 173.80 (CO), 173.62 (CO), 141.84 (Car), 138.24 
(Car), 137.50 (Car), 132.78 (Car), 131.64 (Car), 130.22 (2 x Car), 129.33 (Car), 129.24 (Car), 128.93 
(Car), 128.52 (2 x Car), 63.07 (CH2-O), 56.49 (CH-Car), 47.13 (CH-S), 40.40 (30), 39.21 (CH2-
NH), 38.63 (CH2-S), 34.67 (25), 33.94 (CH2-CON), 28.84 (27), 24.67 (28), 18.79 (CH3) 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C26H31NNaO4S2+ 508.1587; Found 508.1589 
IR (cm-1): 718, 1172, 1291, 1657, 1739, 1531, 1449, 2929, 3307 
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1H NMR spectrum of 38 
13C NMR spectrum of 38 
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KET-TEG-LA 
Scheme 23 : Synthesis ketoprofen derivatives with TEG linkers. Reagents and conditions: i- ketoprofen, EDCI, 
HOBt, DIPEA, 23°C, 12 hr; ii- PPh3, H2O, 23°C, 12 hr; iii- lipoic acid, HOBt, EDCI, DIPEA, 23°C, 12 hr 
Ketoprofen-TEG-azide (39) 
 
Tetra(ethylene glycol) derivative, amine-TEG-azide (22) (0.182 g, 0.71 mmol, 1 equiv) was 
dissolved in DMF (4 mL). Ketoprofen (0.184 g, 0.72 mmol, 1.01 equiv), HOBt (0.164 g, 1.07 
mmol, 1.5 equiv), EDCI (0.274 g, 1.42 mmol, 2.0 equiv) and DIPEA (0.354 mL, 2.14 mmol, 
3.0 equiv) were added to the solution. The reaction mixture was stirred at 23°C for 12 hr. The 
solvent was removed in vacuo and the residue was dissolved in DCM (10 mL). The solution 
was washed with sat. aq. NH4Cl solution (2 x 10 mL) and brine (1 x 10 mL). The organic phase 
was dried over MgSO4 and concentrated in vacuo. The product was purified by FCC 
(DCM:MeOH  = 20:1 ? 9:1) to afford ketoprofen-TEG-azid (39) as a yellow oil (0.223 g, 0.49 
mmol, 69%). 
1H NMR (400 MHz, CDCl3) δ 7.83 – 7.40 (m, 9H, CHar), 6.07 (d, J = 5.3 Hz, 1H, NH), 3.70 
– 3.30 (m, 17H, CH2-CH2-O + CH), 1.54 (d, J = 7.1 Hz, 2H, CH3). 
13C NMR (101 MHz, CDCl3) δ 196.65 (CO), 173.79 (CO), 142.35 (C ar.), 137.91 (C ar), 
137.60 (C ar), 132.58 (C ar), 131.62 (C ar), 130.14 (2 X C ar), 129.23 (C ar), 128.97 (C ar), 
128.64 (C ar), 128.63 (C ar), 128.40 (2 x C ar), 70.55 (CH2), 70.52 (CH2), 70.29 (CH2), 
70.18 (CH2), 70.01 (CH2), 46.77 (CH-CH3), 39.51 (CH2), 18.85 (CH3). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C24H30N4NaO5+ 477.2114; Found 477.2127 
IR (cm-1): 2880, 2095, 1655, 1285, 1115 
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1H NMR spectrum of 39 
13C NMR spectrum of 39 
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Ketoprofen-TEG-amine (40) 
 
Ketoprofen-TEG-azide (39) (0.368 g, 0.81 mmol, 1.0 equiv,) was dissolved in THF (6 mL). 
Triphenylphosphine (0.297 g, 1.1 mmol, 1.4 equiv) was added and the solution was stirred at 
23°C for 1 hr. Water (1 mL) was added and the reaction mixture was stirred at 23°C for 12 hr. 
The solvent was removed in vacuo. The residue was purified by FCC (DCM:MeOH:NEt3 = 
10:1:0.1) to afford ketoprofen-TEG-amine (40) as a yellow oil (0.195 g, 0.45 mmol, 56%). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.38 (m, 9H, ar.), 6.85 (t, J = 5.4 Hz, 1H, NH), 3.74 – 
3.31 (m, 17H, CH2-CH2-O + CH), 1.51 (d, J = 7.1 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 196.65 (CO), 173.79 (CO), 142.35 (C ar.), 137.91 (C ar), 
137.60 (C ar), 132.58 (C ar), 131.62 (C ar), 130.14 (2 X C ar), 129.23 (C ar), 128.97 (C ar), 
128.64 (C ar), 128.63 (C ar), 128.40 (2 x C ar), 70.55 (CH2), 70.52 (CH2), 70.29 (CH2), 70.18 
(CH2), 70.01 (CH2), 46.77 (CH-CH3), 39.51 (CH2), 18.85 (CH3). 
HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C24H33N2O5+ 429.2384; Found 429.2379. 
IR (cm-1): 2925, 1660, 1080. 
1H NMR spectrum of 40 
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13C NMR spectrum of 40 
 
Lipoic acid-TEG-Ketoprofen (41) 
 
To a solution of 40 (0.519 g, 1.21 mmol, 1 equiv) in DMF (4 mL), were added lipoic acid (0.3 
g, 1.45 mmol, 1.2 equiv), HOBt (0.371 g, 2.42 mmol, 2 equiv), EDCI (0.28 g, 1.45 mmol, 1.2 
equiv) and DIPEA (0.51 ml, 3.64 mmol, 3 equiv). The reaction mixture was stirred at 23°C for 
12 hr. The solvent was removed in vacuo and the residue was dissolved in DCM (5 mL). The 
solution was washed with water (3 x 5 mL) and the organic phase was dried over MgSO4 and 
concentrated in vacuo. The product was purified by FCC (DCM:MeOH = 20:1) to afford 41 as 
a yellowish solid (0.52 g, 0.85 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.40 (m, 9H, ar.), 6.17 (2 bs, 2H, 2 x NH), 3.68 – 3.36 
(m, 18H, CH2-CH2-O, CH-Me, CH-S), 3.22 – 3.05 (m, 2H, CH2-S), 2.44 (dq, J = 12.5, 6.3 Hz, 
1H, CH2-CH2S), 2.16 (t, J = 7.5 Hz, 2H, CH2-C(O)NH), 1.89 (dq, J = 13.7, 7.0 Hz, 1H, CH2-
CH2S), 1.75 – 1.58 (m, 4H,2 x CH2), 1.54 (d, J = 7.1 Hz, 3H, CH3), 1.44 (ddd, J = 14.8, 8.3, 5.8 
Hz, 2H, CH2). 
13C NMR (101 MHz, CDCl3) δ 196.70 (CO), 173.75 (CO), 173.00 (CO), 142.19 (C ar.), 138.05 
(C ar.), 137.57 (C ar.), 132.73 (C ar.), 131.68 (C ar.), 130.20 (2 x C ar.), 129.26 (C ar.), 129.20 
(C ar.), 128.78 (C ar.), 128.50 (2 x C ar.), 70.58 (CH2), 70.55 (CH2), 70.36 (CH2), 70.30 (CH2), 
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70.08 (CH2), 69.91 (CH2), 56.58 (CH), 47.03 (CH), 40.38 (CH2), 39.60 (CH2), 39.30 (CH2), 
38.61 (CH2), 36.48 (CH2), 34.78 (CH2), 29.05 (CH2), 25.52 (CH2), 18.90 (CH3). 
HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C32H45N2O6S2+ 617.2719; Found 617.2718 
IR (cm-1): 3314, 2938, 1657, 1560, 1452, 1370, 1267, 1097 
1H NMR spectrum of 41 
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13C NMR spectrum of 41 
 
5.8 PREPARATION OF PEG-KET AND GRAFTING ON ALGINATE 
The following synthesis has been published in Antifibrotic Effect of Ketoprofen-Grafted 
Alginate Microcapsules in the Transplantation of Insulin Producing Cells. Bioconjug. Chem. 
Copyright  2018.”.225 
 
Scheme 24: Synthesis ketoprofen derivatives with PEG linkers. Reagents and conditions: i- ketoprofen, [DCC, 
DMAP] or [HOBt, EDCI, DIPEA] 23°C, 12 hr; ii-HCl 4N, 23°C, 2 hr. 
N-Boc-amine-PEG-ester-ketoprofen (42) 
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(0.234 g, 0.111 mmol, 1.0 equiv) of TBOC-PEG2000-OH was dissolved in DCM (2 mL). 
Ketoprofen (29 mg, 0.112 mmol, 1.01 equiv), DCC (0.025 mg, 0.1224 mmol, 1.1 equiv) and 
DMAP (1 mg, 0.011 mmol, 0.1 equiv) were added to the reaction mixture. The reaction was 
stirred at 23°C for 12 hr. After concentration under reduced pressure, the crude residue was 
purified by FCC (DCM:MeOH = 30:1?10:1) to afford a white solid (0.234 g, 0.098 mmol, 
88%). 
1H-NMR spectrum (400 MHz, CDCl3) δ 7.75 – 7.35 (m, 9H, CHar), 4.27 – 4.09 (m, 2H, CH2-
NHBoc), 3.84 – 3.72 (m, 2H, CH2-OC(O)), 3.58 (s, 174H, CH2, PEG), 3.40 (dd, J = 5.8, 4.1 
Hz, 1H, CH-Me), 3.24 (d, J = 5.4 Hz, 2H, CH2-CH2O), 1.89 – 1.78 (bs, 1H, NH), 1.47 (d, J = 
7.2 Hz, 3H, CH3), 1.38 (s, 9H, CH3(Boc)). 
13C-NMR spectrum (101 MHz, CDCl3) δ 132.66 (Car), 131.71 (Car), 130.21 (2 x Car), 129.38 
(Car), 129.14 (Car), 128.67 (Car), 128.46 (2 x Car), 70.71 (CH2), 70.37 (CH2), 69.13 (CH2), 64.23 
(CH2), 45.40 (CH), 28.57 (CH2), 18.69 (3 x CH3), 18.69 (CH3). 
Mass MALDI m/z: [M + Na]+ Calcd for C111H203NNaO49+ 2357.3321; Found 2356.599 
IR (cm-1): 2870, 1350, 1250, 1105  
1H NMR spectrum of 42 
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13C NMR spectrum of 42 
 
 
Amine-PEG-ester-ketoprofen (44) 
 
N-Boc-amine-PEG-ester-ketoprofen (42) (0.234 g, 0.100 mmol, 1.0 equiv) was dissolved in a 
solution of HCl 4N in dioxane (3 mL) and the mixture was stirred at 23°C until completion of 
the reaction (2 hr, monitored by TLC). The volatiles were removed under air flow and the 
product was dried in vacuo to afford amine-PEG-ester-ketoprofen (44) as a beige solid (0.225 
g, quant.) which was used without further purification. 
1H-NMR spectrum (400 MHz, CDCl3) δ 78.02 – 7.37 (m, 9H, CHar), 4.31 – 4.16 (m, 2H, 
CH2-NH2), 3.91 (s, 2H, CH2-OC(O)), 3.62 (s, 174H, PEG), 3.44 (t, J = 4.8 Hz, 1H, CH-Me), 
3.16 (s, 2H, CH2-CH2O), 1.52 (d, J = 7.2 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 196.49 (CO), 174.08 (CO), 140.88 (Car), 137.96 (Car), 137.58 (Car), 
132.58(Car), 131.65 (Car), 130.14 (2 x Car), 129.31 (Car), 129.06 (Car), 128.60 (Car), 128.40 (2 x Car), 70.67 
(n x CH2), 69.08 (CH2), 67.18 (CH2), 64.18 (CH2), 45.37 (CH), 18.64 (CH3). 
HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C106H196NO47+ 2235.2979; Found 2235.2905 
IR (cm-1): 2880, 1465, 1345, 1280, 1240, 1105, 960, 840 
1H NMR spectrum of 44 
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13C NMR spectrum of 44 
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N-Boc-amine-PEG-amide-ketoprofen (43) 
 
(0.100 g, 0.047 mmol, 1.0 equiv) of TBOC-PEG2000-NH2 was dissolved in DMF (5 mL). 
Ketoprofen (0.012 g, 0.047 mmol, 1.01 equiv), HOBt (0.011 g, 0.070 mmol, 1.5 equiv), EDCI 
(0.018 g, 0.094 mmol, 2.0 equiv) and DIPEA (0.023 mL, 0.140 mmol, 3.0 equiv) were added. 
The reaction mixture was stirred at 23°C for 12 hr. The solvent was removed under vacuum. 
The residue was dissolved in DCM (10 mL) and washed with sat. NH4Cl solution (2 x 10 mL) 
and brine (1 x 10 mL). The organic layer was dried with MgSO4 and concentrated under 
vacuum. Purification by FCC on silica gel (DCM:MeOH = 20:1 ? 9:1) afforded 43 as a white 
solid (0.084 g, 0.036 mmol, 76%). 
1H NMR spectrum (400 MHz, CDCl3) δ 7.84 – 7.35 (m, 9H, CHar), 3.70 – 3.29 (m, 176H, 
CH2, PEG), 1.53 (d, J = 7.1 Hz, 3H, CH3), 1.44 (s, 9H, CH3(Boc)). 
13C NMR (101 MHz, CDCl3) δ 132.66 (Car), 131.73 (Car), 130.22 (2 x Car), 129.09 (Car), 
128.48 (2 x Car), 70.70 (n x CH2), 39.58 (CH2), 28.58(CH2). 
HRMS (ESI/QTOF) m/z: [M + Na]+ Calcd for C111H204N2NaO48+ 2356.3481; Found 
2356.3481 
IR (cm-1): 2866, 1106 
1H NMR spectrum of 43 
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13C NMR spectrum of 43 
 
Amine-PEG-amide-ketoprofen (45) 
 
N-Boc-amine-PEG-amide-ketoprofen (43) (0.084 g, 1 equiv, 0.036 mmol) was dissolved in a 
solution of HCl 4N in dioxane (3 mL) and the mixture was stirred at 23°C until completion of 
the reaction (monitored by TLC). The volatiles were removed under air flow and the product 
was dried in vacuo to afford amine-PEG-amide-ketoprofen (45) as a beige solid (0.083 g, 
quant.) which was used without further purification. 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.38 (m, 9H, ar.), 6.85 (t, J = 5.4 Hz, 1H, NH), 3.74 – 
3.31 (m, 14H, CH2-CH2-O), 1.51 (d, J = 7.1 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 196.58(CO), 173.66(CO), 142.14 (C ar.), 137.99 (C ar.), 
137.58 (C ar.), 132.62 (C ar.), 131.67 (C ar.), 130.16 (2 x C ar.), 129.25 (C ar.), 129.06 (C ar.), 
128.72 (C ar.), 128.43 (2 x C ar.), 70.67 (n x CH2), 66.89 (CH2), 46.92 (CH), 40.63 (CH2), 
39.55 (CH2), 29.80 (CH2), 18.91 (CH3). 
HRMS (ESI/QTOF) m/z: [M + H]+ Calcd for C106H197N2O46+ 2234.3137; Found 2234.3108 
IR (cm-1): 2890, 1103 
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1H NMR spectrum of 45 
 
13C NMR spectrum of 45 
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TBA-Alginate (46) 
 
The following protocol was reported by Passemard et al.197 Na-alg (Kelton HV) (2 g) was 
suspended in ethanol (100 mL) and cooled to 0°C under stirring. To the suspension a solution 
of EtOH:HCOOH = 4:1 (100 mL) was added and the suspension was kept under stirring 
overnight at 0°C. The suspension was then recover on a vacuum filter, washed with EtOH:H2O 
= 1:1 (3 x 50 mL) and acetone (3 x 50 mL). The solid was then re-suspended in water (200 mL) 
and the solution was basified with the addition of aq. TBAOH (1.5 M) until the pH reached 7-
8 which lead to the dissolution of alginate. The mixture was directly freeze in liquid nitrogen 
and placed in a freeze drier to yield TBA-alg (46) (2.3 g, quant.) as a white solid foam. 
1H NMR (400 MHz, Deuterium Oxide) δ 3.97 (dd, J = 108.6, 59.7 Hz, alg), 3.38 – 3.15 (m, 
2H, CH2 (TBA)), 1.77 – 1.57 (m, 2H, CH2 (TBA)), 1.37 (q, J = 7.4 Hz, 2H, CH2 (TBA)), 0.96 
(t, J = 7.4 Hz, 3H, CH3 (TBA)). 
 
1H NMR spectrum of 46 
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Alg-PEG-ester-ketoprofen (47) & Alg-PEG-amide-KET (48) 
 
TBA-Alg (46) (0.100 g, 0.239 mmol, 1.0 equiv) was dissolved in DMSO (20 mL) and the 
solution was stirred at 23°C for 12 hr to ensure homogeneity. 1,1'-Carbonyldiimidazole (0.039 
g, 0.239 mmol, 1.0 equiv) previously dissolved in a minimum volume of DMSO was added and 
the reaction mixture was stirred at 23°C for 30 min. To enhance precipitation of the imidazolide-
alginate intermediate, acetone (40 mL) was added. The resulting precipitate was filtered (70 
μm) and washed with acetone (3 × 10 mL). The solid was further dried for 15 min under vacuum 
at 40 °C and transferred to a round-bottom flask. Distilled water was added (10 mL), and the 
mixture was stirred until complete dissolution. 44 or 45 (0.0239 mmol, 0.10 equiv.) previously 
dissolved in a minimum volume of water was added. The solution was stirred at 23°C for 2 hr. 
The reaction was quenched by addition of 0.05 M NaOH solution until reaching pH 11. The 
solution was directly transferred into a dialysis membrane (14 kDa) and dialyzed against 
distilled water. The first day, water was changed once. The dialysis was continued the next day 
(changing water 3 times that day). The last day, the dialysis was continued against water, with 
the addition of NaHCO3 (180 mg in 9 L distilled water) in the dialysis bucket, to reach pH 7. 
The solution was filtered (70 and 0.22 μm) and freeze-dried to obtain Alg-PEG-ester-KET (47) 
or Alg-PEG-amide-KET (48) as white solids. 
1H NMR (400 MHz, D2O) δ 7.76 – 7.51 (m, CHar), 4.10 – 3.40 (m, CH-Alg + CH2-CH2-O), 
3.14 (m, CH2-NHC(O)), 1.46 (d, J = 7.1 Hz, CH3). 
1H NMR spectrum of 47 
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1H DOSY spectrum of 47 
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Alg-PEG-amide-KET (48) 
1H NMR (400 MHz, D2O) δ 7.76 – 7.53 (m, CHar), 4.10 – 3.47 (m, CH-Alg + CH2-CH2-O), 
3.15 (m, CH2-NHC(O)), 1.43 (d, J = 7.1 Hz, CH3). 
 
1H NMR spectrum of 48 
 
 
5.9 SYNTHESIS OF ALGINATE-LIPOIC ACID 
The following synthesis was reported in “Synthesis Strategies to Extend the Variety of 
Alginate-Based Hybrid Hydrogels for Cell Microencapsulation” by Passemard et al.197 
Azide-PEG-LA (49) 
 
To a solution of compounds azide-PEG-amine (5 g, 4.72 mmol, 1 equiv) and 6 (2.86 g, 9.44 
mmol, 2 equiv) in DMF (35 mL), Et3N (477 mg, 4.72 mmol, 1 equiv) was added. The reaction 
mixture was stirred for 48 h at 23°C. The solvent was removed under reduced pressure. The 
crude product was dissolved in DCM (100 mL) and washed with sat. NH4Cl (2 × 40 mL). The 
organic phase was dried (MgSO4) and concentrated in vacuo. The product was purified by FCC 
(DCM:MeOH = 17:1) to afford 49 as a yellowish amorphous solid (4.63 g, 3.71 mmol, 78%).  
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1H NMR spectrum of 49 
 
Amine-PEG-LA (50) 
 
Compound 49 (1 g, 866 μmol, 1 equiv) was dissolved in THF (5 mL). LiAlH4 (66 mg, 1.73 
mmol, 2 equiv) was added portion wise, and the reaction was stirred for 40 min at 23°C. The 
reaction was quenched by slow addition of EtOAc (2 mL), then water (20 mL), and the product 
was extracted with DCM (3 × 30 mL). The combined organic layers were dried (MgSO4) and 
concentrated in vacuo to afford amine-PEG-LA (50) as a white amorphous solid (895 mg, 791 
μmol, 91%). 
HRMS (ESI/QTOF) m/z: Calcd. for C52H106N2O22S2: 1175.6757; Found: 1175.6735 
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ESI-QTOF-MS spectrum of 50 
 
 
Alg-PEG-LA (51) 
 
TBA-alg (46) (100 mg, 0.239 mmol, 1 equiv) was dissolved in DMSO (20 mL), and the solution 
was stirred for 12 h to ensure homogeneity. CDI (38.7 mg, 0.239 mmol, 1 equiv) previously 
dissolved in a minimum volume of DMSO was added, and the reaction mixture was stirred at 
23°C for 30 min. To enhance precipitation of the imidazolide-alginate intermediate, acetone 
(40 mL) was added. The resulting precipitate was filtered and washed with acetone (3 × 10 
mL). The solid was further dried for 15 min under vacuum at 40 °C and transferred to a round-
bottom flask. Distilled water was added (10 mL), and the mixture was stirred until complete 
dissolution. Heterobifunctional PEG derivative (47.9 μmol, 0.2 equiv,) previously dissolved in 
a minimum volume of water was added. The solution was stirred at 23°C for 2 h. The reaction 
was quenched by addition of 0.05 M NaOH solution until reaching pH 11. The solution was 
directly transferred into a dialysis membrane and dialyzed against distilled water. The first day, 
water was changed once. A second water change was performed with prior addition of TCEP 
(0.1 M, 1 mL) in the dialysis tube. The dialysis was continued for 2 more days, adding TCEP 
(0.1 M, 1 mL) one more time to the dialysis tube, and followed by dialysis against distilled 
water the second day (changing water 3 times that day). The last day the dialysis was continued 
against water, with the addition of NaHCO3 (180 mg in 9 L distilled water) in the dialysis 
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bucket, to reach pH 7. The solution was filtered (70 and 0.22 μm) and freeze-dried to obtain the 
PEG-grafted alginates (51) as white solid. 
1H NMR spectrum of 51 
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5.10 MICROSPHERES FORMATION 
Formation of empty microspheres from pure polymer 
Alg-PEG-KET (47 or 48) polymer was dissolved in MOPS buffer (100 mM, pH = 7.4) to obtain 
1 mL of a 3 wt % solution. The mixture was extruded into a gelation bath (100 mM CaCl2 in 
100 mM MOPS buffer, pH 7.4) containing tween 80 (diluted 1/10 000) using a coaxial air-flow 
droplet generator. MS were rinsed with MOPS buffer and kept in MOPS solution (3 mL) 
containing CaCl2 (100 mM). Quantification of ketoprofen release was performed over different 
time period by LC-MS analysis of aliquots from the supernatant at regular time points (0.5, 1, 
3, 6, 24, 48, 72, 96, 168 h). 
Formation of empty microspheres from a mixture of polymer (alg-A-KET, alg-B-KET) 
Na-alg and Alg-PEG-KET (47 or 48) polymers were dissolved in in MOPS buffer (100 mM) 
adjusted to pH 7.4 to obtain respectively 2 mL of a 1.5 wt. % solution and 0.86 mL of a 3.5 wt. 
% solution. The two solutions of polymer were mixed until homogenization. The resulting 
mixture was extruded into a gelation bath (100 mM CaCl2 in 100 mM MOPS buffer, pH 7.4) 
containing tween 80 (diluted 1/10 000). MS were produced employing a coaxial air-flow droplet 
generator (Encapsulator B-395 Pro, Büchi Labortechnik AG, Flawil, Switzerland). The MS 
were collected by filtration, washed twice for 10 minutes with NaCl 0.9%, and finally stored in 
this solution at 4 °C. The release of ketoprofen was quantified by LC-MS from the supernatant 
at regular time points (0.5, 1, 3, 6, 24, 48, 72, 96, 168 and 336 h). 
Formation of empty microspheres from a mixture of polymer (3C-alg) 
Alg-PEG-acrylate 3 wt. % alg-PEG-thiol 3wt. % and alg-PEG-ester-KET 2.5wt. % were 
dissolved in MOPS buffer adjusted to pH 7.4 to obtain respectively 1 mL 3 wt. %, 1 mL 3 wt. 
% and 1.2 mL 2.5 wt. %. The three solutions of polymer were mixed until homogenization. The 
mixture was extruded into a gelation bath (100 mM CaCl2 in 100 mM MOPS buffer, pH 7.4) 
containing tween 80 (diluted 1/10 000) using a coaxial air-flow droplet generator. MS were 
rinsed with MOPS buffer and kept in MOPS solution (3 mL) containing CaCl2 (100 mM). 
Quantification of ketoprofen release was performed over different time period by LC-MS 
analysis of aliquots from the supernatant at regular time points (0.5, 1, 3, 24, 48, 96, 120, 144, 
168, 336 h). 
Formation of microspheres with MIN6 cells and porcine Islets 
MIN6 cells were cultured in Dulbecco Modified Eagle’s Medium (DMEM) supplemented with 
1 mM Na-Pyruvate, 71 μM β-mercaptoethanol, 15% decomplemented fetal calf serum (FCS), 
25 mM glucose, penicillin and streptomycin (DMEM complete medium). MIN6 cells (3 x 106) 
were centrifuged at 250 g for 5 minutes and the supernatant was completely removed. The 
remaining cell pellet was dispersed in 1 mL of Na-alg-PEG solution using a 10 mL syringe. MS 
were produced using the same procedure as described above for the formation of empty MS. 
Encapsulated MIN6 cells were then cultured in DMEM complete medium at 37°C with 5% 
CO2. The release of ketoprofen was quantified by LC-MS from the supernatant at regular time 
points (0.5, 1, 3, 6, 24, 48, 72, 96, 168 and 336 h). 
Porcine Islets were cultured in neonatal porcine islet culture medium from Corning. The islets 
were placed in a falcon tubes for 5 min and after sedimentation the supernatant was removed. 
The remaining cell pellet was dispersed in 1 mL of the polymers solution using a 10 mL syringe 
to obtain 10000 or 20000 IEQ / ml of polymer. MS were produced using the same procedure 
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described above. Encapsulated Islet were then cultured in Neonatal porcine islet culture 
medium from Corning at 37°C with 5% CO2 and the medium was changed two times per week. 
5.11 DETERMINATION OF THE DEGREE OF GRAFTING 
The procedure is described for alg-PEG-ester-KET (47). The same methodology was performed 
on alg-PEG-amide-KET (48). 
1D 1H-NMR of alg-PEG-ester-KET (47) was run at 800 MHz with a repetition delay of 5s as 
1H longitudinal relaxation time constants (T1) of 47 and alginate were measured to be T1 < 1s. 
Line broadening was set to 0.3 Hz. The baseline was automatically corrected with Bruker 
Topspin routine, using degree 5 polynomial. The percentage of grafting was estimated by 
comparison of integration of 1H resonances of PEG fragment (176 protons) and alginate unit (5 
protons). Due to overlap, separation between PEG and alginate resonances was performed by 
deconvolution with Lorentzian functions, using Bruker Topspin curve fitting and line shape 
analysis tool. The grafting degrees of 47 are of 7% and 20% when using 0.1 and 0.2 equiv. of 
PEG-ester-KET (44), respectively, in the coupling procedure. 
 
 
Figure 5.1: (left): Simulated spectra of PEG-a-KET, Alg, D2O and their sum calculated from lorentzian functions. 
(right): The method was validated by superimposition of the recorded spectrum of Alg-PEG-a-KET with the 
simulated spectrum obtained from the sum of the lorentzian functions 
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5.12 QUANTITATIVE ANALYSIS BY UHPLC-ESI-HRMS 
MS quantitive analysis were performed on a Agilent 6530 Accurate Mass Q-TOF LCMS mass 
spectrometer coupled to an Agilent 1290 series UHPLC system (Agilent Technologies, USA). 
The separation was achieved using an ACQUITY UPLC® BEH C18 1.7μm column, 2.1 mm x 
50 mm (Waters) heated at 30°C. Mobile phase consisted of 0.1% formic acid in water as eluent 
A and 0.1% formic acid in acetonitrile as eluent B. The separation was carried out at 0.4 mL/min 
over a 6 min total run time using the following program: 0-0.5 min, 1-5% B; 0.5-3 min, 5-95% 
B; 3-3.5 min, 95-1% B; 3.5-6 min, 1% B to reequilibrated the system in initial conditions. The 
sample manager was system temperature was fixed at 10°C and the injection volume was 5μL. 
Mass spectrometer detection was operated in positive ionization using the Dual AJS Jet stream 
ESI Assembly. The QTOF instrument was operated in the 4 GHz High Resolution mode in 
profile mode. The Instrument was calibrated in positive full scan mode using ESI-L+ solution 
(Agilent Technologies, USA). The TOF mass spectra were acquired over the range of m/z 100-
1000 at an acquisition rate of 3 spectra/s. ESI AJS settings were as follows RF drying gas flow, 
8 L/min; drying gas temperature, 300°C; nebulizer pressure, 35psi; capillary voltage, 3500V; 
nozzle voltage, 1000V; fragmentor voltage, 175V; skimmer voltage, 65V; octopole 1 RF 
voltage, 750V; Sheath gas temperature, 350°C; Sheath gas low; 11L/min. Data was processed 
using the MassHunter Workstation (Agilent Technologies, USA). Extracted ions 
chromatograms (XIC) were based on a retention time (RT) window of ±0.2 min with a mass-
extraction-window (MEW) of ±50 ppm centered on m/ztheor. Calibration curves were fitted with 
a polynomial order 2 equation, with R2 > 0.995. 
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Figure 5.2: Typical XIC (255.1021 MEW of ±50 ppm) of ketoprofen standard (b) Typical MS of ketoprofen 
standard at 2.6 min 
5.13 TRANSPLANTATION OF MICROSPHERES IN MICE 
All animal experiments were approved by the Geneva veterinary authorities (license GE/ 34/13 
and license GE/151/16). After production, MS were kept for 1 day in culture. Prior to 
transplantation, MS were rinsed three times for 15 min in Hank’s Balanced Salt Solution 
(HBSS), containing Ca2+. Once MS have settled on the bottom of the tube, the supernatant was 
removed and remaining MS were dispersed in minimal amount of HBSS for transplantation. 
1.5 mL of MS, corresponding to ?12 700 MS (We considered the average diameter of MS as 
0.55 mm and used the formula 4/3 π r3 to calculate the sphere volume. Hence, the sphere volume 
of one MS was determined as 0.087 mm3. Total volume of transplanted MS is, 1500 mm3 (1.5 
mL), adjusted by the Kepler conjecture 1500·0.74 resulting in 1110 mm3. Therefore the total 
number of MS contained in 1.5 mL of solution is 1110 mm3 /0.087 mm3 = 12’758), were 
introduced through a small incision into the peritoneum of C57BL/6 mice anesthetized by 
isoflurane. For kidney transplantation, kidneys were exposed through a small dorsal incision 
and ?100 μL of MS were injected under the kidney capsule using a 18G catheter. Thirty days 
after transplantation mice were sacrified and kidneys and MS from peritoneum were retrieved 
for histological analysis. 
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5.14 HISTOLOGICAL ANALYSIS.  
MS were collected from the peritoneum using a spatulas microspoon and added without 
washing to a small volume of NaCl 0.9% for immediate image acquisition using inverted bright-
field microscopy (Leica DM IL) and LAS v 4.5 software (Leica Microsystem, Heerbrugg, 
Switzerland). Kidneys were harvested, fixed in formalin for 24 h, and embedded in paraffin. 
Histological sections of 4 μm of tissue were stained for collagen using Goldner’s trichrome, 
images were acquired by Zeiss Axioscan.Z1 and processed with ZEN 2.3 lite (Carl Zeiss). 
5.15 QUANTIFICATION OF PERICAPSULAR FIBROTIC OVERGROWTH. 
Fibrotic overgrowth around MS retrieved from peritoneum was quantified using ImageJ. 
Briefly, each selected MS was processed with the same parameters for color threshold and 
brightness during analysis. Total area of each MS was determined after manual selection of MS 
shape, which was set as 100%. The pericapsular fibrotic overgrowth (gray levels) was then 
evaluated in the selected area and normalized to the value of the area of each MS and therefore 
expressed as percentage of fibrotic overgrowth/MS. At least, 5 MS per type of polymer were 
analyzed to determine the percentage of fibrotic overgrowth. All values are means ± standard 
deviation (SD). Collagen quantification around MS transplanted under the kidney capsule was 
performed using Definiens Software. Five kidney sections per polymer were quantified. 
Collagen depositions (in green) were quantified and normalized to the number of MS present 
in each section. Since MS size differed in each section, values were additionally normalized to 
the mean of the total area of MS present in a given section; therefore values are expressed as 
fibrosis area/MS count/mean of area. All values are means ± standard deviation (SD). 
5.16 REAL-TIME RT?PCR.  
mRNA expression of α-SMA, COL1A1, and MMP was analyzed by real-time reverse 
transcription PCR (RT-PCR), as previously described.38 Briefly, 1.5 × 105 human fibroblasts 
were plated in DMEM supplemented with 100 IU/mL penicillin, 100 mg/Ml streptomycin (P?
S, Gibco-Invitrogen), and 10% FCS (Gibco- Invitrogen) at 37 °C in humidified air containing 
5% CO2. After 8 h, medium was removed and replaced by DMEM without FCS for 1 day. Then, 
10 ng/mL of TGFβ1 diluted in DMEM with 1% FCS was added to all conditions (except 
negative control) and supplemented with increasing concentrations of KET-TEG-LA (0.125, 
0.25, 0.5, 1 mg/mL). After 24 h of incubation, total RNA was extracted using the Qiagen 
RNeasy Mini kit (Qiagen, San Diego, CA, USA) according to the manufacturer’s instructions. 
Primers listed in Figure 5.3 were designed using Primer3 online software (http://primer3.ut.ee), 
tested with Primer Biosoft (http://www.premierbiosoft.com), and blasted on BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Expression of housekeeping ribosomal protein large 
P0 was used to normalize expression values obtained for α-SMA, COL1A1, and MMP. 
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Figure 5.3: H-RPLP0, human ribosomal protein large P0; H-α-SMA, human α smooth muscle actine; H-
COL1A1, human type 1 collagen; H-MMP-1, human metalloproteinase-1.
5.17 INSULIN SECRETION TEST
Insulin release in response to acute glucose stimulation was determined by incubating the islets 
or MIN6 cells for 1 hour in RPMI 10% FCS medium containing low glucose (2.8 mM) for basal 
secretion, followed by an additional hour of incubation in high glucose (16.8 mM) medium or 
16.8 mM glucose medium supplemented with 5 mM of theophylline. Supernatants were 
collected, frozen and insulin concentrations were determined using insulin ELISA Kit 
according to the manufacturer’s instructions (Mercodia, Uppsala, Sweden). Results were 
normalized to the total insulin content of the islets as measured by the same ELISA kit and 
following ice-cold acid-ethanol extraction. Due to interexperimental variability, and depending 
upon the time of culture and the encapsulation, insulin secretion was expressed relative to the 
basal levels (stimulation index). 
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6 ANNEXES 
 
Figure 6.1: Alg-[carbamate]-PEG-(triazole)-SH 
 
Table 8: Size of Alg-[carbamate]-PEG-(triazole)-SH MS at day 1 and 7 
 Alg-PEG-SH 7.7% 2 w. % 
Size (μm) Day 1 983 ± 168 
Size (μm) Day 7 935 ± 142 
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Figure 6.2: Shape recovery of alg-PEG1000-SH with different degree of grafting 
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Figure 6.3: Alg-PEG-triazole-L.A 
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Table 9: Alg-PEG-triazole-L.A 
 No DTT DTT 
Day 1 1040 ± 214 1103 ± 121 
Day 7 1079 ± 117 1134 ± 108 
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Figure 6.4: fluorescence of un-modified curcumin in supernatant 
 
 
Figure 6.5: Dosy spectrum of alg-PEG-KET 
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Figure 6.6: (A) Bright-field microscopy images of MS retrieved from the peritoneum following 15 days of 
transplantation. Na-alg (left rows), Alg:Alg-PEG-a-KET (middle rows) and Alg:Alg-PEG-b-KET (right rows); 
cell-free MS (upper panels) and MS with MIN6 cells (lower panels). (B) Pericapsular fibrotic overgrowth was 
quantified using ImageJ and expressed as a percentage of fibrotic overgrowth. For each MS, fibrotic overgrowth 
(grey levels) were normalized to the total area of MS measured. Fibrotic overgrowth for empty MS (white bars) 
and for MS with MIN6 cells (striped bars) are represented. All values are means ± standard deviation (SD) of at 
least 5 MS. ***p<0.001. 
 
Figure 6.7: Microscopy image of neo natal pig islets, free, encapsulated in alginate and in alg-A-KET at day 1. 
Top panel: light microscopy, middle panel: staining of live cells with FDA (green), bottom panel: staining of dead 
cells with PI (red). 
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